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Abstract 
A systematic review of trials about screening older people for visual 
impairment found no evidence that screening improved vision. We undertook 
a new trial nested within a larger cluster randomised trial of multidimensional 
screening for people aged 75 years and over. 106 general practices were 
randomised to: targeted screening in which only a small proportion of 
participants with a range of health problems were offered visual acuity 
screening, and universal screening in which all participants were offered 
visual acuity screening. People identified with impaired vision were referred 
to the eye services. Around 220 participants were randomly sampled from 
ten practices in each group and visual outcomes measured at three to five 
years. 
The response rate to the baseline assessments was 76.1 Over one third of 
eligible participants died before having an outcome assessment. Of those 
alive, 67.8% in the targeted screening group and 57.9% in the universal 
group completed an outcome assessment. At outcome 37.0% (307/829) in 
the universal group had visual acuity of less than 6/18 in either eye compared 
with 34.7% (339/978) in the targeted group (odds ratio 1.11,95% confidence 
interval 0.76 to 1.62, P=0.58). The 25 item National Eye Institute Visual 
Function Questionnaire composite score was 86.03 in the universal group 
and 85.62 in the targeted group (difference 0.41,95% confidence interval - 
1.68 to 2.50, P=0.69). Although visual impairment was common, few people 
benefited from subsequent intervention. Possible explanations for the lack of 
effect include: chance; under-detection of uncorrected refractive error and 
that only around half the recommendations for referral to an ophthalmologist 
resulted in referral. 
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CHAPTER 1. BACKGROUND 
1.1 Introduction 
Visual impairment and older people 
The Vision 2020 initiative recently launched by the World Health 
Organisation highlighted the need to identify effective strategies to improve 
vision among older people. ' The importance of ageing populations has 
been- recognised for many years. However because of patterns of declining 
mortality, official forecasts have severely under estimated the likely 
proportions of people aged over 65 years in developed countries. 2 
The introduction of the sight test fee in 1990 increased concern about 
untreated visual problems in older people in the United Kingdom, 3 and a 
report from the Royal National Institute for the Blind renewed concern about 
sight loss in older people. 4 The Department of Health has called for 
deterioration in sight among older people to be given 'particular attention'. 5 
There have been repeated calls for screening for visual impairment to be 
undertaken in primary care. 6-9 
Multidimensional assessment of older people 
In practice screening for visual impairment is only likely to be one part of a 
broader screening package (multidimensional screening assessment). 
Multidimensional assessment of older people was originally developed in 
response to studies suggesting high levels of undetected medical or social 
problems among older people. '"' Multidimensional assessment aims to 
determine an older person's medical, social, psychological and functional 
problems and to form a plan for treatment and follow-up. 12 While 
multidimensional assessment has been shown to produce some small 
overall benefits, 13-16 exactly which procedures within the assessment are 
effective and which ineffective is uncertain. 17 Most forms of assessment 
include some attempt to assess vision. Screening older people for visual 
impairment using a Snellen chart is recommended for inclusion in the 
Canadian Periodic Health Examination. " 
I 
Over the past decade there has been increasing recognition of the need to 
base preventive health interventions on sound evidence. ' 9; 20 Referring to 
health promotion interventions, the 1997 MRC Topic Review of Primary 
Health Care stated that: 
"Appropriate research is needed to discriminate between current ineffective 
approaches that should be stopped, and effective programmes which 
should be introduced and maintained F? . 
21 
The current situation in the United Kinq-dom 
Since 1990 in the United Kingdom the primary care team have been 
required to offer an annual screening assessment to all patients aged 75 
and over, 22 specifically including an assessment of vision. There has been 
concern that the over 75 programme was introduced without adequate 
evaluation, 23 and one survey found that 68% of general practitioners 
24 thought the assessments unnecessary. At the time this work commenced 
the over 75 programme was under review. 25 
The method for assessing vision, threshold for action and the purpose of 
the visual assessment in the over 75 check were not specified in the GP 
contraCt, 22 but the Royal College of General Practitioners recommended a 
simple question about visual function to identify unreported problems. 26 
Vision is specifically listed as a domain to be included in the Single 
Assessment Process to be offered to all older people proposed in the 
National Service Framework for Older People. 27 In the most recently issued 
guidance about the Single Assessment Process, 28 the Department of 
Health states that "the following scales - or elements from them - may be 
used to explore the domains and sub-domains of the single assessment 
process, " and includes the following two questions about vision from the 
Lambeth Disability Screening Questionnaire. 29 
Do you have difficulty 
seeing newsprint even with glasses? 
2 
recognising people across the road even with glasses? 
1.2 Review of non-trial literature around screening older 
people for impaired vision 
Criteria used for the review 
Specific criteria for reviewing the evidence around community screening 
programme have been proposed 30 (tablel. 1). The criteria are an adaptation 
of those proposed by Wilson and JungeP1 and have been used in other 
published reviews of community screening programmes. 32; 33 
a. Does the burden of suffering warrant screening? 
b. Is there a good screening test? 
c. Are efficacious treatments or preventative measures available? 
d. Will those at risk attend for or accept screening? 
e. Why is there under-reporting and do people accept interventions 
f. Can the health system cope with the programme? 
Table 1.1 Suggested criteria for assessing the effectiveness of screening 
programmes 
Results 
(a) Does the burden of suffering warrant screening? 
The prevalence of unreported visual problems among older people 
The best estimates of prevalence of relevance to mass screening come 
from community based surveys in unselected populations. Different 
assessment techniques, definitions and criteria for visual problems have 
been used, but some consistent trends have emerged. 
A recent survey found binocular visual acuity of less than 6/12 (below the 
UK driving requirementS34) in around 30% of people aged 65 and over . 
35 
Only 12% of older people with a cataract causing impaired vision were in 
touch with eye care services and only one third of those with substantial 
uncorrected refractive error had seen an optician in the past 12 months. 35 
3 
Similar results have been found in other surveys undertaken in the United 
Kingdom. 36-38 In one of these less than half the older people with impaired 
vision were known to by their GP to have an eye problem and less than half 
had ever been in contact with the eye services. 37 
Other prevalence surveys have used different methods of sampling (such 
as whether people living in institutions were included), diagnostic criteria, 
and methods of correcting refractive error producing contributing to 
differences in the results obtained. When these differences are taken into 
account, estimates for the prevalence of visual impairment among older 
people in other developed countries have been broadly similar, although on 
the whole slightly lower than estimates from United Kingdom populations. 39- 
44 
Cataract, age related macular degeneration and uncorrected or 
inadequately corrected refraction defects are the commonest disorders. 
While glaucoma is a much less common cause of visual impairment, it is an 
important cause of blindness. 45 
Adverse effects of visual problems 
A variety of adverse factors have been reported as associated with visual 
impairment. Functional status and quality of life are lower; 
41-50 
social 
contacts are lower; 
42,47; 51; 52 
and visual impairment is strongly associated 
with depression, 51; 53 fallS, 54-56 and hip fractures . 
57-60 
(b) Is there a good screening test? 
In a primary care setting a screening test needs to be quick, cheap, 
available, and able to be carried out easily by different members of the 
primary health care team who often play a leading role in screening older 
people . 
57; 61 The assessment of visual screening tests is hampered by the 
lack of a gold standard, i. e. something that'truly' measures vision and the 
impact of visual loss on a person's life. 
4 
Distance acuity 
Snellen charts for testing acuity are available in 95% of general practiceS. 62 
However, inadequate attention to testing distance and illumination are 
63 64 
common, and poor lighting is a particular problem in patients' homes. 
Design problems in the Snellen chart are the alteration in the number of 
letters on each line, and the irregular progression of the size of the letters 
65 
as one moves up or down the chart. Newer charts with equal numbers of 
letters on each line and which measure the minimal angle of resolution on a 
logarithmic scale (logMAR) are available. 66; 67 The repeatability of acuity 
measurements is higher with these newer charts than the Snellen chart. 68-70 
In patients with reduced visual acuity, the pinhole test usefully differentiates 
refractive visual failure from non-refractive . 
71 However, although pinhole 
correction fairly reliably indicates that visual loss is due to refractive error, 
failure to correct acuity by using the pinhole does not exclude refractive 
error. 71 
Visual function 
Reduced visual acuity may not accurately reflecl "need" for measures to 
improve vision, and other factors have been shown to be independent risk 
factors for self-reported visual disability among older people. 72-74 Visual field 
loss (for example due to glaucoma) is found in 10-15% of people aged over 
80 years, 43; 75 and even with the retention of good central vision and 
therefore normal or near normal visual acuity, visual field loss is itself 
disabling. 75'79 Reduced contrast sensitivity is also a strong predictor of 
difficulties with everyday tasks . 
52; 80; 81 The ability to read letters on a chart, 
particularly in a clinic setting with optimal lighting levels, may not provide a 
good measure of the impact of visual problems on a person's life nor 
equate with the person's perceived need for intervention. While vision 
related quality of life and visual acuity are correlated, this correlation is 
nowhere near complete. 82-85 However, to date the visual function indices 
that have been shown to be valid 85 would be too long to be feasible 
5 
screening tools. The development of screening tools that are better able to 
measure the impact of vision on peoples' lives are needed. 
Methods of measuring visual function are discussed in more detail in 
Chapter 3. 
Questions about vision 
Questions about visual problems have been compared to visual acuity 
measurements in a number of studies8"9 (table 1.2). These show that 
single questions are generally poor at detecting clinically significant 
reductions in acuity. 
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The rather different figures found in the study by Cullinan 86 may reflect the 
fact that all people in the study had previously identified themselves as 
having some kind of visual problem. Sensitivity in detecting an acuity less 
than 6/12 can be improved to 86% by combining scores from three 
questions, 90 (compared to 28-64% for one question), but clearly asking 
three questions takes considerably longer than a single question. 
While one or two questions about self-reported visual difficulties are poor 
predictors of low visual acuity, the extent to which they can identify impaired 
visual function is not known. 
Action threshold 
There are no agreed criteria for the level of visual acuity which warrants 
intervention. Many of the adverse associations of reduced visual acuity 
outlined above are found to some degree at a visual acuity less than 6/12. 
The United Kingdom driving requirements correspond to an acuity of 
around 6/1 0.34 The majority of patients undergoing cataract surgery achieve 
a visual acuity of 6/12 or better, 91; 92 and this level is also achievable for 
most patients with refractive errors . 
36 Although the World' Health 
Organisation defines low vision as binocular visual acuity less than 6/18 
following correction of refractive error, 93 the American criteria for visual 
impairment is a best corrected acuity of less than 6/12. 
Recent work has shown that the levels of vision at which people have 
difficulties with everyday tasks depend on the task, indicating the limitations 
of trying to define a level of vision as disabling. 81 ; 83 
Although somewhat arbitrary (being dependent on the context of the health 
system), a pragmatic action threshold can be set by considering the level of 
vision below which a person is likely to be offered interventions to improve 
their vision. 
8 
(c) Are efficacious treatments or preventative measures available? 
It has been estimated that over 70% of the visual impairment (defined as 
binocular visual acuity less than 6/12) present in people aged 65 and over 
is potentially remediable. 35 However, in older age groups, among whom 
macular degeneration is relatively more common, the proportion of people 
whose vision can be improved is likely to be considerably lower than this. In 
addition, using a lower cut-off to define visual impairment (such as visual 
acuity less than 6/18), visual problems are more likely to be due to serious 
eye disease such as macular degeneration or glaucoma and less likely to 
be due to refractive error. Therefore for more severe visual loss, the 
proportion of people whose vision can be improved with treatment is again 
likely to be lower than the 70% estimate. 
Acuity can be improved for most patients with refractive defects. Surgical 
treatment for cataracts is effective. 92; 94 Although visual loss due to 
glaucoma is usually irreversible, the identification and treatment of people 
with glaucoma can slow visual loss. 95 Similarly, treatment can slow visual 
loss for people with diabetic retinopathy. 96 A minority of people with age 
related macular degeneration may benefit from photocoagulation 97 or 
photodynamic therapy. 98 For the remainder, attention to lighting" and 
rehabilitation measures, 100-103 can improve function and help lessen the 
disabling effects of the visual impairment. However, the evidence base for 
the effectiveness of visual rehabilitation to date is weak, limited to several 
small tr . ials that mostly report different outcomes. ' 04 Larger high quality trials 
are underway. 104 Registration as blind, and to a lesser extent as partially 
sighted mobilises social support and makes people eligible for increased 
social security benefits. 105 
(d) Will those at risk attend for or accept screening? 
The proportion of older patients who receive regular assessments as part of 
the over 75 programme is difficult to assess because there is no obligation 
on practices to collect this data. In surveys, rates of 55%, 106 63% '24 and 
48%1" have been found, but practices, which responded to the survey 
9 
questions, are likely to represent the best performing practices. Ninety 
percent of people in the over 75 age group see their general practitioner at 
least once a year, 108 making high coverage rates feasible. Very high uptake 
rates have been achieved in the European based trials of screening older 
people 12 and in general practice based eye surveys. 35; 37 Although these 
rates may reflect the extra resources available in a research setting, they 
do show that high rates are possible. 
(e) Why is there under-reporting and do people accept interventions 
and advice? 
Factors influencing use of eye services 
Work to date suggests there may be a variety of complex factors that 
influence older people's use of eye services. 
The likelihood of having been in contact with an eye care provider has been 
shown to be higher among people with more education, higher income, and 
known eye disease or self-reported visual difficulty. 109; 110 While older age 
has been shown to increase the likelihood of someone being in contact with 
eye services, older people are also more likely to have under corrected 
refractive error. ' 11; 112 In the United States, African Americans have been 
found to be less likely than white Americans to use eye services""" and 
more likely to have visual impairment amenable that would benefit from 
interventions. ' 14 However in the Women's Health Study, black women were 
more likely and Asian/Pacific Islanders less likely than white women to have 
had a recent eye examination. 110 
One study in the United Kingdom used focus groups of older visually 
46 impaired people to explore their experiences and needs. This study 
suggested that decreased patient expectation in old age, a belief that 
nothing can be done to help and worries about costs were possible factors 
in under reporting visual problems. A qualitative study assessing barriers to 
eye services among Asian people (with no particular focus on older people) 
in Ealing has recently been undertaken. Reports from this study are 
currently being prepared. Major themes that emerged were a perception by 
10 
those people not in contact with the eye services were that general 
practitioners were uninterested in eye problems, and, for those people who 
were already in touch with the eye services language difficulties were a 
major problem (I Murdoch, personal communication). 
A study has been undertaken to investigate the uptake of rural outreach 
eye care services in South India. ' 15 This study found that service 
attendance amongst adults identified with an eye problem was very low 
(7%). People who attended were more likely to be male and live close to 
the service facility. People who did not attend had a range of reasons for 
not doing so including fear of their eyes being damaged by treatment, cost, 
ageism, fatalism and an attitude of being able to cope. 
A number of studies have briefly considered the issues of why older people 
do not report visual problems or what influences their uptake of eye 
services as a small part of broader studies. Fear of costs has been cited 
consistently by older people in studies looking at reasons for non- 
4; 46; 111; 116 attendance at opticians. Although free sight tests for older people 
were recently re-introduced, the cost of obtaining glasses was specifically 
detailed in all of these studies. Poor ability of older people to recognise their 
own visual loss was found in a screening project undertaken in hospital 
outpatients. "' In a community survey, the presence of other functional 
difficulties was associated with non-reporting of visual problems. 86 The 
author suggested that the non-visual difficulties dominated some peoples' 
perceptions of their problems. In the same survey some people raised the 
stigma of being labelled as blind as an explanation for not reporting their 
visual loss. Transport difficulties have also been suggested as barriers to 
attending eye services. ' 18; 119 
Patient preferences and patient concern have been found to be strong 
determinants of demand for cataract extractions in large scale 
surveys. 110; 121 
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Uptake of interventions following screening 
There are little data on whether older people attend referrals or accept 
interventions for previously unreported visual problems discovered by 
screening. In a general practice based survey one third of those referred to 
the eye services with a visual problem did not attend. 37 Estimates of 
attendance at referrals arising from multidimensional screening 
assessments have ranged from 46% to 76%. 122 For assessments that 
specifically included a visual assessment, attendance rates of 70%, 123 
61 %124 and a range of 60-80% depending on the specific reason for the 
referral have been found '125 although data specifically about vision related 
referrals are not available for any of these studies. 
(Q Can the health system cope with the programme? 
It could be argued that the United Kingdom health system is currently 
coping with visual screening as part of the over 75 programme. However, 
there are wide variations in the way the checks are performed. 106; 126 The 
coverage rate of the programme is not accurately known, and neither are 
the methods of testing vision, action thresholds and interventions offered by 
different primary health care teams. A recent questionnaire survey found 
that only around two thirds of practices responding offered a regular 
screening assessment to older people and that only half included a vision 
component. All practices that reported including vision used questions 
about visual difficulties to detect problems: none reported using acuity 
testing. 127 The additional effect on the health services of a national standard 
screening protocol with a high coverage rate achieved cannot therefore be 
assessed. Any increase in referrals to the eye services would clearly 
consume additional resources. 
There has been a great deal of recent interest in the level of unmet need for 
cataract surgery in the United Kingdom and elsewhere. 128; 129 The 
Department of Health has recently announced a new initiative aimed at 
improving the level of and access to cataract services. 130 
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Summarv 
Unreported visual problems are common among older people and 
associated with a variety of adverse factors. A range of effective 
interventions exist and vision could be improved for a substantial proportion 
of people affected. 
Possible screening tests exist, although to date there are no validated tools 
for screening visual function. High levels of population coverage for a 
screening programme are feasible within primary care. There is little good 
information available about whether older people found to have visual 
impairment at screening are likely to adhere to recommendations for 
investigation and treatment. Universal screening of older people for 
impaired vision and adequate management of all those people found to 
have a visual problem would have major consequences for the health 
service. Establishing the effectiveness of such a programme is therefore of 
great importance. 
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CHAPTER 2. SYSTEMATIC REVIEW OF RANDOMISED 
CONTROLLED TRIALS OF SCREENING OLDER PEOPLE 
FOR VISUAL IMPAIRMENT 
2.1 Background 
Most forms of multidimensional assessment for older people include some 
attempt to assess vision. Specific screening procedures for chronic open 
angle glaucoma or diabetic retinopathy have not been included in either 
trials or programmes of multidimensional screening assessments. 
While the aims of multidimensional screening of older people are broad, 
any benefit arising from the inclusion of a vision component in the 
assessment will necessarily be dependent on improved vision or visual 
function. Therefore this review uses improvement in vision as the outcome 
measure of interest. 
2.2 Objectives 
To assess the effectiveness in improving vision of mass screening of older 
people for visual impairment. 
2.3 Methods 
Criteria for considering studies for this review 
Types of studies 
All randomised trials of visual or multidimensional screening in unselected 
people aged 65 or over in a community setting were included. 
Types of participants 
Participants were people aged 65 or over not identified as belonging to a 
particular risk group. 
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Types of intervention 
Any attempt at population screening for visual impairment in a community 
setting, either vision screening alone, or as part of a multidimensional 
screening assessment, was included. 
Types of outcome measures 
The outcome included was the level of visual impairment in the population 
at the end of the trial. Assessment of vision by any method (questions 
about vision, measures of visual function or use of an acuity chart), at least 
six months after the initial vision screening assessment was included. 
Search strategy for the idetitification of studios 
1. Electronic searching 
Trials were identified from the Cochrane Controlled Trials Register 
(CENTRAL), the Cochrane Eyes and Vision Group specialised register, 
MEDLINE and EMBASE. 
MEDLINE was searched using the following exploded MeSH terms: 'mass 
screening', 'preventive health services', 'eye diseases, and 'diagnosis, 
eye', and the non-exploded MeSH terms: 'health promotion' and 'geriatric 
assessment'. Titles and abstracts were searched for the words 'geriatric' or 
'elderly' combined with any of the following, using the Boolean operator 
"AND"; 'screening', 'assessment', 'health', 'function' or 'surveillance'. Other 
free text searches used the words 'macular degenerations, Icataract' and 
I presbyopia'. Wild card characters were used to ensure all forms of words 
are included. At all stages articles about animals and children were 
excluded. The results of this search were combined with the Cochrane 
Highly Sensitive Search Strategy phases one and tWo, 131 see appendix 1- 
Free text terms were used to identify possible trials in EMBASE, and the 
MeSH headings and free text terms were used to search CENTRAL. 
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Each of the studies selected was sought as a citation on the SciSearch 
database, and reports of articles that cited these trials were reviewed for 
relevance to the selection criteria. I 
2. Reference searching 
Reference lists of both identified trial reports and of review articles were 
scanned for further relevant reports. 
3. Personal communication 
The named author for correspondence for each of the selected trials was 
contacted for information about any other trials. 
4. Unpublished data 
A vision screen may have been only one small part of a multidimensional 
screening programme, and data about vision outcomes may not have been 
included in published reports of trials. Therefore trial authors were 
contacted for further information about visual outcome data if this was not 
reported. 
The inclusion criteria were applied in two stages. In the first stage, articles 
were included only if they were randomised controlled trials of either visual 
or multidimensional screening of unselected participants in a community 
setting which included patients aged 65 and over. Trials of screening 
undertaken on selected groups of patients were excluded on the grounds 
that the results would not answer the question under review. Studies 
including only adults aged under 65 were also excluded. The named author 
for correspondence for all trials identified in the first stage was contacted (at 
their current addresses verified by telephone), asking for any further 
unpublished data about visual screening tests us ' ed and visual outcomes. Non-responders were sent two reminders and were telephoned. The 
second stage inclusion criteria were then applied ' 
to all the trials included 
from the first stage: the availability of any visual outcome data, whether 
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formally tested or self-reported; and a follow up of at least six months to 
allow intervention for detected visual problems. 
Selection of trials 
The abstracts and titles of all identified citations were assessed, and full 
reports were obtained for studies which possibly fulfilled the selection 
criteria. Studies for which vision outcome data were available were selected 
for quality assessment and data extraction. 
Assessment of methodological quality 
Trial quality was assessed based on the recommendations in Section 6 of 
the Cochrane Reviewer's Handbook. 132 Four parameters were considered. 
Each parameter of trial quality was graded: adequate (A), not clear (B), or 
inadequate (C). The criteria used were: 
1. Concealment of allocation. 
This was scored as Adequate (A) if there was some form of centralised 
randomisation scheme, an on-site computer system or sequentially 
numbered sealed opaque envelopes were used. 
2. Attrition bias. 
Graded Adequate (A) if follow-up rates were similar in the comparison 
groups. 
3. Intention to treat analysis. 
Graded Adequate (A) if performed. 
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4. Masking of outcome assessment 
Scored Adequate (A) if the outcome assessors were masked to the 
allocation. Because of the nature of the intervention, it would not have been 
possible to mask either recipients or providers of care to their allocation. 
Therefore, masking of recipients or providers were not used as quality 
parameters for this review, although information when available is 
presented. 
For any trial graded B on any criteria (or C unless an explicit statement was 
made about the quality component in the trial report), the trial authors were 
contacted for clarification. There is strong empirical evidence that 
inadequate allocation concealment in randomised controlled trials leads to 
biased results. 133 For this reason trials scoring C on allocation concealment 
were excluded from the review. 
Data extraction 
Data about visual outcomes were extracted using paper data extraction 
sheets (appendix 2). The proportions of people with visual impairment in 
the experimental and control groups formed the comparison. 
Sensitivity analyses 
Three possible effect modifiers were identified prior to analysis. Firstly, trials 
of visual screening alone might be expected to produce a different effect to 
trials of visual screening included in a broader assessment. It was decided 
that these two sub-groups of trials would be analysed separately, because 
a pooled result would be difficult to interpret. Secondly, it is known that 
questions about vision, formal assessment using an acuity chart, and 
measures of visual function differ in their sensitivity and specificity for 
detecting reduced visual acuity, and use of different types of screening 
134 tools may lead to differences in the effects of Screening . Thirdly, 
differences in trial quality may produce differences in the effect size seen. 
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S6-nNtivity analyses to assess the effects of including or excluding trials 
which differed in these three characteristics were planned. 
Data analysis 
Analysis was undertaken using the meta commandS135 in Stata statistical 
software. 136 Heterogeneity among trial results was tested for using a 
standard chi-square test. Results of studies that were similar with respect to 
participants, interventions and outcome measures and for which there was 
no statistical evidence of heterogeneity of effect were combined to produce 
a summary relative risk using the fixed effects weighted variance method. 
2.4 Results 
Description of trials 
2516 citations and abstracts were screened and 154 full text articles were 
reviewed in detail. Seventeen studies met the first stage inclusion criteria 137, 
153 (randomised controlled trials of either visual or multidimensional 
screening of unselected participants in a community setting which included 
patients aged 65 and over). All 17 were trials of multidimensional screening. 
There were no trials which primarily assessed visual screening. 
Requests for further information led to replies from authors of all 17 trials. 
Five trial met the final inclusion criteria i. e. visual outcome data with follow 
up of at least six months. 
139; 145; 149; 150; 152 
The five trials included a total of 3494 participants (table 2.1). 
Response rates, visual screening methods and outcome measures are 
shown in table 2.2. 
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Setting and participants 
Three of the studies were undertaken in the United Kingdom (McEwan 1990; 
Vetter 1984; Vetter 1992), all of which recruited participants from general 
practice (family practice). One study was undertaken in The Netherlands (Van 
Rossum 1993), and recruited from a defined geographic area. One study was 
undertaken in the United States (Wagner 1994), and recruited from a health 
maintenance organisation. 
Response rates 
Response rates to the invitation to have a screening assessment in the three 
United Kingdom based studies were all high (McEwan 1990; Vetter 1984; 
Vetter 1992). All three trials recruited participants from general practice. In the 
trial by van Rossum et al (1993), the initial response rate (people agreeing to 
take part in the study) was quite high at 76.5%. A sample was then drawn 
from all those eligible people who had agreed to participate, sampling 580 
people from 1036. The method of sampling was unclear, but it was 
undertaken prior to randomisation. The response rate in the trial by Wagner et 
al (1994) was noticeably low. This was largely due to over 40% of the eligible 
participants not responding to the invitation to talýe part, and a further 13% 
actively refusing. Lower response rates in United States based trials 
compared with European based trials is a consistent feature of trials of 
multidimensional assessment of older people. 12 A response rate as low as 
35% raises questions about the generalisability of the trial findings, because 
participants are likely to be a selective group. 
Interventions 
In all trials visual screening was undertaken as part of a broader assessment 
of health and functioning. In the trial by Wagner et al (1994), the assessments 
were undertaken at a clinic. In the remaining trials the assessments were 
undertaken in participants' homes. All five trials used questions about vision 
for the screening assessment. They did not measure vision. In the trials by 
Vetter et al (1984 and 1992), the questions about vision were part of a semi- 
structured interview. Assessments in all trials were undertaken by specially 
trained nurses or health visitors. 
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Outcome measures 
All five trials used questions about vision to assess visual outcome. In Wagner 
1994-, visual outcome was assessed as part of a postal questionnaire. In the 
remaining trials the outcome assessment was by face to face interview. 
Length of follow up ranged from two to four years. 
Methodological quality 
1. Concealment of allocation. 
All five trials were gr. 1ded adequate (A). Descriptions of the randomisation 
process were obtained for all five trials. Randomisation was undertaken 
centrally in all trials using random number tables or random number 
generators. 
2. Aftrition bias. 
Because of the ages of the trial participants, there was a high mortality rate in 
most of the trials. However, loss to follow-up was low in all trials. Follow up 
rates were similar between the comparison groups in all the trials, and all five 
were graded adequate (A). 
3. Intention to treat analysis. 
All five trials were analysed by intention to treat, and were graded adequate 
(A). 
4. Masking of outcome assessment. 
The trial participants would clearly have been aware of whether they had 
received a screening assessment. Thus, in spite of attempts to mask the 
outcome assessors, which arm of the trial participants were in could have 
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emerged during the face to face outcome assessments. This phenomena was 
noted to a small degree in Vetter 1984 and Vetter 1992. Predicting that this 
phenomena was likely, such masking was considered impossible in McEwan 
1990. In Van Rossurn 1993, outcome assessors were masked as far as 
possible. Postal questionnaires to participants were used to assess outcomes 
in Wagner 1994. 
Effects of screening 
The results in all five trials were very similar (figure 2.1 and table 2-3). There 
was no evidence of heterogeneity of effect between the five trials (Q=0.87, 
degrees of freedom=4, P=0.93). The pooled risk ratio for self-reported visual 
problems at the time of outcome assessment comparing the intervention and 
control groups was 1.03 (95% confidence interval 0.92 to 1.16, P=0.57). The 
pooled odds ratio was 1.04 (95% confidence interval 0.89 to 1.22, P=0.63). 
The trials were similar in all the aspects identified a priori as possible effect 
modifiers (visual assessment method used for screening, visual outcome 
used, whether visual screening was undertaken as part of a wider screening 
assessment, and trial quality). Therefore no sensitivity analyses were 
performed. 
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Figure 2.1 Relative risk of visual impairment at end of trial periods: individual 
studies and pooled estimate. 
(The shaded squares and horizontal lines correspond to the studies' risk ratios and 95% confidence 
intervals. The area of the shaded squares reflects the weight each study contributes to the analysis, 
given by the reciprocal of the square of the standard error of the risk ratio. The diamond represents the 
combined relative risk with its 95% confidence interval. The solid vertical line corresponds to no effect. 
The dashed vertical line corresponds to the combined relative risk. ) 
Trial Risk ratio 
(95% confldence Interval) 
Vetter 19841'9 (UK) 1.06 (0.88 to 1.28) 
McEwan 1990145 (UK) 
Vetter 1992149 (UK) 
van Rossum 1993 150 (Netherlands) 
Wagner 1994152 (USA) 
Pooled estimate 
1.04 (0.59 to 1.83) 
0.95 (0.73 to 1.25) 
1.09 (0.87 to 1.36) 
0.97 (0.74 to 1.28) 
1.03 (0.92 to 1.16) P--0-57 
Test for heterogeneity: Q=0.87,4df 
(p= 0.93) 
Table 2.3 Relative risk of visual impairment at end of trial periods: individual 
study and pooled estimates 
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2.5 Discussion 
The evidence from randomised controlled trials undertaken to date does not 
currently support the inclusion of questions about vision in regular 
multidimensional assessment programmes for unselected older people in a 
community setting. Although a reduction of 8% in the number of older people 
with visual impairment cannot be excluded, even this figure is disappointingly 
low. Visual impairment is common among older people, is frequently 
unreported, and is associated with a variety of adverse factors. Quick accurate 
screening tools exist and effective interventions exist for symptomatic patients. 
In light of this, the lack of improvement seen in these trials is somewhat 
surprising. It is of course possible that screening older people for visual 
impairment is an ineffective intervention. However, before coming to this firm 
conclusion, it is worth considering possible explanatory factors within the trials 
carried out to date. 
A number of factors can be identified that may have contributed to the 
observed lack of effect on visual impairment. Firstly, a screening procedure 
alone would not be expected to lead to improvements in vision. Such 
improvements would be dependent on the subsequent interventions to 
improve vision. In four of the triaIS139; 145; 149; 150 those reporting visual problems 
were given advice and referred to either an optician or to their general 
practitioner. In the other trial' 52 those reporting problems received information 
about resources in the community designed to assist those with poor vision. 
Information about whether participants attended these referrals, the diagnoses 
made, and interventions offered and accepted was not available. It is therefore 
possible that the management of those people found to have a visual problem 
was inadequate. 
Secondly, the use of questions about vision both for the initial screening 
assessment and for the outcome assessment may have affected the results. 
Questions about vision have a low sensitivity and to a lesser extent a low 
specificity for detecting visual impairment when compared to formal acuity 
26 
testing. None of the trials used any kind of chart to measure vision either for 
the baseline screen or as an outcome measure. 
A third possible factor is that visual function was not measured as an outcome 
in any of the trials. Visual function indices provide a measure of the impact of 
visual problems on a person's life. Interventions such as home lighting and 
visual rehabilitation may improve a person's vision related quality of life, but 
have-no effect on distance visual acuity. ' 54 In recent years the value of visual 
function indices in assessing the effectiveness of interventions to improve 
vision has become widely accepted. 48; 155 
Finally, the visual assessment was only one component of the screening 
package in all five trials, and it is possible that visual screening performed in 
isolation may have produced a greater effect. This hypothesis was previously 
suggested as an explanation of the lack of effectiveness of screening for 
visual impairment seen in a trial of a multidimensional screening assessment 
87; 156 
among middle aged men. The general practitioners in this study felt 
swamped by the number of abnormal findings, and visual impairment was not 
usually considered a high priority. 
This systematic review indicated the need for a large randomised trial of 
screening older people for visual impairment as part of a multidimensional 
screening assessment which overcomes the limitations of the trials to date. 
Specifically this trial should: 
have a clear plan of intervention for those people found to have visual 
impairment; 
use a formal assessment of visual acuity for the initial screening and 
outcome assessment; 
* measure visual function as an additional outcome measure. 
The proposal described below is for a trial that takes all these issues into 
account. 
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CHAPTER 3. SCREENING OLDER PEOPLE FOR IMPAIRED 
VISION: TRIAL DESIGN 
3.1 Background 
The IVIRC Trial of the Assessment and Management of Older People-in 
the Communitv 
Overview 
The initial randomisation and the interventions being assessed in this study 
had already occurred as part of the MRC Trial of the Assessment and 
Management of Older People in the Community. This is a large randomised 
controlled trial taking place in 106 general practices recruited from the MRC 
General Practice Research Framework. Practices are representative of the 
United Kingdom population as assessed by deprivation (as measured by the 
Jarman score' 57) and mortality rates (Standardised Mortality Rates). Appendix 
3 gives more details of the study which is described in more detail 
elsewhere. '"" In brief, the aim of the study is to determine the optimum 
methods of identifying disease and need in people aged 75 years and over 
within primary care (as required by the GP contract). The study encompasses 
a wide range of health problems among older people; that is, it is a 
multidimensional model of screening. Practices were randomised to several 
methods of assessment and management of older people. This trial will 
provide information on the overall effectiveness of different models of 
multidimensional screening. It also offers a unique opportunity specifically to 
determine the effectiveness of screening for visual impairment as part of a 
broader screening package. This trial will overcome the design problems 
identified with previous trials. Specifically this will be the first trial to use formal 
visual acuity testing and to have a clear plan of intervention for those people 
found to have visual problems. 
Randomisation 
In the MRC Trial of the Assessment and Management of Older People in the 
Community, practices were randomly allocated as follows: 
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(A) brief assessment by questionnaire followed by a detailed assessment, 
including visual acuity, only if indicated (the control group for this study) - the 
targeted screening group 
(B) brief assessment by questionnaire followed by a detailed assessment 
including visual acuity for all patients (the intervention group for this study) - 
the universal screening group 
Randomisation in the MRC Elderly Screening Trial was by practice. It was felt 
that individual randomisation would produce practical difficulties within the 
practices and may introduce bias (see discussion of cluster trials below). 
Randomisation by practice ensured that everyone in the same practice was 
offered the same model of screening, thus reducing the scope for 
contamination bias. A computer generated randomisation list, stratified by 
Jarman and SIVIR tertile, was drawn up by the statistician and practices were 
randomly allocated centrally at the London School of Hygiene and Tropical 
Medicine as they were recruited to the trial. Because of the nature of the 
intervention, it was not possible to blind participants or researchers to the 
group assignment. Randomisation was undertaken by computer, with 
stratification on the key factors (Jarman score and mortality rates) which may 
influence the outcome measures. 
The basic design of the trial and visual assessments undertaken at baseline 
are shown in figure 3.1. 
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All patients aged 75 and over in 106 
general practices 
(excluding those In long-term care or 
with terminal disease) 
Randomised 
Targeted 
53 general practices 
Brief assessment Including self 
reported difficulty seeing 
Targeted 
Selected participants offered 
detailed assessment Including 
visual acuity assessment 
Universal 
53 general practices 
Brief assessment Including 
self reported difficulty seeing 
Universal 
All participants offered 
detailed assessment Including 
visual acuity assessment 
Figure 3.1 Design and vision screening at baseline in the MRC Trial of the 
Assessment and Management of Elderly People in the Community 
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The intervention 
In the brief assessment, as one of the 35 questions about their health, 
participants were asked the following question on vision: "Do you have 
difficulty seeing newsprint, even if you are wearing glasses? ". Possible 
answers were "No difficulty", "A little difficulty" and "A lot of difficulty". This 
question is one of the ten items in the Organisation for Economic Co-operation 
and Development long term disability minimum core set, 159 and was 
recommended as a brief screening too] by the Royal College of General 
Practitioners. 26 
In the targeted screening arm, criteria for triggering to the detailed assessment 
were three or more problems identified from the brief assessment or any one 
of four "serious" symptoms (unexpected weight loss, frequent falls in previous 
month, vomiting blood, coughing blood). In the universal screening arm, all 
participants had a detailed assessment. 
Visual acuity testing 
During the detailed assessment, the participants' distance visual acuity was 
measured at 3 metres using a Glasgow Acuity Chaft67 This chart was 
developed by researchers at Glasgow Caledonian University and is designed 
according to the same principles as the Bailie-Lovie chart. It measures the 
minimal angle of resolution on a logarithmic scale (logMAR). The use of the 
logMAR chart is discussed in more detail below. All nurses taking part in the 
study were given a detailed training session on how to assess vision using the 
chart, and were specifically instructed that participants be encouraged to try 
and read as many letters on each line as possible. Vision was measured at 
one metre if there was no three metre space available (for example in some 
participants' homes) or people were unable to read any letters at three metres. 
Referral criteria 
The nurses were asked to refer as follows: 
(1) For anyone with a pinhole vision of less than 6/18 in either eye (logMAR 
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score 0.5 or more), referral to an ophthalmologist was recommended, 
unless: 
- they had been seen by an ophthalmologist in the previous year; 
- they were registered blind or partially sidhted. 
(2) Anyone with presenting vision of less than 6/18 that improved with pinhole 
to better than 6/18 was advised to visit an optician. 
The referral criteria were an attempt to ensure that people referred were those 
likely to benefit from interventions (discussed in Chapter 9). 
Baseline data collection occurred between 1995 and 1999. Prior to 
commencing the assessments, the nurses and lay interviewers attended a 
training session (with the exception of a few practices that joined the study 
late in which case the training took place at the practice). The nurses involved 
in the study were mostly existing practice nurses involved in practice based 
research: some of the nurses devoted all their time to research activity. 
Ethical approval for all aspects of the study was obtained from relevant ethics 
commiffees. 
We undertook a nested trial within the MRC trial, specifically to examine the 
effectiveness of the visual acuity screening component of the study. 
Cluster randomised trials 
Cluster randomised controlled trials are trials in which the unit of allocation 
consists of clusters (such as whole communities, organisations or 
160-162 geographical areas) rather than individuals. A commonly used cluster 
unit is the primary care clinic (general practice). ' 63-173 
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Reasons to randomise clusters 
There are a number of reasons to randomise at the cluster rather than at the 
individual level, including: 
e The intervention occurs at a cluster level, for example a practice wide 
smoking cessation intervention. 
174 
It may be considered unethical or clinicians may feel uncomfortable about 
offering an intervention to some patients in a clinic while not offering the 
intervention to others, for example a new screening test. 175 
Risk of contamination between the allocation groups. Information, 
educational strategies or advice could easily be shared between individuals 
within a practice creating a clustering effect. 176 For example in a trial of 
safety advice at child health surveillance consultations, randomising 
families within the same practice could have led to some families in the 
control group being inadvertently exposed to elements of safety advice 
intervention. 171 Randomising at the level of the general practice aims to 
avoid this contamination between the randomised groups. 
All three of these reasons contributed to the decision to adopt a cluster design 
for the MRC Elderly Screening Trial and the nested trial of vision screening. 
Statistical considerations 
Individuals within the same cluster may be more similar than individuals 
selected from other practices i. e. observations may be correlated. 177 The 
intraclass correlation coefficient is a commonly used measure of the extent of 
the correlation between clusters. 178 Because correlated responses do not 
contain as much information as independent responses, within cluster 
correlation reduces the power of a trial and widens confidence intervals and 
increases P values of the results. Ignoring "intraclass correlation" will lead to 
studies that are too small to be useful and will underestimate the degree of 
random error in the effects observed. See description of analyses below. 
Repqrting of cluster randomised trials 
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Poor reporting of cluster trials is a recognised problem and attempts are being 
made to extend the CONSORT statementl 79 to include cluster trials. 180 
Reporting in this thesis follows these guidelines as much as possible. 
3.2 Screening older people for impaired vision: a nested trial 
within the MRC Trial of Assessment and Management of Older 
People in the Community 
Aims and oblectives 
To determine the effectiveness of mass screening for visual impairment in 
unselected older people (aged 75 or over) in a community setting as part of a 
multidimensional screening programme. A secondary aim is to assess barriers 
to treatment of visual impairment among older people. 
Plan of investiqation 
Overview 
The use of simple screening procedures (including a question about visual 
problems) with subsequent detailed assessment (including visual acuity 
testing) for those people found to have problems at the initial screen was 
recommended by the Royal College of General Practitioners in response to 
the introduction of the over 75 checks in 1990.26 This was the intervention 
used in arm (A) which therefore represented current "usual practice" at the 
time pf the study and formed an ideal control group. Baseline data from the 
MRC Elderly Screening Trial showed that on average less than 20% of the 
participants in group (A) had a formal test of visual acuity. Arm (B), in which all 
participants received a formal test of visual acuity, comprised the intervention 
group. 
We measured visual acuity, visual function (self-reported disability) and 
collected data about use of eye services on a sample of participants from 
each arm of the MRC Elderly Screening Study. 
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Practice recruitment and selection 
We planned to re-examine a minimum of 2000 participants from 20 practices 
within the main trial (see study power below). Ten practices were selected 
from each of the two arms (A) and (B) of the main trial. Full details of practice 
and participant recruitment and selection are given in Chapter 6. 
Inclusion criteria 
All people who were eligible for the baseline assessment in the MRC Trial of 
the Assessment and Management of Elderly People in the Community. This 
means all people who were aged 75 or over and registered with participating 
general practices at the time of the baseline assessments (1995 to 1998 
depending the practice concerned). 
Exclusion criteria 
The only people who were specifically excluded from the outcome 
assessment were people who were: too ill to participate (defined as it being 
likely that the person would have found it unpleasant or impossible to 
complete an assessment); had died; or had moved away from the practice 
area. People who were in long-term care or had terminal disease at the time 
of the baseline assessments were excluded from the MRC Elderly Screening 
Trial and were therefore not included as part of the nested vision screening 
trial. 
Outcome measures 
Primary 
There were two primary outcome measures. 
Visual acuity 
Impaired vision (defined as visual acuity less than 6/18) in one or both eyes. 
In developed countries interventions (such as cataract extraction) are 
undertaken on the basis of reduced acuity in one eye, even if the acuity is 
good in the other eye. The justification for the choice of primary outcome 
measure is that it directly measures the intervention which was aimed at 
impaired vision in either (or both) eyes. The primary outcome measures will 
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answer the primary research question: "does testing vision during 
multidimensional health assessment for persons over 75 lead to a significant 
reduction in the prevalence of visual impairment in those screened when 
corfipared to those given only a brief assessment during which a single 
question on visual difficulty is asked? " 
Visual function 
The composite (overall) score from the National Eye Institute Visual Function 
Questionnaire (25 item version). 
Secondary 
Visual acuity 
Binocular presenting impaired vision (defined as a visual acuity les than 
6/18). The binocular acuity measures functional "everyday" vision. 
Impaired vision (defined as visual acuity less than 6/18) in one or both 
eyes after pinhole correction. This is a measure of visual impairment 
that is unlikely to be due to refractive error. 
e Visual acuity less than 6/12 in one or both eyes. 
e Binocular presenting visual acuity of less than 6/12. 
Visual acuity less than 6/18 represents a considerable level of impairment. An 
acuity between 6/12 and 6/18 can itself represent substantial loss of vision, 
and interventions such as cataract extraction would be undertaken (in 
developed countries) at a visual acuity between 6/12 and 6/18. A binocular 
acuity of less than 6/12 is well below the United Kingdom driving 
requirements. It is therefore of some interest to see the effect of screening on 
milder levels of visual loss. 
In addition to the above binary outcomes, the mean logMAR acuity in the two 
groups will be compared as follows: 
e binocular presenting vision; 
* best eye acuity both with and without pinhole correction; 
* worse eye acuity both with and without pinhole correction. 
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Visual function 
Sub-scales of the National Eye Institute Visual Function Questionnaire (25 
item version) which measure specific areas of visual function. 
BarTiers to improving vision in olderpeople 
We also aimed to assess possible barriers to improving vision in older people. 
Notes on specific outcome measures 
(a) Visual acuity 
67 Visual acuity was measured at 3 metres with a Glasgow Acuity Chart. This 
chart was developed by researchers at Glasgow Caledonian University. The 
chart overcomes specific problems with the Snellen chart discussed in 
Chapter 1: it has the same number of letters on each line, and there is regular 
progression of the size of the letters as one moves up or down the chart. The 
Glasgow Acuity Chart measures vision on the logMAR scale. The logMAR 
score is the log (base 10) of the minimal angle of resolution of the letters read 
for that score. This chart was chosen because: 
* it applies modern scientific principles to the measurement of visual acuity; 
* the regular progression in letter size moving up or down the chart allows 
the modelling of visual acuity data on a continuous scale; 
9 it is relatively cheap; 
it is portable meaning the research nurses could use the chart on home 
visits; 
it was used for the baseline detailed assessments thus providing a 
repeated measure for a sample of participants. 
The chart is designed for use at 3 metres, or 1 metre for the measurement of 
very poor vision when people can see no letters correctly at 3 metres. The 
whole test can be performed at 1 metre if there are space restrictions. 67 
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The chart has previously been used in a large survey of visual acuity among 
older people in the United Kingdom. 38 
Appendix 12 shows the relationship between Snellen visual acuity and 
logMAR scores. 
(b) The pinhole test 
Visual acuity measured through a pinhole (for each eye separately) provides 
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an estimate of acuity corrected for any refractive error. In patients with 
reduced visual acuity, the pinhole test therefore usefully differentiates 
refractive visual failure from non-refractive. This facilitates a rational referral 
plan: to an optician for people with uncorrected or inadequately corrected 
refractive error, and to an ophthalmologist for people with reduced acuity not 
due to refractive error. 
(c) Visual function 
Visual acuity may not always correlate with visual functioning i. e. how well a 
person functions in everyday tasks which require vision. 
72-74 in recent years 
the value of visual function indices in assessing the effectiveness of 
interventions to improve vision has become widely accepted. 
48; 85; 1 55 A range of 
assessment tools have been developed to try and assess the impact of visual 
problems on level of functioning and quality of life. 85; 1 81-187 Scales that 
specifically assess visual problems are more sensitive to differences in vision 
related functional impairment better than generic health status scales. 76; 188; 189 
Two of the most widely recognised scales are the VF-141 82 and the National 
Eye-institute Visual Function Questionnaire. ' 83,184 
The VF-14 was developed and validated earlier' 
90-192 and has been widely 
used, 76; 92; 189; 193-200 notably in the assessment of cataract outcomes 
The NEI VFQ was developed in an attempt to overcome two perceived 
limitations in existing questionnaires: ' 134 
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e existing measures of visual function emphasised difficulty with tasks and 
symptoms rather than emphasising the influence of visual disability on other 
aspects of health related quality of life such as emotional well being or 
social function validation; 
41 the best validated measures (such as the VF-14) were designed for use 
among people with one specific eye disease: cataract in the case of the VF- 
14. 
The NEI VFQ has been validated and used 
76; 183; 184; 189; 195; 201 in a range of eye 
conditions and is now widely used for vision research in the United States. A 
shortened version consisting of 25 items (NEI VFQ-25) has recently been 
developed specifically for settings such as clinical trials where length of 
interview is a major consideration . 
202; 203 The NEI VFQ-25 has been shown to 
be reliable and valid across a range of eye conditionS202; 203 and in different 
populationS204and has been used in a number of studies . 
205-207 
Although the NEI VFQ appeared to be preferable as a visual function outcome 
measure, we could not identify any published reports of its use with older 
people in the United Kingdom. We therefore decided to pilot its use, 
specifically comparing it with the VF-14, a measure that that has been 
successfully used to assess visual function in older people in the United 
Kingdom. "' 
(d) Use of eye services 
Information was collected from people found to have visual impairment at the 
screening assessments on whether they had attended any eye services they 
were referred to, and whether they adhered to interventions or advice offered. 
Possible reasons for not taking up available services were elicited. For all 
people who had ever seen an ophthalmologist or who were eligible for referral 
to an ophthalmologist following the baseline assessment the research nurses 
undertook a search of medical records for any letters relating to vision. A 
structured data extraction form was used for obtaining data from the 
participants GP records. 
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Studv Power and sample size 
Power calculations for and analysis of controlled trials in which the unit of 
allocation is the individual assume that observations on individuals are 
independent. In a cluster trial this is not true: observations on individuals 
within the same cluster may be correlated. 177; 208; 209 Because correlated 
responses do not contain as much information as I, ndependent responses, 
within cluster correlation affects the power of a trial and the precision of the 
estimates of effect. Failure to take this intraclass correlation into account when 
planning a trial will lead to underpowered studies that are too small to provide 
useful estimates of the effects of interventions. 
The intraclass correlation coefficient 
The extent to which within cluster correlation increases the sample size 
required for a study is known as the design effect or inflation factor. The 
desi6n effect depends on the average cluster size (m) and the intraclass 
correlation coefficient (p), and is given by: 210 
design effect =1+ (m-1) p [11 
The design effect is the ratio of the variance of an estimator under cluster 
sampling to its variance under individual random sampling : 178 
02 b/ (CF 
2 
b+ a2 
where a2b is the between cluster component of the, variance and a2w is the 
within-cluster component of the variance. 
If the design effect is 4, then a cluster trial will require 4 times the number of 
individuals required by a simple randomized trial of individuals. When m=1, we 
have a simple randomized controlled trial with a design effect of 1. Similarly if 
there is no within cluster correlation, the between cluster variance will be zero, 
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the intraclass correlation coefficient will be zero and again the design effect 
will be 1. 
Statistical methods 
To calculate the intracluster correlation coefficients, the methods presented by 
Donner and Klar were used. 162 Formula 2 given above for p represents a 
hypothetical situation in which both clusters and individuals within clusters are 
drawn at random from a population. An estimate of p (pi) can be obtained by 
performing a one way analysis of variance (ANOVA) . 
21 1 This method is valid 
211; 212 for both binary and continuous outcomes: 
PI *ý (MSb - MSw)/ (MSb + (M - 1) MSw) [3] 
where MSb and MS,, are the mean squares from the ANOVA table for 
between and within clusters and again m is the average size of the cluster. 
Because the size of each cluster varied, we substituted mo for M: 
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mo = (1 / (k-1))(n _ (,: Mj2 /n)) 
where n is the total sample size, k is the number of clusters, and mj is the 
cluster size in the "jth" cluster with j ranging from 1 to k. 
The intracluster correlation coefficients were used to calculate required 
sample sizes using previously presented methodS. 210; 214; 21 5 The Acluster 
216 statistical software package was used for the sample size calculations. 
Sample size calculation 
From the baseline data available, the prevalence of visual acuity<6/18 in one 
or both eyes was 32%, with an intracluster correlation coefficient of 0.022. 
The baseline prevalence of binocular visual acuity <6/18 among participants in 
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the universal screening practices was 12% with an intracluster correlation 
coefficient of 0.0 18. 
Reidy et al in their recent paper on visual impairment among older people 
estimated that as much as 70% of the visual impairment could be improved by 
interventions, mostly spectacles or cataract surgery. 35 We planned sufficient 
power (80%) significant at the 5% level to detect a 30% reduction in the 
prevalence of visual impairment in one or both eyes (from 32% to 22%), and a 
50% reduction in the prevalence of binocular visual impairment overall (from 
12% to 6%). 
Inviting an average of 150 patients from 20 practices (anticipating a minimum 
66% response) would deliver that power. An total of 2000 participants would 
need to be examined. 
Referral criteria 
The referral criteria used were identical to those used for the baseline 
assessments. 
The nurses were asked to refer as follows: 
1. For anyone with a pinhole vision of less than 6/18 in either eye (logMAR 
score 0.5 or more), referral to an ophthalmologist was recommended, 
unless: 
they had been seen by an ophthalmologist in the previous year; 
they were registered blind or partially sighted. 
2. Anyone with presenting vision of less than 6/18 that improved with pinhole 
to better than 6/18 was advised to visit an optician. 
The letter the nurses used to communicate their findings to the general 
Practitioners is included as appendix 10. 
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Impaired vision and drivinq 
A question about current driving habits is included in both the National Eye 
Institute Visual Function Questionnaire and in the VF-14. It was therefore 
possible that when the research nurses measured visual acuity, they would 
discover some participants who were driving but whose vision was below the 
currently recommended level for fitness to drive. 
We took advice on this issue from the Medical Unit of the Driver and Vehicle 
Licensing Agency (DVLA). The current United Kingdom guidelines for fitness 
to drive state: 34 
[drivers must be able to] "read in good light (with the aid of glasses or contact 
lenses if worn) a registration mark fixed to a motor vehicle and containing 
letters and figures 79.4 millimetres high at a distance of 20.5 metres. In 
practice this corresponds to between 619 and 6112 on the Snellen chart". 
The DVLA advice was to use a cut off point of a binocular logMAR score of 
0.4 or more, the equivalent of a Snellen visual acuity of 6/15 or worse. 
If the patient scored 0.4 or more when testing both eyes together and had 
answered that they currently drove, the nurses were instructed to take the 
following steps: 
tell the patient their vision may fall below the level required by law for 
driving; 
tell the patient it is their responsibility to inform the Driver and Vehicle 
Licensing Agency if your findings are confirmed by an optician, 
ophthalmologist or their GP. The address of the DVLA is given in the 
information leaflet; 
advise the patient not to drive until they have had their eyes checked by an 
6-ptician, their GP or an ophthalmologist; 
tell the patient that it is their responsibility not to drive; 
tell the patient that you are informing the GP of your findings; 
9 refer the patient to their GP using the standard notification letter; 
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* advise the patient it may be helpful for them to see an optician; 
4P give the patient the specially designed information leaflet. 
3.3 Plan of analysis 
Data cleaninq 
Categorical variables were tabulated and continuous variables displayed 
graphically to assess the distributions and check for outliers. All missing 
values were identified. For all outliers and missing values the original data 
collection forms were reviewed to check the accuracy of the data entry. 
Approaches to the analysis 
The unit of analysis 
In this study the primary target of inference was the individual participant: the 
intervention was aimed at improving the vision of individual people. The 
choice of practice as the unit of randomisation was largely made for ethical 
and logistical reasons. Therefore individual level analyses (taking clustering 
effects into account in the generation of standard errors and P values) were 
und&rtaken and used as the primary method of assessing the trial outcomes. 
Thus the analysis was dictated by the primary research question of intereSt. 217 
The need to take clustering into account 
Individuals within the same practice (cluster) may be more similar to each 
other than to individuals in other practices, and thus observations on 
individuals within a cluster may be correlated. The between cluster variation is 
in addition to the between individual variation seen in non-cluster trials. Failure 
to take the clustering effect into account is likely to lead to spuriously low P 
values and narrow confidence intervals and produce misleading results. All 
analyses arising from this trial therefore took the clustering effect into account. 
Small numbers of clusters per group 
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The fact there were only 10 practices (clusters) in each arm of the trial limited 
the complexity of the analyses undertaken. This is because more complex 
models require reasonable estimates of the between cluster correlation 
structure as a basis, and the estimates available from only 10 clusters per trial 
arm are likely to be inadequate. Although it is of course quite possible to fit 
such models, there is empirical evidence that these models can lead to 
misleading conclusions when the number of clusters is not large (generally 
greater than 20 - 40 per intervention group). 
160; 162; 218; 21 9 The following 
approaches were considered and rejected as likely to produce misleading or 
invalid results: 
9 Ratio estimator and parametric modelling of proportions; 162 
Generalised estimating equations '220 mixed effect linear regression 
221 
and 
multilevel models. 
222 
Intention to treat 
"Intention to treat" is a strategy for the analysis of randomised controlled trials 
that compares patients in the groups to which they were originally randomly 
assigned. The intention to treat approach aims to gives a pragmatic estimate 
of the benefit of a change in treatment policy rather than of potential benefit in 
participants who receive treatment exactly as planned. 223 Full application of 
intention to treat is possible only when complete outcome data are available 
for all randomised subjects. 224; 225 Clearly not all eligible individuals in 
randomised practices in this trial were likely to complete an outcome 
assessment. However, as discussed in the revised CONSORT statement, the 
key principle is that practices and individuals are analysed in the allocation 
group to which they were randomised . 
179 For this trial, this meant that the 
analysis included all participants with outcome data available, regardless of 
whether they actually had a screening assessment at baseline. 
As an additional exploratory measure, a per protocol analysis was performed 
to assess the efficacy of the different screening strategies among participants 
who adhered completely to the intervention. Such a per protocol analysis was 
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intended to help explain the effects observed, not in any way replace the 
intention to treat analysis as the trial outcome. 
Analytical methods used 
The main . analyses were undertaken using the 
"survey" commands in 
Stata. 136; 226 The survey commands were specifically designed for the analysis 
of complex survey data. The number of clusters are taken into account in the 
degrees of freedom utilised for all significancp tests . 
227; 228 All variance 
estimators are multiplied by a correction factor derived from both the number 
of individual observations and the number of clusters. A key feature of the 
survey commands is their ability to produce proper variance estimates for 
subpopulations, using the data structure of the subpopulation to correct 
variance estimates rather than utilising the corrections based on the whole 
dataset. 
When deriving "survey" regression models, point estimates for coefficients are 
made using a weighted maximum likelihood estimator. The point estimates 
are identical to non-clustered estimates (as they intuitively should be). 
However, the weighted likelihood used is not the distribution function for the 
clustered data, and is therefore called a psuedo-likelihood . 
229 The main 
consequence of this is that likelihood ratio tests for the comparisons of 
regression models are not valid. Individual Wald tests for coefficients are 
however valid. Fortunately in the analysis of a randomised trial, each model 
employed has a single outcome of interest and a single key explanatory factor 
- the allocated intervention group. The focus of the analysis is on the effect of 
group allocation on the outcome being modelled. This means that the inability 
to test different models against one another using likelihood ratio tests is of 
little importance. 
Software 
All analyses were carried out using Stata"' unless otherwise stated. The 
World Health Organisation recently developed a software package called 
Acluster . 
21 6Acluster can be used to undertake the adjusted chi-squared and t- 
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test analyses described above, but does not have the power of Stata to 
undertake more complex modelling. The main unadjusted analyses were 
repeated in Acluster as a method of checking the validity of the analyses 
undertaken in Stata. 
Visual acuity 
Initially the adjusted chi-squared approach based on a computation of 
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clustering correction factors for each group was used for binary outcomes. 
It is important to note that this approach cannot take into account any effect of 
the variable time period between the screening intervention and the outcome 
assessment. The clustering correction factors are essentially the observed 
design effect, measures of the inflation in variance due to the clustered 
design. This approach has been previously used in a range of cluster trials. 231- 
233 
Regression modelling to assess confounding factors and effect modification 
was then undertaken using logistic regression, modelling the odds ratio for the 
outcome. 
The logMAR scores as continuous measures were modelled as described 
below for the visual function scores. 
Visual function 
The visual function outcome, both the composite score and the sub-scale 
scores, are continuous outcomes on a scale of 1 to 100. In the initial simple 
analyses, a similar approach to the adjustment described above can be 
adopted to adjust the two sample t test. 162; 234The West assumes that the 
cluster specific rates are normally distributed and have equal variances. 
Extensive simulation research has shown that the West is remarkably robust 
to these assumptions being violated . 
177; 235 The Mest is particularly robust 
when there are equal numbers of clusters in each allocation group, as there 
are in this particular trial. In addition there is evidence to support the use of the 
Mest applied to cluster specific rates in trials with as few as three clusters per 
inte'Nention group. 177; 236 
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Multiple regression of the mean scores by group will then be undertaken 
taking the cluster design into account by using the survey commands in Stata 
as described above. 
Potential confoundinq factors 
The baseline characteristics of the two randomised groups were compared 
with regard to age and sex. Level of self reported visual problems could be 
expected to influence the effectiveness of screening for visual problems, either 
because people perceiving themselves to have a problem may already havý. 
sought treatment, or because they may be more likely to accept 
recommendations for treatment they had not already obtained. Therefore the 
levels of self reported visual problems in the two randomised groups were also 
compared. 
Time period between baseline screen and outcome assessment was also 
considered as a potential confounding factor: discussed in more detail below. 
In the simple analyses, potential confounding effects could not be assessed. 
In the logistic regression of binary outcomes and multiple regression of 
continuous outcomes, exploration of possible confounding effects on the 
primary trial outcomes was undertaken. The analysis of the primary outcome 
was repeated while controlling for the potential confounding factor. The 
unadjusted and adjusted estimates were compared to assess the degree of 
confounding. If controlling for one or more co-variates substantially affected 
the effect estimate, then the adjusted estimate would be reported as the main 
outcome measure. 
Effect modification 
The trial was not designed to have adequate power to assess the 
effectiveness of screening for visual impairment in specific sub-groups. The 
48 
analysis of possible effect modifiers can however usefully inform attempts to 
explain the effects or lack of effects of screening seen in a trial. Such analyses 
were therefore planned as a hypothesis generating approach, not hypothesis 
testing. For example, if the analysis demonstrated that screening was more 
effective among people who were socially isolated, this could usefully point 
towards further research into unidentified visual problems and access to eye 
services among this group. However, it would be wrong to conclude on the 
basis of such exploratory analyses that screening could be recommended for 
one sub-group but not another. 237 
The following possible effect modifiers were considered: 
(a), Age 
The prevalence of visual impairment increase with increasing age. In addition 
the causes of visual impairment vary with age, in particular with macular 
degeneration increasing in importance among older age groups. Access to 
eye services may also be influenced by age. It is therefore quite plausible that 
the effects of screening could vary by age. 
(b) Gender 
Even when the effects of age are controlled for, women are at a greater risk of 
visual impairment than men . 
38; 238AIthough not soecifically known for vision 
interventions, there is some evidence that gender is associated with 
adherence to recommendations arising from community-based screening 
programmes for older people, although the pattern of the association is 
inconsistent. 122 
(c) Social isolation 
People who are socially isolated may be at greater risk of not accessing the 
eye health services they need and therefore could potentially gain greater 
benefit from screening. A question about social isolation was included in the 
baseline brief screening questionnaire. 
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In the baseline brief screening assessment, participants were asked the 
following question: "Do you see friends, neighbours or relatives (other than 
those you live with)? " Possible answers were "Daily", "2-3 times per week", 
"Less than twice per week" and "Rarely". The effectiveness of screening was 
assessed separately for participants who reported seeing other people rarely 
or less than twice per week and for participants who reported seeing other 
people twice a week or more. 
(d) Self reported visual difficulties at the baseline assessment 
Questions about visual problems are not a sensitive measure of detecting 
visual impairment. 134 However, people who perceive themselves to have 
problems with their eyesight may well respond differently to recommendations 
to see an optician or ophthalmologist following screening. 
In the baseline brief screening assessment, participants were asked the 
following question on vision: "Do you have difficulty seeing newsprint, even if 
you are wearing glasses". Possible answers were "No difficulty", "A little 
difficulty" and "A lot of difficulty". The effectiveness of screening was assessed 
separately for people reporting a lot of difficulty and for people reporting no or 
a little difficulty. 
(e) Time period between baseline screen and outcome assessment 
This is considered in the section below. 
Time period from screening intervention to outcome 
The time period from screening to outcome assessment could have an effect 
on the outcome of the screening. For example, if the period was very long, it is 
possible a person could initially have gained some improvement in vision as a 
result of an intervention following screening, but have subsequently worsened 
or developed a new cause for visual impairment. Alternatively, a short period 
between screening and outcome assessment could mean someone was still 
waiting for an intervention to improve their vision, such as cataract surgery. If 
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the time period from screening to outcome assessment varied by randomised 
group, then it could potentially confound the effect of screening. In addition, it 
is possible that time period from screening to outcome assessment could be 
an effect modifier, with the effectiveness of screening varying according to the 
follow-up period. 
Analysis of follow-up time 
In the logistic regression of binary outcomes and multiple regression of 
continuous outcomes, the time period of follow-up was considered as a 
potential confounding factor. 
Time period from screening to follow-up was also considered as a potential 
effect modifier. To maximise power to detect any effect modification, 
participants were divided into two strata above and below the median time 
period of follow-up. 
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CHAPTER 4. PILOT STUDY 
Rationale and oboectives 
Although the National Eye Institute Visual Function Questionnaire 183; 184 (NEI 
VFQ) is widely used in the United States, we could not identify any published 
reports of its use with older people in the United Kingdom. We therefore 
decided to pilot its use, specifically by comparing it with an earlier and shorter 
visual function questionnaire, the VF-14,1 82 that has been used to assess 
visual function in older people in the United Kingdom. ' 93 
The visual acuity testing procedure in the outcome assessments of the nested 
visual screening trial was planned to be identical to the procedure used in the 
baseline assessment. We therefore decided that the visual acuity testing did 
not need to be part of the pilot study. 
The objectives of the pilot were therefore to: 
* Assess the acceptability and ease of use of the National Eye Institute 
Visual Function Questionnaire compared to the VF-14 questionnaire in 
older people in the United Kingdom. 
* To assess the use of "flashcards" in the administration of the visual 
function questionnaires (appendix 9). 
Assess the acceptability and clarity of the: invitation letters; patient 
information leaflets; consent forms and the questionnaire about use of eye 
services. 
" Assess the ease of use of the data extraction forms by the research nurse 
to extract data about contact with eye services form participants' notes. 
" Provide an estimate of how long the assessments take to complete. 
Practice and nurse selection 
The Leatherhead practice was included in the MRC Elderly Screening Trial. 
However the practice was unable to take part in the nested visual screening 
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trial because of the retirement of the research nurse. The research nurse was 
however happy to undertake a pilot study of the questionnaire. 
Ethical approval 
Ethical approval for the pilot study was obtained from the East Surrey Local 
Research Ethics Committee in early February 2000. 
Traininq 
Training of the research nurse for the pilot study was undertaken by Martine 
Donoghue and myself at the Leatherhead practice. Martine Donoghue is a 
research fellow in the Epidemiology Unit at the London School of Hygiene and 
Tropical Medicine and has extensive experience in the training and conduct of 
interviews in the area of vision research. 
The research nurse was sent the questionnaires one week before the training 
day for comments. On the training day the nurse had a two hour training 
session with both trainers. She then undertook a full assessment with a 
participant who previously agreed to help on the training day. I observed the 
assessment. Immediately following the assessment the views of the 
participant were obtained verbally. There was then a full discussion between 
the trainers and the research nurse. 
Methods 
Participants were selected by the research nurse based on the results of the 
baseline assessments (see below for details). The nurse recruited the 
participants by invitation letter: a patient information sheet was included. The 
assessments could take place either in the general practice surgery or in the 
participants' homes - the location was decided by discussion between the 
research nurse and the participant. 
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Results and conclusions 
The research nurse saw 16 people during the second half of February 2000. 
All participants were aged over 75 years and were categorised as follows: 
e found to have visual impairment at the baseline screening assessment that 
improved with use of a pin-hole occluder: therefore advised to see an 
optician (5 people); 
e found to have visual impairment at the baseline screening assessment with 
no pinhole improvement: therefore referred to an ophthalmologist. This 
group included two people with known severe visual impairment, both of 
who were registered as partially sighted (total 5 people); 
found to have no visual impairment at the baseline screening assessment 
(4 people); 
* did not attend the baseline assessment (2 peop'le). 
The response rate for those asked was high with only one refusal. However 
the sample was purposefully selected by the nurse as likely to be willing to be 
involved in the pilot study. 
The VF-14 was used in eight of the interviews and the NEI VFQ was used in 
the other eight. The two different questionnaires were used in around half the 
people in each of the four groups above. 
The median age of participants who completed the VF-14 was 84 years 
(range 81 to 95). The median age of participants who completed the NEI VFQ 
was 89 years (range 79 to 91). 
Twelve interviews were undertaken in the general practice and four in 
participants' homes. The nurse reported that the location made no substantial 
difference to carrying out the assessments. 
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The mean time taken to complete the assessment was 24.3 minutes (range 
20 to 35) for the eight assessments that included ýhe VF-14 and 26.4 minutes 
(range 20 to 35) for the eight that included the NEI VFQ. 
Several amendments were made to the questionnaire as a result of 
discussions during the training day. Comments made by participants and the 
research nurse about the questionnaires, the invitation letter and the consent 
form led to amendments. Other than formatting to improve clarity, no changes 
were made to the standard questionnaires (the VF-14 and NEI VFQ). 
Following the amendments, participants found both interviews acceptable and 
could understand all the questions. 
The research nurse expressed a slight preference in terms of ease of use for 
the VF-14. However she had no difficulties using the NEI VFQ and felt that it 
was as acceptable to and as easily understood by participants as the VF-14. 
The use of "flashcards" was successful: they helped both the research nurse 
and participants. We therefore decided that use of the National Eye Institute 
Visual Function Questionnaire with "flashcards" was feasible in the study. 
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CHAPTERS. TRIAL EXECUTION 
5.1 Ethical approval 
I 
The nested trial was approved by the Trial Steering Committee of the MRC 
Trial of Assessment and Management of Elderly People in the Community in 
February 1999 (when funding was applied for). Ethical approval was obtained 
from Trent Multi-Centre Ethics Committee in December 1999. Approval from 
the 19 Local Research Ethics Committees that cover the 20 practices included 
in the trial was obtained between December and April 2000. 
5.2 Recruitment and sampling of practices and participants 
Practice recruitment and samplinq 
For practical reasons only practices with at least 150 people eligible for 
inclusion at baseline and who were thought likely to be able to complete 
another study were invited to participate in the nested vision screening trial. 
Seventy three practices (out of 106 in the main trial) were invited to participate 
by letter. Forty practices agreed to participate in the nested vision screening 
trial. The overwhelming reason for not wanting to participate was that the 
practices thought that the research nurses in the practice would not havý- 
sufficient time to undertake the assessments (stated by 28 practices of 31 
giving any reason for not participating). Two practices gave no reason for not 
wanting to participate. 
Among the 40 practices that agreed to participate in the nested vision 
screening trial, 19 were in the targeted screening arm and 21 were in the 
universal screening arm of the main trial. The practices in the two groups were 
of similar size (mean 414 eligible people in the Universal screening arm and 
422 in the targeted arm). For the main Elderly Screening Trial, randomisation 
of practices to universal or targeted screening Was stratified by SIVIR levels 
and -Jarman scores in tertiles (see description above). As expected therefore, 
the distributions of SIVIR levels and Jarman scores were similar for practices in 
the two groups. 
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Because of the similarity of the two groups of practices that agreed to 
participate, random sampling of practices from each group without further 
stratification was undertaken. The uniform set of commands within Stata were 
used to randomly select 10 practices from each arm. 136 Six weeks after 
selection, prior to any data collection, one of the practices in the universal 
screening arm withdrew because their research nurse left the practice. A 
further practice was therefore randomly sampled from the nine remaining 
practices in the universal screening arm that had agreed to participate. 
Comparison of practices included in the nested viSlon trial with 
practices not included 
The practices included in the MRC Elderly Screening Trial were selected to be 
representative of the population of Great Britain. It was therefore useful to 
establish whether the 20 practices included in the nested trial were similar to 
the 86 practices not included. Table 5.1 presents comparisons between the 
practices included and those not included. 
The table shows that practices selected for inclusion in the nested vision 
screening trial did not differ substantially from the remaining practices in the 
WG Elderly Screening Trial in terms of size, mortality experience or Jarman 
deprivation score. 
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Characteristic Included (20 Not included (86 
pr ctices) practices) 
Mean number of eligible participants 402 405 P=O. # 
SMR tertile (number and %) 
Low 7 (3 5%) 26(30%) 
Medium 4(20%) 31(36%) 
High 9(45%) 29(34%) P=0.38* 
Jarman tertile (number and O/o) 
Low 5(25%) 30 (35%) 
Medium 7(35%) 26(30%) 
High 8(40%) 30(35%) P--0.70* 
P value from t test comparing means 
P value from chi squared test for difference in distribution of characteristics by group 
Table 5.1 Comparison of practices included in the nested vision screening trial 
and those not included 
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Participant samplinq- 
The power calculation indicated we needed to obtain outcome data on an 
average of 100 people in the 20 practices. Assuming a 66% response rate, for 
each practice we would need to invite around 150 people thought to still be 
alive and still registered with the general practice. From the data available in 
the main MRC Elderly Screening Trial, it was estimated that around 30% of 
participants at baseline would have died or moved away by the time invitations 
for vision outcome assessments would be sent. We therefore randomly 
sampled 220 participants from the list of those eligible for a baseline 
assessment in each of the 20 practices. Again, the unifonn set of commands 
within Stata were used. 
Two practices had less than 220 people eligible for the baseline assessment. 
In both practices, all people eligible for a baseline assessment were included: 
170 in one practice and 210 in the other. Both these practices were in the 
universal screening group. The final sample therefore included 2140 people in 
the universal screening arm and 2200 people in the targeted screening arm of 
the trial. Baseline characteristics of the participating practices and people are 
described in Chapter 6. 
5.2 Study procedure 
Invitations 
All patients sampled and who were alive and still registered with the practice 
were invited by letter to take part in the study (appendix 5). An information 
leaflet about the study was enclosed (appendix 6). Patients were asked to 
bring any glasses currently worn. 
Unless they stated that they did not wish to take part in the study, participants 
were either telephoned or written to (at an address verified as correct) at least 
three times before non-response was recorded. 
The assessment 
Written consent was obtained using a standard consent form (appendix 7). 
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The assessment was undertaken at the general practice unless the participant 
was housebound or a home visit meant someone could be seen who would 
otherwise would not have completed an assessment. The assessment 
schedule (appendix 8) was in four sections as follows: 
Section 1: basic data and a repeat of the vision data collected at baseline 
Section 2: visual function questionnaire 
Section 3: use of eye services 
Section 4: visual acuity 
Eligible participants were advised to see an optician by the research nurse. A 
recommendation that the GP refer the patient to an ophthalmologist was 
included in the GP information letter as appropriate. 
The procedure for people who were current drivers and whose visual acuity 
appeared to fall below the recommended level is described in detail in Chapter 
3. 
Data extraction 
A data extraction form was completed for all participants who: 
1. Reported ever having seen an ophthalmologist. 
2. Were eligible for referral to an ophthalmologist following the baseline 
assessment of the MRC Elderly Screening Trial. 
The nurses examined the GP notes and identified all letters which related to 
eye problems or dealt with referrals to or from any eye specialist. 
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Record keepinq 
Research nurses were issued with logsheets for record keeping. Completed 
assessment schedules, consent forms and data extraction forms were 
returned to the London School of Hygiene and Tropical Medicine every month. 
Data entrv 
Data from the assessment schedules was double entered by a data entry 
consultancy company. A 5% sample of records was verified by the 
investigators. Data from the data extraction forms was coded and entered at 
the London School of Hygiene and Tropical Medicine. 
5.3 Nurse training 
A training day was held in London for all research nurses. Twenty four (from a 
total of 28 in the 20 practices) attended. Two of the remaining four nurses 
were trained at a second training day in London and two were trained at their 
practice surgeries. 
The training included the following aspects: 
*A description of the study. 
Day to day running of study. 
The assessment schedule. 
o Measuring visual acuity: ensuring the measurement is taken as far as 
possible under standardised conditions at the correct distance, with 
optimum lighting. 
a Use of the pinhole occluder. 
9 Extracting data from patients' notes. 
The nurses were issued with a procedures manual (appendix 4). 
61 
5.4 Trial monitoring 
The trial was monitored by the Trial Steering Committee of the main MRC 
Elderly Screening Trial. Annual reports of study progress were provided and 
approved by the Trial Steering Committee and all study procedures were also 
approved. 
62 
CHAPTER 6. RESULTS OF BASELINE SCREENING 
ASSESSMENTS 
6.1- Baseline comparison of randomised groups 
The following factors were identified as possibly having an effect on the 
estimate of effectiveness of screening obtained. 
At the practice (cluster) level: 
Jarman score for practice area (a measure of deprivation), because 
adverse socioeconomic factors are associated with lower use of eye 
services and with visual impairment; 109; 239-243 
Standardised Mortality Ratio for practice area, because visual 
impairment is associated with higher morbidity and with mortality; 244-250 
Geographical location: because of possible effects on access to eye 
services . 
251 The MRC General Practice Research Framework has 
classified the location of participating practices as rural, urban or 
suburban based on the population density of the geographical area 
where the practice is based. Clearly this is a rather inexact classification 
and concordance with access to services will only be partial. However, it 
is only used to compare balance across the two arms of the trial and 
therefore does serve a useful purpose. 
At the individual level. 
o Age; 
o Sex; 
Response to the invitation to have a baseline screening assessment; 
Self reported difficulty seeing at baseline; 
Time interval between screening assessment and outcome assessment 
(therefore time of baseline assessment was compared); 
Social isolation: as described in Chapter 3, social isolation was 
assessed from a question included in the baseline brief screening 
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assessment. Participants were asked the following question: "Do you see 
friends, neighbours or relatives (other than those you live with)? " 
Possible answers were "Daily", "2-3 times per week", "Less than twice 
per week" and "Rarely". The results are presented as a binary measure: 
participants who reported seeing other people rarely or less than twice 
per week (classified as socially isolated) and participants who reported 
seeing other people twice a week or more. 
In line with CONSORT guidelines, 179; 180 baseline characteristics are presented 
separately at the practice and participant level as appropriate. 
Baseline comparison at the cluster (practice) level 
Table 6.1 shows the baseline characteristics at the practice level by 
randomised group. The two groups of practices were similar with regards to 
Jarman deprivation score and rural/urban location. The Standardised 
Mortality Ratios were somewhat higher in the targeted screening group 
practices, with more practices in the highest tertile and less in the lowest tertile 
compared with the universal screening group. 
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Characteristic Targeted Universal All 
screening screening (n-20) 
group (n=10) group (n-10) 
Jannan tertile 
High 448 
Medium 437 
Low 235 
SMR tertile 
High 6 3 9 
Medium 2 2 4 
Low 2 5 7 
Location 
Urban 2 3 5 
Suburban1town 5 5 10 
Rural 3 2 5 
Table 6.1 Baseline characteristics: practice (cluster) level 
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Baseline comparison at the individual level 
Table 6.2 shows the baseline characteristics at the individual level for all 
sampled participants (both responders and non-responders) by randomised 
group. The two groups of participants were similar with regards to age, sex 
and response rates to the invitation to have a brief assessment. 
66 
Targeted Universal All 
screening screening group (n=4340) 
group (n=2200) (n- 2140) 
Male (%) 
Median age (years) 
Ages-categories: 
74 to 79 
80 to 94 
85 to 90 
>90 
Number and proportion (%) of 
eligible people completing a 
baseline brief assessment 
797 (36.2%) 
80.0 years 
833(38.9%) 
80.5 years 
1630 (37.6%) 
80.16 years 
1072 (48.7%) 983 (45.9%) 2055 (47.4%) 
646 (29.41/o) 671 . 
(3 1 Mo) 1317 (30.4/o) 
349 (15.9%) 3 63 (17.0'/o) 712 (16.4%) 
133 (6.1%) 123 (5.8%) 256 (5.9%) 
1684 (76.6%) 1662 (77.6%) 3346 (77.1%) 
Table 6.2 Baseline characteristics at the individual level for all sampled 
participants 
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Table 6.3 shows the baseline characteristics at the individual level for all 
participants who had a baseline assessment by randomised group. The two 
groups were broadly similar on all measures. There were some differences, 
for example in the sex distribution and the prevalence of self reported visual 
problems, but all such differences were small. 
Among the 3318 people who completed a baseline brief screening 
assessment, a total of 28 (0.8%) had a missing or invalid response to the 
question about difficulty seeing. Of those with missing values, 16 were in the 
universal screening group and 12 in the targeted group. 
Significance tests for the comparisons between the two randomised groups 
were not carried out because such tests are not useful in deciding whether 
important baseline imbalance exists. 252 
Overall the two groups were similar indicating that the practice randomisation 
and subsequent sampling of practices and participants had resulted in 
reasonably well balanced groups. Although the differences were small, there 
were some baseline differences between the two randomised groups for three 
factors that could affect the outcome: age, sex and self reported visual 
problems. Confounding of the trial results by these three factors was therefore 
assessed (see Chapter 7). 
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Other descriptive factors 
The data below (table 6.4) are presented in order to provide a fuller 
description of the type of people in the trial. These factors were not included in 
the analysis of confounding and effect modification. Consideration of 
excessive numbers of different factors as potential confounding factors or 
effect modifiers can lead to spurious significant results and needlessly 
complicates the analysis. 
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6.2 Response rate and comparison of responders and non- 
responders to the baseline brief assessment. 
Overall 77.1% (3346/4340) of participants had a baseline assessment. As 
seen in table 6.2 above, this response rate was similar across the two 
randomised groups. Of the 994 people who did not have a brief assessment, 
902 refused, there was no response after two attempts by letter and/or 
telephone from 75 people. A further 17 people did not have an assessment for 
a variety of reasons including administrative error at the research centre or 
practice (seven people), recorded as having had an assessment by the 
research nurse but no questionnaire located (four people), and six people who 
were initially seen by a research nurse but were too ill to undertake an 
assessment. % 
The sampling of practices and participants and the baseline assessments 
undertaken are summarised in figure 6.1. 
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73 practices invited to 
participate 
'kýý Targeted screening 
19 practices 
1 10 practices sampled I 
2200 participants sampled 
(220 from each practice) 
1684 (76.6%) had a brief 
screening assessment 
- 467 refused 
- 37 no response 
- 12 other* 
150 eligible for 
detailed assessment 
120 had detailed 
assessment 
23 refused 
7 no response 
04 too ill, 5 admin error, 3 lost questionnaires 
02 too ill, 2 admin error, I lost questionnaire 
$ admin error meant 2 people were not invited 
Universal screening 
21 practices 
I 10 practices sampled I 
2140 participants sampled 
(220 from 8 practices 
210 and 170 from the other 2) 
1662 (77.6%) had a brief 
screening assessment 
- 435 refused 
- 38 no response 
-5 othe? 
1565 had a detailed assessment 
- 94 refused 
- 32 no response 
-4 died 
-2 other' 
Plus 35 people who had not had 
a brief assessment 
Figure 6.1 Practice and participant sampling, and baseline screening 
assessments undertaken 
41 practices agreed to 
participate 
I 
73 
The individual information about people who did not have a baseline 
assessment was limited to age and sex. The median age of people who 
responded was 80.0 years and for people who did not respond was 81.0 
years: a difference of only one year. Regarding se)ý distribution, 38.2% of 
people who responded and 35.0% of non-responders were male, a non- 
significant difference of 3.2% (95% confidence interval -4.2% to +9.1%, 
P=0.14). 
In conclusion, the response rate to the baseline screening assessment was 
high, especially for a study in this age group. Respondents were younger than 
non-responders but the difference was around I year. Women were more 
likely to respond than men, but the difference was small and not significant. 
74 
6.3 Vision findings at baseline screening assessment 
. 
Brief assessment 
In the universal screening group 1662 out of 2140 (77.7%) eligible participants 
had a brief assessment. In the targeted screening group 1684 out of 2200 
(76.6%) eligible participants had a brief assessment. 
In the brief assessment participants were asked the following question about 
vision: "Do you have difficulty seeing newsprint, even if you are wearing 
glasses". Possible answers were: "none"; sla little"; or "a lot" (see Chapter 3.1). 
The results broken down by randomised group are shown in table 6.5. 
The proportion of people reporting a lot of difficulty was relatively low given the 
previous estimates of impaired vision in this age group, with only around 8% 
of people reporting a lot of difficulty reading newsprint. 
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Universal Targeted All 
screening screening (n=3346) 
(n= 1662) (n=l 684) 
Proportion (number) of those 
responding who reported: 
no difficulty seeing 71.2% (1183) 69.3% (1167) 70.2% (2350) 
newsprint 
a little difficulty seeing 20.2%(336) 20.4%(343) 20.3%(679) 
newsprint 
a lot of difficulty seeing 7.6% (127) 9.6%(162) 8.6%(289) 
newsprint 
missing 1%(16) 0.7%(12) 0.8%(28) 
Table 6.5 Baseline vision findings at the brief assessment 
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Detailed assessment 
In the universal screening arm all participants were offered a detailed 
assessment. In the targeted arm, people found to have a pre-specified 
number and type of problems were eligible for a detailed assessment, as 
described in Chapter 3. 
In the targeted screening group, of the 1684 people who had a brief 
assessment, 150 (8.6%) reported sufficient problems to be eligible for a 
detailed assessment. People eligible for a detailed assessment were slightly 
older: 82.6 years versus 80.6 years. Women were much more likely than men 
to be eligible for a detailed assessment. Of the 150 people eligible, 111 
(74.0%) of them were women compared to 62% of participants in the targeted 
screening group as a whole being women. 
Of the 162 people reporting "a lot of difficulty" seeing newsprint, only 51 
(31.5%) were eligible for a detailed assessment. This meant that although 111 
other participants reported a lot of difficulty seeing, the number or severity of 
other problems found at the brief screening assessment were not sufficient to 
make them eligible for a detailed assessment. In the trial design it would not 
have been practical to offer a detailed assessment to all people found to have 
any single problem at the brief screen. Such a policy would have resulted in 
virtually all participants going on to have a detailed screen - the very 
procedure being tested in the other arm of the trial. This relates to the issue of 
screening for visual impairment being one element of a broader 
multidimensional assessment first discussed in Chapter 2. Thus although self- 
reported visual problems did contribute to the overall eligibility of participants 
for a more detailed assessment, the screening strategy adopted in the 
targeted screening group meant that many people reporting a lot of difficulty 
seeing did not go on to have a more detailed assessment of their vision. 
Response rate to detailed assessment 
Universal screening group 
In the universal screening group, 1565 people had a detailed assessment 
from a total eligible of 2140, a response rate of 73.1%. Thirty five people who 
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had a detailed assessment in this group had not previously had a brief 
assessment. Of people who had completed a brief assessment, 132 (7.1%) 
did not go on to have a detailed assessment. Men were slightly more likely 
than women to have a detailed assessment (75% for men versus 72% for 
women). Respondents and non-respondents were similar in age (median age 
of responders 81.1 years versus 81.9 for non-responders). 
Targeted screening group 
Of the 150 people eligible, 120 completed a detailed assessment, a response 
rate of 80.0%. Of people eligible, men were more likely than women to have a 
detailed assessment (response rate for men was 89% versus 76% for 
women). Responders and non-responders were similar in age (median age of 
responders 82.3 years versus 83.6 years for non-responders). 
Place of detailed assessment 
In the universal screening arm, 33.9% (519/1533) of assessments were 
undertaken in peoples' own homes, the remainder being undertaken at the 
general practice surgery. Of the 120 people in the targeted arm who had a 
detailed assessment, a higher proportion were done at home: 58.3% (70/120). 
People in the targeted arm were identified as eligible for a detailed 
assessment on the basis of having a range of health problems: hence the 
higher proportion of people who needed the nurse to visit them at home. 
Distance used to measure vision 
In the universal screening arm, vision was measured at one metre for 4.4% 
(69/1565) of participants because of space restrictions. Nearly all these 
people had their vision measured at home. Four people had their vision 
measured at one metre in the clinic setting: the reasons for this are unclear. In 
the targeted screening arm, vision was measured at one metre for 15.0% 
(18/120) of participants because of space restrictions. This higher proportion 
reflects the higher proportion of assessments undertaken at home. (These 
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people are in addition to those people who had their vision measured at one 
metre because they could not see any letters on the chart at three metres). 
Findings at detailed assessment 
Findings from the detailed screening assessments by randomised group are 
presented in table 6.6. 
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Targeted screening Universal screening 
group group 
Number eligible 150 2140 
Proportion completing detailed assessment 80.0%(120) 73.1% (1565) 
(numbgr) 
Ofpeople completing a detailed assessment: 
Proportion male (0/6) 29.2% 40.0% 
Median age (years) 82.3 years 81.1 years 
Visual acuity < 6/18 in either eye 43.2%(53) 28.8%(451) 
Proportion with visual acuity < 6118 51.0% (27153) 49.5% (2231451) 
in either eye who had a pinhole 
assessment 
Visual acuity <6/18 in either eye that 6.7%(S) 5.1%(79) 
corrected to >6/1 8 with pinhole correction 
Visual acuity <6/18 binocular 22.0%(26)l 12.1% (179)* 
Visual acuity <6112 in either eye 60.0%(72) 47.0%(736) 
Visual acuity <6/12 binocular 45.8% (54ý 34.3% (508)* 
Owned glasses 87.5%(105) 88.3% (1382) 
Eligible for referral to an optician 6.7%(8) 5.1%(79) 
Eligible for referral to an ophthalmologist 24.2%(29) 14.1%(220) 
Registered: 
blind 3.3%(4) 1.1%(18) 
partially sighted 5%(6) 2.2%(35) 
data on registration status missing 2.5%(3) 1.5%(24) 
excluding 84 people with missing values 
excluding 2 people with missing values 
Table 6.6 Baseline findings from the detailed screening assessments by 
randomised group 
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Visual acuity 
Universal screening group 
In the universal screening group, 451 people (28.8%) had a logMAR visual 
acuity of 0.5 or more in either eye, equivalent to Snellen acuity less than 6/18. 
One hundred and seventy nine people (12.1%) had presenting binocular 
vision of logMAR score 0.5 or more (again, equivalent to Snellen acuity less 
than 6/18). As would be expected, the numbers with a logMAR visual acuity 
of 0.3 or more (equivalent to Snellen acuity less than 6/12) in either eye or 
presenting binocular vision were somewhat higher, with over one third of 
people having a presenting visual acuity of less than 6/12. 
Targeted screening group 
In the targeted screening group among the 120 people who had a detailed 
assessment, 53 people (43.2%) had a logMAR visual acuity of 0.5 or more in 
either eye, equivalent to Snellen acuity less than 6/1 B. Twenty six people 
(22%) had presenting binocular vision of IogMAR score 0.5 or more. Again, as 
would be expected, the numbers with a logMAR visual acuity of 0.3 or more 
(equivalent to Snellen acuity less than 6/12) in either eye or presenting 
binocular vision were correspondingly higher. 
The higher levels of reduced visual acuity among the people in the targeted 
arm is not surprising. In the targeted screening arm eligibility for a detailed 
screening assessment was largely based on health related problems detected 
at the brief assessment, including self reported visual problems. 
Pinhole correction 
Universal screening group 
Of the 451 people found to have visual acuity of less than 6/18 in either eye, 
223 (49.5%) had a pinhole corrected visual acuity assessment. The reasons 
why almost half the people eligible for a pinhole corrected measurement did 
not have measurements recorded are partly unclear. However, several of the 
research nurses reported that many participants found the pinhole occluder 
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difficult to use or said they could not see properly through it. This issue is 
discussed in more detail in Chapter 9. People with visual acuity less than 6/18 
in either eye who did not complete a pinhole assessment were still referred to 
an ophthalmologist. 
Of the 223 who did have pinhole corrected visual acuity measurements 
recorded, vision improved to greater than 6/18 in 79. These people were thus 
eligible for referral to an optician. 
Targeted screening group 
Of the 53 people found to have visual acuity of less than 6/18 in either eye, 
27 (51.0%) had a pinhole corrected visual acuity assessment. Of these 27, 
vision improved to greater than 6/18 in 8 people. These people were thus 
eligible for referral to an optician. 
Glasses ownership 
Of the 1685 people who had a detailed assessment, overall 1487 (88.3%) 
reported owning glasses. The proportion of people owning glasses was 
similar in the universal screening group and among the people from the 
targeted screening groups who had a detailed assessment (see table 6.6). 
Registration as blind or partially sighted 
People in the targeted screening arm who were eligible for and completed a 
detailed screening assessment were more likely to be registered blind or 
partially sighted than people in the universal sc 
' 
reening arm, although the 
actual numbers are small (table 6.5). Again, the higher levels among the 
people in the targeted screening group is not a surprising finding because the 
people who had a detailed assessment in the targeted screening group were a 
selected minority. 
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Eligibility for referral to eye services 
The criteria for eligibility for referral were as follows: 
(1) For anyone with a pinhole vision of less than 6/18 in either eye (logMAR 
score 0.5 or more), referral to an ophthalmologist was recommended, 
unless: 
- they had been seen by an ophthalmologist in the previous year; 
- they were registered blind or partially sighted. 
(2) Anyone with presenting vision of less than 6/18 that improved with pinhole 
to better than 6/18 was advised to visit an optician. 
Universal screening group 
In the universal screening group, 79 out of the 1565 people who had a 
detailed assessment were eligible for referral to an optician (5.1%). A further 
220 people (14.1 %) were eligible for referral to an ophthalmologist. 
Targeted screening group 
In the targeted screening group, 8 out of the 120 people who had a detailed 
assessment were eligible for referral to an optician (6.7%). A further 29 people 
(24.2%) were eligible for referral to an ophthalmologist. 
The people in the targeted screening group who had a detailed assessment 
had been selected on the basis of having a range of health problems. The 
higher proportion of visual problems in this group is therefore not surprising. 
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CHAPTER 7. RESULTS 1: PRIMARY OUTCOME MEASURES 
7.1 Response rate to outcome assessment 
Proqress of outcome data collection 
The target and achieved rates of completion of outcome assessments are 
shown in figure 7.1. The rate of data collection in several practices exceeded 
the target rate, and all outcome assessments were completed in these 
practices within several months. There were problems with either changes in 
the research nurses or excessive workload for the existing research nurses in 
several other practices, leading to some delays in outcome data collection. 
The eventual response rates achieved in two practices were particularly low, 
both of which were reflections of excessive workload for the existing research 
nurses and inability (in one practice) or unwillingness (in the other practice) to 
recruit additional research nurses to undertake the remaining assessments. A 
total of 1807 assessments were completed, 90.4% of the target of 2000. 
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Reasons for non-response 
The reasons for non-response to the outcome assessment are given in table 
7.1. 
Death 
As expected in this age group, a high proportion of participants (around one 
third) had died by the time they were invited for an outcome assessment. 
34.4% of people in the targeted screening group had died compared with 
33.8% in the universal screening group, a difference of -1.3% (95% 
confidence interval -6.4% to 3.7%, P =0.59). There was some imbalance in 
response rate by randomised group, with an overall 5.7% difference between 
the two groups. 
In any such trial the objective is to improve the vision among people who 
survive, and therefore the response rate needs to be judged amongst 
survivors. Excluding people who had died, the response rate was 62.8%, 
which for a trial in this, age group is comparatively high. Only 28% of people 
who could have completed an outcome assessment (i. e. were alive and were 
not too ill, in hospital or had moved away) refused or did not respond, 
meaning that 72% of people who could have been seen by the study nurses 
did have an outcome assessment. 
After excluding those people who had died before they could be invited to 
have an outcome assessment, the response rate was 67.8% (829/1432) in the 
targeted group and 57.9% (829/1432) in the universal screening group 
(difference -9.9%, 95% confidence interval -19.4% to -0.003%, P=0.042). This 
difference in response rates could be a potential source of bias in the trial. 253 
Low response rates from individual centres are never desirable in a 
multicentre clinical trial. However in cluster trials, pentre specific low response 
rates are recognised as being particularly problematic because they can lead 
to imbalance across the randomised groUpS. 162 Because of the potential bias 
due to the imbalance in response rates, the issue of response to the outcome 
assessment is considered in some detail. 
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Refusal 
A number of factors could have contributed to the difference in refusal rates 
between the two groups. The two practices in which the eventual response 
rates were particularly low (due to research nurse w! orkload problems) were 
both in the universal screening arm. The response rates by different practices 
are shown in table 7.2. 
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Clinic code Eligible 
participants 
Died Responded Response rate among 
those alive at time of 
Invitation (%) 
Targeted 
screening group 
A 220 91(41.4%) 112 86.8% 
B 220 91(41.4%) 86 66.7% 
C 220 76 (34.6%) 86 59.7% 
D 220 61 (27.7%) 94 59.1% 
E 220 77 (35.0%) 95 66.4% 
F 220 66 (30.0%) 117 76.0% 
G 220 82 (37.3%) 96 69.6% 
H 220 87(39.6%) 92 69.2% 
1 220 55(25.0%) 114 69.1% 
1 220 71(32.3%) 86 57.7% 
Group sub-total 2200 757 (34A/o) 978 67.8% 
Universal 
screening group 
K 220 68 (30.9%) 80 52.6% 
L 220 76 (34.61/o) 85 59.0% 
m 220 57(25.9%) 87 53.4% 
N 220 83(37.7%) 68 49.6% 
0 220 96 (43.6%) 83 66.9% 
P 170 44(25.9%) 75 59.5% 
Q 220 75(34.1%) 47 32.4% 
R 220 67 (30.5%) 95 62.1% 
S 210 76 (36.2%) 102 76.1% 
T 220 66 (30.0%) 107 69.5% 
Group sub-total 2140 708(33.1%) 829 57.9% 
Total 4340 1465 (33.8%) 1807 62.9% 
Table 7.2 Response rate to outcome assessment by general practice (anonymous 
alphabetic codes assigned to practices) 
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In the universal screening group all participants had had a detailed baseline 
assessment, while in the targeted screening group only a small number of 
participants had a detailed assessment. People in the universal screening arm 
may well have remembered the fairly lengthy detailed assessment they had at 
baseline, and this could have deterred them from re-aftending. In addition, the 
detailed baseline assessment included a visual acuity test. In the invitation to 
attend for outcome assessment outcome, having a free eye test was 
highlighted as a benefit of attending. It is possible that some people in the 
universal screening group recalled having a test of their vision at baseline and 
hence the prospect of an eye test did not encourage them to attend the 
outcome assessment. 
Other reasons for non-response 
The proportions of people who had moved away, were too ill, were in hospital 
or who could not be traced were quite low and were similar in the two 
randomised groups. 
Comparison of responders and non-responders 
Among people still alive at the time of invitation to have an outcome 
assessment, a comparison of participants who completed an outcome 
assessment with participants who did not complete an assessment is 
presented in table 7.3 
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Age and sex 
Among those people alive at the time of invitation, responders to the outcome 
assessment were slightly younger than non-responders. Men were slightly 
less likely than women to have an outcome assessment. 
Baseline factors 
Not surprisingly, people who had attended the baseline screening assessment 
were much more likely to complete an outcome assessment than people who 
had not had a baseline screen. 
People who completed a baseline assessment were slightly more likely than 
non-responders to have self reported visual problems at baseline. The 
difference was small but is consistent with the idea that people who perceive 
themselves to have visual problems are more likely to attend for a visual 
examination. Responders were less likely to have reported being socially 
isolated at the time of the baseline assessment. The differences between 
resýp6nders and non-responders remained similar after controlling for age. 
Visual acuity 
In the universal screening arm only, it was possible to assess whether people 
responding to the outcome assessments differed to non-responders by 
baseline visual acuity. Because reduced visual acuity is known to be 
associated with an increased mortality risk, 244-250 people who did not have an 
outcome assessment because they had died were more likely to have had 
visual impairment at baseline. Therefore the analysis was restricted to people 
who were still alive at the time of invitation to the outcome assessment. 
Participants who had an outcome assessment were slightly less likely to have 
had visual acuity <6/18 in one or both eyes at baseline that participants who 
did not have an outcome assessment (23.0% of responders versus 26.1% of 
non-responders, difference 3.1%, P=0.33). 
These results are discussed in more detail in Chapters 9 and 10. 
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Comparison of responders by randomised qroup 
The people who completed an outcome assepsment are compared by 
randomised group for various factors in table 7.4 
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Although there were differences between the two groups, these differences 
were generally small, and more importantly, were consistent with the baseline 
differences for all participants described in Chapter 6 (see especially table 
6.3). Of particular note is that the small difference in self reported visual 
problems at baseline between the two groups is similar to the difference 
observed for all participants (table 6.3). Thus there is no good evidence to 
suggest that the imbalance in response rates between the two randomised 
groups produced any systematic differences between the two groups which 
could affect the result of the trial. 
The one possible exception is that the proportion of people reporting social 
isolation at baseline was substantially higher among people in the universal 
screening group, although the difference was not significant (difference 4.2%, 
95% confidence interval 1.9% to 10.2%, P=0.17) and was In the same 
direction as that noted for all participants (table 6.3). Social isolation was 
already identified as a potential confounding factor in the analysis and thus 
any effect of this imbalance would be explored. 
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Location of outcome, assessments 
The locations where the outcome assessments were undertaken are shown in 
table 7.5. Just over half the outcome assessments were undertaken at general 
practice surgeries and just under half were undertaken in participants' homes. 
The high proportion of home visits reflects the age of the participants and the 
fact that nurses were instructed to offer to come and visit participants if this 
would increase the likelihood of the person participating in the outcome data 
collection. 
A total of 47 assessments were undertaken at other locations. Of these, the 
majority (29) were undertaken in residential homes, 17 were undertaken in 
nursing homes, and 2 were undertaken at day centres. 
There were differences in the distribution of location of outcome assessments 
across the randomised groups. The lower level of home visiting in the 
universal screening group was largely explained by the two practices in this 
group that had lower response rates overall (see above). These two practices 
had very low home visiting rates, the nurses having concentrated on those 
assessments that could most easily be done in the time available. 
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Location Targeted Universal All 
screening group screening group (n-1807) 
(n--978) (n=829) 
GP surgery 477 (48.9%) 
Participant's home 462 (47.2%) 
Other* 39(4.0%) 
* see text for details 
493 (59.5%) 
328 (39.6%) 
8(1.00/0) 
970 (53.7%) 
790 (43.7%) 
47 (2.6%) 
Table 7.5 Location where outcome assessments were undertaken 
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Distance used to measure vision 
Vision was measured at one metre for 6.2% (112/1807) of participants 
because of space restrictions, with the proportion being approximately equal 
in the two arms. All these people had their vision measured at home. (in 
addition some people had their vision measured at one metre because they 
could not see any letters on the chart at three metres). 
Time period between baseline screening and outcome assessments 
The time period in years between the first baseline screening assessment and 
the outcome assessment was calculated for all participants who had an 
outcome assessment. For the 236 people who completed an outcome 
assessment but who did not attend for screening at baseline, the date of 
invitation for baseline screening was used to calculate the time interval. 
The time intervals broken down by randomised group are shown in table 7.6. 
Results for all people who completed an outcome assessment and who are 
included in the intention to treat analysis are shown first. The results are then 
presented for people who both attended the baseline screening assessment 
they were allocated to and who had an outcome assessment. This is the sub- 
group of people included in the per-protocol analysis (see below for more 
details). 
The overall median time interval from baseline screening to outcome 
assessment was around 3.9 years. The figures in the table show that the time 
periods and their distributions are similar across the randomised groups and 
were also similar for all participants who had an outcome assessment and for 
the sub-group who attended the baseline screening. 
The median follow-up time in the universal screening group was 3.87 years 
and in the targeted screening group was 3.90 years. 
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7.2 Visual acuity 
The results below refer to the intention to treat analysis. The per-protocol 
analysis is presented in the next section. 
Primary outcome measure 
The primary outcome measure was the odds ratio of having impaired vision 
(defined as visual acuity <6/18 in one or both eyes) comparing the universal 
screening group with the targeted screening group. In the targeted screening 
group 34.7% of people had a visual acuity of less than 6/18 in either eye 
compared with 37.0% in the universal screening group. The odds ratio was 
1.11,95% confidence interval 0.76 to 1.62, P=0.58. The result is shown in 
table 7.7. 
The relative risk ratio was 1.07,95% confidence interval 0.84 to 1.37, P=0.58. 
loo 
Targeted Universal Odds ratio (95% P value 
screening group screening group confidence 
n-- 978 n-- 829 interval) 
Visual acuity<6/18 in 
either eye 
Number (%) 339(34.7%) 307(37.0%) 1.11 (0.76 to 0.58 
1.62) 
Missing 00 
Table 7.7 Primary visual acuity outcome (intention to treat analysis) 
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Confoundinq 
As -described in Chapter 3, four factors were considered as potential 
confounders of the effect of screening: gender, age, levels of self reported 
visual problems and time period from baseline screening to outcome 
assessment. Therefore further analyses were undertaken to assess whether 
controlling for these factors affected the odds ratio estimate for the primary 
outcome measure. 
Assessment of effect of potential confounding factors on trial outcome 
The analysis of the primary outcome measure was repeated while controlling 
for each potential confounding factor in turn. The results are shown in table 
7.8. The odds ratio for visual impairment comparing the two randomised 
groups was virtually identical after controlling for the potential confounding 
factors. There was no evidence of confounding by any of these factors and 
therefore the unadjusted estimate was accepted as the most reliable measure. 
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Odds ratio risk P value 
(95% confidence 
interval) 
Unadjusted I 
Adjusted for: 
sex 
age 
self reported visual difficulty 
at baseline* 
time period of follow-up 
1.11(0.76tol. 62) 0.58 
1.12 (0.77 to 1.62) 0.54 
1.12 (0.75 to 1.68) 0.56 
1.18 (0.79 to 1.77) 0.39 
1.11(0.78tol-59) 0.54 
4 excludes 258 people without self reported vision at baseline: 249 did not have a baseline assessment 
plus 9 with missing data 
Table 7.8 Odds ratio of visual acuity<6/18 in either eye comparing universal 
i with targeted screening: unadjusted and adjusted for potential confounding 
factors 
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Effect modification 
As discussed in Chapter 3, the trial was not specifically powered to detect 
sub-group effects. The analysis of possible effect modifiers was undertaken as 
an exploratory measure, and as a possible pointer towards future research. 237 
The following possible effect modifiers were considered: 
9 age; 
9 gender; 
* time period between baseline screen and outcome assessment; 
e social isolation; 
e self reported visual difficulties at the baseline assessment; 
See Chapter 3, section 2 for a justification for these factors and a description 
of the measures used. 
The time period of follow-up was divided into three groups as shown in table 
7.6. 
Age was considered in three groups: 74 to 79 years, 80 to 84 years and 85 
years and over. 
The odds ratios for the primary outcome stratified by these potential effect 
modifying factors are shown in table 7.9. 
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Odds ratio (95% P value for 
confidence interaction 
interval) 
Overall effect 1.11 (0.76 to 1.62) 
Subgroup: 
Age 
74 to 79 1.16 (0.73 to 1.86) 
80 to 84 1.20 (0.80 to 1.82) 
85 to 96 0.85 (0.47 to 1.55) 0.37 
sex 
Male 1.17 (0.81 to 1.71) 
Female 1.09 (0.71 to 1.68) 0.69 
Follow-upperiod 
Minimum (1.6) to 2.9 years 1.10 (0.64 to 1.90) 
3.0 to 3.9 years 1.12 (0.76 to 1.65) 
3.9 to maximum (5.8) years 1.13 (0.59 to 2.14) 0.95 
Social isolatim? 
Not isolated 1.09 (0.72 to 1.67) 
Isolated 1.06 (0.53 to 2.13) 0.92 
Selfreported visual difficulty at 
baseline 
None or a little 
A lot 
1. IS (0.79 to 1.79) 
1.12 (0.33 to 3.83) 0.93 
test for heterogeneity of effect across sub-groups: see text for details of how P values were derived 
see text for explanation 
Table 7.9 Odds ratios for visual acuity<6/18 in eithe r' eye comparing universal 
with targeted screening: potential effect modifiers. 
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The "P value for interaction" column in table 7.9 shows the P values from the 
Wald tests for the interaction terms introduced into the models. The null 
hypothesis of such a Wald test is that the interaction term is the null value: i. e. 
1 for an odds ratio. 
Foreach factor the stratum specific odds ratios are very similar to each other 
and none of the interaction terms approach significance. The one exception is 
in the oldest age group (85 years and older), where the odds ratio is 
noticeably lower. However, the confidence intervals are wide and overlap 
greatly with the estimates from the younger groups. The P value for the 
interaction term is 0.32. In addition this age group Was relatively small (15% of 
all participants with outcome data). Therefore there is no strong evidence that 
the effect of the intervention differed in the oldest age group. 
Of particular note was that the estimate of effectiveness differed very little by 
follow-up period. 
Per protocol analysis 
Participants who completed baseline screening and outcome 
assessments 
All the analyses presented so far are based on the "intention to treat' principal 
- that is all participants with outcome data available were analysed according 
to the group they were randomised to, regardless of whether they actually 
completed the screening assessment they were randomised to. A per protocol 
analysis in which only participants who adhered completely to the intervention 
are analysed gives a measure of efficacy of the screening intervention given 
100% uptake. Such a measure is of interest when trying to explain the effects 
observed, but does not serve to replace the main analyses as the measure of 
effectiveness. 
Among the 1807 people who completed an outcome assessment, 1524 had 
fully complied with the baseline screening intervention. In the universal 
screening arm, 701 out of 829 people who had an outcome assessment had 
undergone a detailed visual screening assessment. In the targeted screening 
arm, out of 978 people who had an outcome assessment, 780 people had a 
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brief assessment, 51 of whom were eligible for a detailed assessment. Of 
these 43 people completed a detailed assessment. Therefore 823 people in 
the targeted screening arm who completed an outcome assessment had 
undergone baseline screening as per the study protocol. 
The numbers of people included in the per-protocol analysis by randomised 
group are shown in table 7.10. 
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Universal Targeted All 
screening screening (n-1807) 
(n= 829) (n--978) 
Number of those with outcome data available 
who: 
completed a baseline brief assessment 727 780 
eligible for a detailed assessment All 51 
completed a detailed assessment 701 43 
Underwent baseline screening as specified in the 701 (84.6%) 823 (84.2%) 1524 
study protocol and therefore included in the per- (84.3%) 
protocol analysis 
Table 7.10 Adherence to baseline screening assessments among people with 
outcome data available 
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Per protocol result 
Only the primary outcome measure (the proportion of people with visual acuity 
<6/1 8 in one or both eyes) was analysed. In the targeted screening group 278 
out of 823 people (33.8%) had a visual acuity of less than 6/18 in either eye, 
compared with 253 out of 701 people (36.1%) in the universal screening 
group. The odds ratio was 1.11,95% confidence interval 0.72 to 1.70, P=0.63. 
The relative risk was 1.08,95% confidence interval 0.84 to 1.38, P=0.53. 
Other than a slightly wider confidence interval (due to smaller numbers 
included in the analysis), the per protocol result foý the primary outcome 
measure was virtually identical to the intention to treat analysis. 
7.3 Visual function 
Method 
Description of content of questionnaire 
The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) 
was described in Chapter 3. The actual questionnaire used is included in 
appendix 8. 
The questionnaire consists of a set of vision targeted questions representing 
eleven vision-related constructs. As well as providing a composite overall 
score, the VFQ-25 generates scores for the following subscales: 
* global vision rating (question 2) 
e difficulty with near vision activities (questions 5,6 and 7) 
e difficulty with distance vision activities (questions 8,9 and 14) 
e limitations in social functioning due to vision (questions 11 and 13) 
o role limitations due to vision (questions 17 and 18) 
dependency on others due to vision (questions 20,23 and 24) 
9 mental health symptoms due to vision (questions 3,21,22 and 25) 
e driving difficulties (questions 15c and 16) 
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* limitations with peripheral vision (question 10) 
e limitations with colour vision (question 12) 
e ocular pain (questions 4 and 19) 
Questions 15,15a and 15b are filter questions designed to determine whether 
someone has ever driven a car and whether they are currently driving or have 
stopped. The VFQ-25 also includes an additional single-item general health 
rating question. This was originally included during the developmental phase 
of the National Eye Institute VFQ to ensure that researchers had a minimal 
amount of information about a person's general health status to use as a 
benchmark against other published samples or cohorts. The single non-vision 
related health question is still included in the standard questionnaire and was 
therefore included in the assessment undertaken for this study. However, the 
score for this question does not contribute to the composite VFQ-25 score. 
Scoring 
Scoring the VFQ-25 is undertaken using a published algorithm. '-' There are 
two-stages. First, the numeric values from the questionnaire are re-coded onto 
scales ranging from 0 to 100 for each question. All items are scored so that a 
high score represents better functioning. This means that scores represent the 
achieved percentage of the total possible score, e. g. a score of 50 represents 
50% of the highest possible score. Second, items within each sub-scale are 
averaged together to create the twelve sub-scale scores. 
Items that are left blank (missing data) are not taken into account when 
calculating the sub-scale scores. Sub-scales with at least one item answered 
can be used to generate a sub-scale score. Hence, scores represent the 
average for all items in the subscale that the respondent answered. The issue 
of missing data is considered in more detail below. 
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Composite score calculation 
The overall composite score for the VFQ-25 is deriveý by taking the average 
of the vision-targeted subscale scores, excluding the general health rating 
question. By averaging the sub-scale scores rather than the individual items, 
equal weight is given to each sub-scale, whereas averaging the items would 
give more weight to scales with more items. 
Transfonnation of data 
The VFQ-25 scores were not normally distributed and were negatively 
skewed. A log transformation was therefore performed with an additional 
correction factor to reduce the skewness. The test for normalcy on the 
transformed data was satisfied (P=0.27, where the null hypothesis is that the 
data are normally distributed). All analyses were undertaken using the 
transformed data with re-transformation of results. 
Primary outcome measure 
The results of the NEI VFQ-25 composite score by randomised group are 
shown in table 7.11. For the composite score, the difference between the two 
groups was small at 0.41,95% confidence interval -1.68 to 2.50, P=0.69. 
Sub-scales 
The results for the 11 vision sub-scales and for the general health question 
are presented in Chapter 8. 
III 
Targeted Universal Difference 95% CI of P value for 
screening, screening, (universal difference difference 
mean (SE) mean (SE) - targeted) 
Number of 975 828 
participants 
Missing value 3 
Composite 85.62 (0.34) 86.03(0.94) 0.41 -1.68 to 2.50 0.69 
score 
Table 7.11 Composite score result for the VFQ-25 by randomised group 
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Missina and incomplete responses 
Of the 1807 people who were seen by a research nurse for an outcome 
assessment, 1803 completed sufficient items of the VFQ-25 to derive a 
composite score. Four participants were unable to complete the questionnaire. 
The research nurses reported that this was because of cognitive impairment 
(three people) or the participant being too ill to continue with the assessment 
(one person). Of the four respondents who did not complete the VFQ-25, 
three were in the targeted screening group and one was in the universal 
screening group. 
The sub-scale and composite scores are derived from non-missing values, 
thus missing values are ignored. Caution is required in the interpretation of 
such derived scores if missingness is related to comparison group or if there 
were high levels of missing values. However, there was no evidence for a 
differential bias in levels of missing values by randomised group, and the level 
of missing values overall was low. Even for the sUb-scale with the most 
missing values (colour vision), the total of 15 missing was less than 1% of the 
total sample. However, because of the potential effect of missing data, a 
sensitivity analysis was undertaken, repeating the analysis for the primary 
outcome measure restricted to people with data for all sub-scales. 
A total of 140 people out of the 1807 (7.8%) who had an outcome assessment 
had missing scores for one or more VFQ subscales (excluding the driving 
subscale among non-drivers). The proportion of people with missing data did 
not differ significantly by randomised group: in the targeted screening arm 
65/829 people (7.8%) and in the universal screening arm 75/903 (7.7%). 
P=0.89 for the test of difference in proportions by randomised group. 
Restricting the analysis of the composite score to those people with complete 
data on all sub-scales (excluding driving for non-drivers) had almost no effect 
on the results (table 7.12). 
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Targeted Universal Difference 95% Cl of P value for 
screening, screening, (universal difference difference 
mean mean - targeted) 
Number of participants 975 828 
Participants with 75 65 
missing values 
Composite score 86.12 (0.42) 86.62 (0.95) 0.50 -1.67 to 2.67 0.64 
Table 7.12 Composite score result for the VFQ-25 by randomised group for 
people with no missing sub-scale scores 
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Confoundinq 
As described in Chapter 3, four factors were considered as potential 
confounders of the effect of screening: gender, age, levels of self reported 
visual problems and time period from baseline screening to outcome 
assessment. Therefore further analyses were undertaken to assess whether 
controlling for these factors affected the odds ratio estimate for the primary 
outcome measure. 
The assessment of confounding was undertaken only using the composite 
score for two reasons. Firstly to avoid excessive numbers of comparisons with 
the likelihood of spurious "significant' findings. Secondly, there were no good 
prior hypotheses relating to the NEI VFQ-25 sub-scales to guide the analysis. 
The same approach to the assessment of confounding was used as for the 
visual acuity outcomes. 
Assessment of effect of potential confounding factors on trial outcome 
The analysis of the NEI VFQ-25 composite score was repeated while 
controlling for each potential confounding factor in turn. The results are shown 
in table 7.13. 
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Difference in means P value" 
(universal -targeted) and 
95% CI of difference 
Unadjusted 
Adjusted for: 
sex 
age 
self reported visual difficulty 
at baseline* 
follow-up period 
0.41 (-1.68 to 2.50) 0.69 
0.41 (-1.74 to 2.40) 0.75 
0.37 (-1.56 to 2.29) 0.70 
-0.49 (-2.82 to 1.84) 0.66 
0.43 (-1.67 to 2.53) 0.68 
* excludes 258 people with out self reported vision at baseline: 249 did not have a baseline assessment 
plus 9 with missing data 
# test of whether the difference in mean scores comparing universal and targeted groups differs 
significantly from zero 
Table 7.13 Difference in mean composite VFQ-25 score comparing universal 
with targeted screening: unadjusted and adjusted for potential confounding 
factors 
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The difference in mean scores between the universal and targeted groups is 
equal to the regression coefficient for the randomised group variable. This is 
an estimate of the change in the composite VFQ-25 score for a change in 
randomised group of one unit, from targeted to universal screening. 
The differences in the composite score comparing the two randomised groups 
were virtually identical before and after controlling for the potential 
confounding factors. Although controlling for self reported visual problems 
changed the estimated difference from 0.41 to -0.49, this is actually less than 
a single point change, and the difference between the universal and targeted 
screening groups remained non-significant. 
Thus there was no evidence of confounding by any of these factors and 
therefore the unadjusted estimate was accepted as the most reliable measure. 
Effect modification 
The possible effect modifiers considered were the same as for the visual 
acuity outcome: 
o age; 
9 gender; 
e time period between baseline screen and outcome assessment; 
e social isolation; 
e self reported visual difficulties at the baseline assessment. 
The results for the NEI VFQ-25 composite score stratified by these potential 
effect modifying factors are shown in table 7.14. The "difference in means" 
column shows the mean composite VFQ-25 score in the universal screening 
group minus the mean score in the targeted screening group by sub-group. 
The P value is from the test for heterogeneity: that the sub-group results 
differed significantly from one another: the null hypothesis being that the effect 
size (difference in means) is the same for each sub-group. 
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Difference in means P value for interaction- 
(universal -targeted) and 
95% CI of difference 
Overall 0.41 (-1.68 to 2.50) 
Subgroup: 
Age 
74 to 79 0.95 (-1.35 to 3.25) 
80 to 84 -1.36 (-5.35 to 2.63) 
85 to 96 1.36 (-3.01 to 5.72) 
Sex 
Mate -1.53 (4.21 to 1.14) 
Female 1.39 (-0.96 to 3.73) 
Follow-upperiod 
Minimum (1.6) to 2.9 years 0.15 (-3.66 to 3.97) 
3.0 to 3.9 years 0.77 (-2.11 to 3.64) 
3.9 to maximum (5.8) years 0.04 (-2.78 to 2.85) 
Social isolation' 
Not isolated 
Isolated 
Setfreported visual difficulty at 
baseline 
None or a little 
A lot 
0.42 (-2.03 to 2.86) 
1.0 1 (-5.06 to 7.09) 
0.20 (-2.45 to 2.05) 
-4.48 (-17.96 to 9.00) 
* test for heterogeneity of effect across sub-groups 
# see text for explanation 
0.75 
0.09 
0.80 
0.84 
0.52 
Table 7.14 Difference in mean composite VFQ-25 score comparing universal 
with targeted screening: potential effect modifiers 
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For each factor the stratum specific difference in means between the 
randomised groups are similar, the confidence intervals overlap, and none of 
the interaction terms approach significance. The one exception is for gender, 
where the P value for interaction is 0.09. However, the difference in the effect 
between the two genders is small. Therefore there is no good evidence that 
the effect of the intervention differed in any of the sub-groups. Of particular 
note was that the estimate of effectiveness differed very little by follow-up 
period. The sub-group results for the visual function outcome are therefore 
consistent with the sub-group results for the visual acuity outcome. 
Per protocol analysis 
Participants who completed baseline screening and visual function 
outcome assessment 
There were four people who had outcome data for the primary visual acuity 
outcome who had insufficient data to calculate a composite NEI VFQ-25 
score: one person in the universal screening group and three in the targeted 
group. Other than these four people, the people included in the per-protocol 
analysis for the visual function outcome were the same as those people 
included in the per-protocol analysis of the visual acuity outcome (table 7.10). 
Among the 1803 people who completed the visual function questionnaire part 
of the outcome assessment, 1521 had fully complied with the baseline 
screening intervention. In the universal screening arm, 700 out of 828 people 
who had an outcome assessment had undergone a detailed visual screening 
assessment. In the targeted screening arm, out of 975 people who had an 
outcome assessment, 779 people had a brief assessment, 50 of whom were 
eligible for a detailed assessment. Of these 42 people completed a detailed 
assessment. Therefore 821 people in the targeted screening arm who 
completed an outcome assessment had undergone baseline screening as per 
the study protocol. 
Per protocol result 
Only the co ' mposite score was analysed. The mean score in the universal 
screening group was 86.44 and in the targeted screening group was 86.11. 
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The difference (the mean score in the universal arm minus the mean score in 
the targeted arm) was 0.33,95% confidence interval -2.13 to 2.80, P=0.78. 
Other than a slightly wider confidence interval (due to smaller numbers 
included in the analysis), the per protocol result for the visual function primary 
outcome measure was virtually identical to the intention to treat analysis. 
7.4 Summary 
Offering visual acuity screening for all people aged over 75 years as part of a 
multidimensional screening assessment was no more effective at improving 
either visual acuity or visual function than a strategy of only offering visual 
acuity screening to people found to have a range of problems at a brief 
screening assessment. There was no evidence of confounding by age, sex, 
time period from screening assessment to outcome assessment or levels of 
self reported visual difficulty at baseline. The effectiveness of universal 
compared with targeted screening did not vary by age, sex, whether people 
lived alone or not, frailty, level of self reported visual difficulty at baseline or 
time period from screening assessment to outcome assessment. 
Restricting the analysis to people who completed the screening assessments 
they had been randomised to produced virtually identical results, strongly 
suggesting that the lack of effect seen was not due to people failing to 
complete their screening assessments. 
The results for visual function and visual acuity were consistent. 
The results are discussed in more detail in chapters 9 and 10. 
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CHAPTER 8. RESULTS 2: SECONDARY OUTCOMES 
8.1 Secondary visual acuity outcomes 
Missing and incomplete data 
A total of 28 people from the 1807 who had outcome assessments had no 
recorded valid binocular visual acuity measurement, 16 in the targeted group 
I 
and 12 in the universal screening group. Given the low level of missing values, 
the approximately equal distribution between the two groups, and the fact that 
binocular measures were only secondary outcomes, it is unlikely that these 
missing data would have a substantial impact on the results of the trial. 
Pinhole assessments 
A total of 554 participants (30.7%) who had an outcome visual acuity 
assessment were eligible for a pinhole assessment, 316 (32.3%) in the 
targeted group and 238 (28.7%) in the universal screening group. However 
only 388 (70.0% of those eligible) completed a pinhole assessment, with 
similar proportions in the two groups (67.2% in the targeted group and 71.3% 
in the universal group). The possible reasons why substantial numbers of 
people eligible for a pinhole assessment did not complete the assessment are 
discussed in Chapter 9. The incompleteness of the pinhole corrected outcome 
data would have had no influence on the primary trial outcomes presented in 
Chapter 7. However, it will have led to an underestimate of the proportion of 
visual impairment at outcome that could be attributed to refractive error. 
However, because the missing data was approximately balanced across the 
two groups, it will not have substantially affected the pinhole corrected visual 
acuity outcome comparison between the two groups. 
Results 
Dichotomous outcomes 
The results for the secondary visual acuity dichotomous outcome measures 
are shown in table 8.1. 
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Using binocular presenting vision less than 6/18 as the outcome produced a 
slightly different results. The odds ratios indicates a possibly small beneficial 
effect of universal compared with targeted screening. However, the difference 
between the two intervention groups are far from significant and the 95% 
confidence interval ranges from a beneficial effect to a harmful effect of 
universal screening. 
The pinhole corrected visual acuity less than 6/18 in one or both eyes result 
differs from the non-pinhole corrected, with a small but non-significant benefit 
shown for people in the universal screening group. 
Using a cut-off of visual acuity less than 6/12, the results follow a very similar 
pattern to that observed for visual acuity less than 6/1 B. 
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Continuous visual acuity outcomes 
As previously discussed (Chapter 3), one advantage of using logMAR 
measures of acuity is that they can analysed as a quantitative variable. The 
mean logMAR acuity and the difference between the two groups are shown in 
table 8.2. 
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The differences in the mean logMAR acuity between the two groups are small 
and not significant for all the outcomes. All outcomes were slightly better 
(smaller logMAR average scores) in the universal screening group. 
The logMAR score is the log (base 10) of the minimal angle of resolution of 
the letters read for that score. Because of the irregular progression of letter 
sizes on a Snellen chart, interpreting differences in logMAR scores in terms of 
differences in Snellen acuity is not straightforward, because the Snellen 
equivalent difference depends on the actual acuity level. However, for all 
outcomes, the differences between the two groups were less than -0.03 
logMAR units. To put this in context, a -0.1 logMAR change is equivalent to a 
change in Snellen score from 6130 to 6/24, or from 6/15 to 6/12 (see appendix 
12). The differences observed were around one third to one fifth of this order 
of magnitude. 
8.2 Secondary visual function outcomes 
The secondary visual function outcomes were the NEI VFQ-25 sub-scale 
scores. 
Missing and incomplete data 
As described in Chapter 7, a total of 140 people out of the 1807 (7.8%) who 
had an outcome assessment had missing scores for one or more VFQ 
subscale (excluding the driving subscale among non-drivers). The proportion 
of people with missing data was similar for the two randomised groups: 7.8% 
in the universal screening arm and 7.7% in the targeted arm. However, there 
was no evidence for a differential bias in levels of missing values by 
randomised group, and the level of missing values overall was low. Even for 
the sub-scale with the most missing values (colour vision), the total of 15 
missing was less than 1% of the total sample. 
Comment on the interpretation of sub-scale results 
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The NEI VFQ-25 is divided into 12 separate sub-scales. However, four of 
these sub-scales are based on a single question, and a further four are based 
on only two questions. In addition the extent to which the NEI VFQ sub-scales 
actually measure different domains has been questioned. 85 Because of the 
large number of sub-scales (and hence the likelihood of false positive results 
due to multiple comparisons), the developers of the NEI VFQ advise a priori 
specification of those sub-scales that are of most relevance to the intervention 
or effect being measured. 203 However in this study all possible causes of 
reduced vision were included and participants potentially could have received 
a broad range of interventions. We therefore had no specific sub-scales we 
wished to focus on as outcomes, hence the specification of the composite 
score as the primary outcome measure. These factors (discussed in more 
detail in Chapters 9 and 10) mean that caution is required when interpreting 
the results for the different sub-scales. 
Results 
The differences for all 11 vision sub-scales and for the general health question 
are shown in table 8.3. All differences between the two randomised groups 
were very small and none were significant. 
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8.3 Summary 
Thejesults for the secondary outcomes were consistent with those of the 
primary outcomes, showing that offering visual acuity screening for all people 
aged over 75 years as part of a multidimensional screening assessment was 
no more effective at improving visual function than a strategy of only offering 
visual acuity screening to people found to have a range of problems at a brief 
screening assessment. 
Following pinhole correction of refractive error, the proportion of people with 
a visual acuity of less than 6/18 in either eye fell by around 10%. The pinhole 
corrected vision is a better reflection of reduced visual acuity likely to be due 
to eye disease rather than refractive error, although it is likely that not all 
refractive error would have been corrected. The resulting proportion of 
people with a corrected visual acuity of less than 6118 in either eye was 
somewhat lower in the universal screening arm, but the difference between 
the two groups was not significant. 
The binocular presenting acuity results also showed that the proportion or 
participants with reduced vision was slightly lower in the universal screening 
arm. However, again the differences were not significant and were 
compatible with random variation in the results obtained. 
The conclusions from the analysis of visual acuity as a continuous measure 
were the same: a very small but non-significant difference in favour of the 
universal screening group. 
For the NEI VFQ-25 sub-scale results, there were no significant differences 
between the two groups and all the differences observed were small. 
The results are discussed in more detail in Chapters 9 and 10 
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CHAPTER 9. RESULTS 3: EXPLANATORY AND PROCESS 
MEASURES 
9.1 Approach to the analysis 
An approach to analysing the effectiveness of different stages of a preventive 
intervention was developed 255 and subsequently updated by the Canadian 
Task Force on the Periodic Health Examination . 
256 This approach is similar to 
the approach used in Chapter 1 (section 2) of this thesis, the review of non- 
trial literature around screening older people for impaired vision. A causal 
pathway is mapped out identifying different elements of the intervention 
package and considering the effects of each stage separately. 
For the intervention assessed in this trial these stages were: 
a) Accuracy and validity of the screening test used. 
b) Levels of visual impairment found. 
c) Proportion of people with visual impairment already known to the eye 
services. 
d) Eligibility for referral. 
e) Causes of visual impairment found. 
f) Likely effectiveness of interventions for visual impairment found. 
g) Uptake and consequences of referrals. 
h) Reasons for non-uptake of referrals or interventions. 
9.2 Explanatory factors 
Accuracv and validitv of the screenina test used 
A possible drawback of the previous trials of multidimensional screening of 
older people that included a screen for visual problems was that all trials had 
used a self-reported measure of visual problems as a screening tool. In the 
universal screening arm of this trial, all participants had a visual acuity 
measurement. There is no "gold standard" against which to judge visual 
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acuity. However this does not mean that visual acuity has no possible 
shortcomings as a screening tool. 
Measurement effor 
There was likely to be some measurement error in the screening visual acuity 
assessments undertaken at baseline. Although the nurses all received the 
same training and were all observed undertaking measurements during the 
training session, it is likely that there were some inconsistencies in the 
procedures adopted by different nurses, as well as a varying level of errors 
made. Although the research nurses were asked to take steps to ensure 
adequate lighting, lighting levels were not standardised. In the clinic setting it 
is likely that lighting levels were adequate. However, around one third of 
screening assessments were undertaken in participants' homes where 
lighting levels are likely to have been more variable. 64 
The proportion of people who had their vision measured at one metre 
because of space restrictions was small at around 
ý% 
overall. Although the 
chart used was designed to be able to be used at one metre, there is a small 
loss of accuracy of measurement. 67 
Some impression of the specificity of the visual screening measurements can 
be gained by looking at those people found to have visual impairment who 
were eligible for referral to an ophthalmologist. For those people with 
available data who were eligible for referral, only 3 out of 116 (2.6%) had no 
previously diagnosed eye disease. 
The pinhole test 
The pinhole occluder was used to distinguish refractive error as a likely 
cause of visual impairment found. However. some older neonle find the 
pinhole occluder difficult to use . 
71 This may be because one effect of the 
pinhole occluder is to greatly reduce the amount of light reaching the eye, 
and older people are known to already have reduced retinal illumination. 257 
As seen in section 6.3, only around half the participants who were eligible to 
have a pinhole corrected visual acuity assessment actually had 
measurements recorded by the research nurses. The reasons why around 
half the people eligible did not have pinhole corrected measurements 
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recorded are unclear. However, several of the research nurses reported that 
many participants found the pinhole occluder difficult to use or said they 
could not see properly through it. Given that the pinhole occluder led to 
substantial visual improvement in around one third of the people who did 
have pinhole corrected acuity measurements recorded, it is likely that 
refractive error as an easily correctable cause of visual impairment was 
under detected. People with visual acuity of less than 6/18 in either eye who 
did not have a pinhole assessment were referred to an ophthalmologist, and 
would have had refractive error diagnosed in the ophthalmology clinic. 
Visual acuity as a measure of the need for interventions 
As discussed in Chapters 1 and 3, reduced visual acuity may not accurately 
reflect "need" for measures to improve vision. However, to date the visual 
function indices that have been shown to be valid 85 would be too long to be 
feasible screening tools. The development of screening tools that are better 
able to measure the impact of vision on peoples' lives are needed. 
Criteria for refeffal ý following screening 
The criteria were chosen at the time the main trial was designed in the early 
to mid-1990s. The referral criteria were an attempt to ensure that people 
referred were those likely to benefit from interventions. Therefore people who 
were already registered as blind or partially sighted and people who had 
seen an ophthalmologist in the past year were not eligible for referral on the 
grounds that they were unlikely to benefit from a new referral. 
As discussed in Chapter 1, recent work has shown that the levels of vision at 
which people have difficulties with everyday tasks depend on the task, 
indicating the limitations of trying to define a level of vision as disabling. 81 ; 83 
Although somewhat arbitrary (being dependent on the context of the health 
system), a pragmatic action threshold set by considering the level of vision 
below which a person is likely to be offered interventions to improve their 
vision provides a coherent method of determining referral criteria. 
Clearly referral was appropriate for the people who attended ophthalmology 
clinics and who benefited from cataract extraction (16 out of 41 people 
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referred and who had outcome data available). For the other people who 
were referred to and attended ophthalmology clinics, a range of new 
diagnoses were made. Although visual acuity was not improved, there is no 
evidence to suggest that the referrals were inappropriate. 
Many of the people advised to see an optician obtained new lenses (24 out of 
40- people with outcome data available) and their level of uncorrected 
refractive error was reduced, again suggesting that their referrals were 
appropriate. 
Levels of visual impairment found 
As reported in Chapter 6, a substantial proportion of participants were found 
to have disabling levels of visual loss at the baseline screening assessment 
(table 9.1). In the universal screening group, 28.8% (451/1565) of people had 
a visual acuity of less than 6/18 in either eye, and 12.1% (179/1481, 
excluding 84 people with missing values) had a binocular acuity less than 
6/18. The nested vision screening trial included only a sample of the 
practices participating in the MRC Trial of the Assessment and Management 
of Elderly People in the Community, and a sample of people from within 
these practices. The levels of visual impairment found in the nested vision 
screening trial were similar to those found in the main trial, indicating that a 
representative sample was included in the nested vision screening trial. 238 
Taking into account methodological differences in the measurements made 
and the fact that people in long4erm residential care or with terminal disease 
were excluded, the levels are similar to prevalence estimates from previous 
surveys in the United King d OM. 35; 37; 38 
In the targeted screening group, 44.2% (53/120) of people who had a visual 
acuity screening assessment had an acuity less than 6/18 in either eye, and 
22.0% (26/118, excluding two people with missing values) had binocular 
acuity less than 6/18. As already explained, the higher levels of visual 
impairment in the small sub-group from the targeted screening group are not 
surprising, given that these people were selected for a detailed assessment 
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on the basis of having a range of problems found at the brief screening 
assessment. 
As would be expected, the numbers of people with visual problems found 
using a cut-off of Snellen acuity less than 6/12 were substantially higher. 
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Targeted screening Universal screening 
group group 
Number eligible ISO 2140 
Proportion completing detailed assessment 
(number) 
Ofpeople completing a detailed assessment. ý 
Visual acuity < 6/18 in either eye 
Proportion with visual acuity < 6118 
in either eye who had a pinhole 
assessment 
80.0%(120) 73.1% (1565) 
n=120 n-1565 
43.2%(53) 28.8%(451) 
51.0% (27153) 49.5% (2231451) 
Visual acuity <6/18 in either eye that 6.7%(8) 5.1%(79) 
corrected to >6/18 with pinhole correction 
Visual acuity < 6/18 binocular 22.0% (26ý 12.1% (179)* 
Visual acuity <6/12 in either eye 60.0%(72) 47.0%(736) 
Visual acuity <6/12 binocular 45.8%(54)4 34.3% (508)* 
Owned glasses 87.5%(105) 88.3% (1382) 
exc ud ng 84 people with missing values 
I excluding 2 people with missing values 
Table 9.1 Summary of baseline vision findings from the detailed screening 
assessments by randomised group 
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Proportion of people with reduced vision alreadv known to the eve 
services 
Glasses ownership among people with probable refractive error 
As shown in table 9.1, the overall level of glasses ownership was high (88%). 
Among the sub-group of people found to have reduced acuity (<6/18) in 
either eye that corrected with use of the pinhole occluder, levels of glasses 
ownership were similar to levels among the whole sample (table 9.2). 
Participants were asked to wear their usual glasses for the visual acuity 
screening assessment. Thus in spite of the high proportion of people already 
owning glasses, there was evidence that many still had refractive error that 
could be improved using a pinhole occluder, suggesting their glasses were 
inadequate. 
Contact with ophthalmology services 
In the universal screening group, 28.8% of those people found to have visual 
acuity less than 6/18 in either eye reported that they had seen an 
ophthalmologist in the previous year (table 9.2). In the targeted screening 
group, the corresponding figure was lower at 15.1%. This difference may 
partly be a reflection of the higher levels of registration as blind or partially 
sighted in the targeted group. People who had been registered as blind or 
partially sighted more than one year before the screening assessments 
would be unlikely to have seen an ophthalmologist in the previous year. 
Registration as blind or partially sighted 
The numbers of people who reported being registered blind or partially 
sighted are shown in table 9.2. The criteria for registration in the United 
Kingdom are based on accurate best corrected acuity measurements and 
visual field assessments. Given that only around half the people with reduced 
vision actually had a pinhole assessment, that the pinhole occluder is only a 
crude way 'of correcting possible refractive error and that visual fields were 
not measured, we could not fully assess the accuracy of this self-reporting. 
In summary, taking the universal screening arm as representative of the 
population screened, among the people with visual impairment that did not 
136 
appear to be due to refractive error, 35.0% (1301372) of people had seen an 
ophthalmologist in the previous year and a further 14.2%% (53/372) were 
registered blind or partially sighted. 
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Targeted screening Universal screening 
group group 
n=53 n-451 
Visual acuity corrected to >6/18 with pinhole 
assessment 
Proportion who ownedglasses among 
people whose vision corrected with pinhole 
Seen by ophthalmologist in previous 12 months 
Registered: 
blind 
partially sighted 
data on registration status missing 
15.1%(8) 17.5%(79) 
75.0%(618) 90.0% (71179) 
15.1%(S) 28.8%(130) 
7.5%(4) 4.0%(18) 
11.3%(6) 7.8%(35) 
5.7%(3) 5.3%(24) 
Table 9.2 Contact with eye services by randomised group among people found 
to have visual acuity less than 6/18 in either eye at baseline screening 
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Eligibility for referral 
Among people found to have visual acuity of less than 6/18 in either eye, 
many were not eligible for referral to an ophthalmologist for a variety of 
reasons. These are shown in table 9.3 along with the numbers eligible. Note 
that the column totals do not add up because people can be in more than 
one category. For example someone could have reduced acuity visual that 
corrected to greater than 6/18 with a pinhole occluder and therefore be 
eligible for referral to an optician, but also have seen an ophthalmologist in 
the previous 12 months. 
Universal screening group 
In the universal screening group, 451 out of 1565 people who had a 
screening assessment had a visual acuity less than 6/18 in either eye. From 
the 1565 people who had an assessment, 220 (14.1%) were eligible for 
referral to an ophthalmologist and 79 (5.1%) were eligible for referral to an 
optician. 
Targeted screening group 
In the targeted screening group, 53 out of 120 people who had a screening 
assessment had a visual acuity less than 6/18 in either eye. From the 120 
people who had an assessment, 29 (24.2%) were eligible for referral to an 
ophthalmologist and 8 (6.7%) were eligible for referral to an optician. 
The people in the targeted screening group who had a detailed assessment 
had been selected on the basis of having a range of health problems. The 
higher proportion of visual problems in this group is therefore not surprising. 
The total number of referrals in the targeted arm was however still low, 
reflecting the small proportion of participants in the targeted arm who 
completed a detailed assessment. 
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Targeted Universal 
screening group screening group 
n- 53 n- 451 
Reason why not eligiblefor referral to 
ophthalmologist 
Registered blind or partially sighted 10 (18.9%) 53 (1 1.89/o) 
Seen by an ophthalmologist in 8(15.1%) 130 (28.81/6) 
previous 12 months 
Acuity >6/18 with pinhole coffection 8(15.1%) 79(17.5%) 
Eligiblefor referral 
To ophthalmologist 29 (54.71/o) 220 (4 8.81/6) 
To optician 8(15.1%) 79 (17.5%) 
Note column totals do not add up because people can be in more than one category 
Table 9.3 Eligibility for referral from baseline assessment by randomised group 
among people found to have visual acuity less than 6/18 in either eye at baseline 
screening 
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Causes of visual impairment found 
Refractive error 
Proportion attributable to refractive error 
In the universal screening group, of the 451 people with visual acuity less 
than 6/18 in either eye, 79 (17.5%) had a pinhole corrected acuity of greater 
than 6/18, suggesting that the reduced vision could be at least partly 
attributed to refractive error (table 9.4). In the targeted screening group, the 
corresponding proportion was 8/53 (15.1%). As discussed above, the 
proportion attributable to refractive error will have been under-estimated 
because many eligible people did not complete a pinhole assessment. 
Other causes 
Sources of data 
Of-the 249 people eligible for referral to an ophthalmologist following the 
baseline assessment, data on the likely causes of the visual loss found on 
screening came from two sources. Firstly, the search of patient general 
practice records undertaken by the study nurses at the time of the outcome 
assessment in the vision screening trial. All letters and entries in the patient 
records that were about eyes were extracted. Diagnoses and treatments 
recorded both before and after the date of the baseline assessment were 
summarised using a structured data extraction form (appendix 11). The data 
about diagnoses and treatments following the baseline screening are 
presented below in section (g). The second source of data about the likely 
causes of the visual loss was from an additional study that was undertaken 
by Jenny Evans and colleagues (Moorfields Eye Hospital). This study 
(referred to below as the Causes of visual impairment study) aimed to identify 
the causes of visual impairment of participants in the MRC trial of the 
assessment and management of older people in the community. For the 
causes study, in addition to the data extracted from letters from eye services 
which were included in general practitioner notes, a one-page questionnaire 
was sent to the hospital ophthalmologist who had last seen the patient. This 
questionnaire was in the form of a check-list that'covered: age-related 
macular degeneration, cataract, glaucoma, diabetes, myopic degeneration, 
or other (asked to specify). The ophthalmologist was asked to rank, if 
possible, any conditions ticked in order of their contribution to visual loss. 
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Both sources of data were incomplete for a variety of reasons, so that even 
after combining information from the two sources, the cause of visual 
impairment could not be identified for a substantial number of people eligible 
for referral. 
Of the 249 people eligible for referral to an ophthalmologist, 108 (43.4%) had 
died before having an outcome assessment, meaning that general practice 
notes were not available to the study nurses (the high mortality rate is 
discussed in more detail below in Chapter 10). An additional 10 people had 
moved away. Although our original intention had been to collect data from the 
medical records of all remaining participants, in practice the data extraction 
from notes was only undertaken for people who completed an outcome 
assessment. The main reasons for this restriction were high workload and 
time constraints for the study nurses. We asked them to focus on achieving a 
high uptake rate for outcome assessments, to undertake notes searching at 
the time of outcome assessment for participants, and go on to search the 
notes of people who did not complete an outcome assessment when they 
had time. In practice the latter did not happen. A secondary factor raised by 
some of the research nurses was that they did not feel comfortable searching 
the medical records of people who had refused to participate in the outcome 
data collection part of the study. In spite of the fact that we had ethical 
approval to search the medical records of all people who were screened at 
baseline, it was difficult to override the nurses' reluctance on this issue. 
The Causes of visual impairment study only included people from the 
universal arm of the main trial. The cause of visual impairment was identified 
for around 70% of visually impaired participants. However, a limitation in 
using data from the Causes of visual impainnent study was that the study 
only attempted to assess the cause of visual impairment in those people 
found to have a pinhole corrected visual acuity of less than 6/18 in their 
better eye at the baseline assessment. Eligibility for referral to an 
ophthalmologist was based on a corrected visual acuity of less than 6/18 in 
either eye, meaning that many people who were eligible for referral to an 
ophthalmologist were not eligible for inclusion in the Causes of visual 
impairment study. Conversely, many of the people with data on diagnoses 
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available from the causes of visual impairment study had seen an 
ophthalmologist in the previous year or were registered blind or partially 
sighted, and were therefore not eligible for referral to an ophthalmologist in 
the trial. 
Causes identified 
Of the 75 people eligible for referral to an ophthalmologist at the baseline 
screening assessment who also completed an outcome assessment, data 
about eye disease and treatments were extracted from the general practice 
records for 72 people (96.0%). For three people there was no record of them 
ever having been seen by any eye services, and this accorded with their 
response to the outcome assessment questionnaire. The cause of visual 
impairment at baseline could be identified for a further 41 people from the 
causes of visual impairment study. Therefore the likely cause of visual 
impairment at baseline could be identified for a total of 113/249 (45.4%) of 
people eligible for referral to an ophthalmologist. 
The causes of visual impairment broken down by randomised group are 
shown in table 9.4. 
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Cause identified All Targeted Universal 
number screening group screening group 
number number 
Total eligiblefor referral to 249 29 220 
ophthalmologistfollowing baseline 
screen 
Eligible for referral and data on 113(100%) 15(100%) 980000/0) 
cause of visual loss available 
Age related macular degeneration 28 (24.71%) 
(AMD) 
Cataract with no record of extraction 19(16.8%) 
Cataract with record of previous 18(15.9%) 
extraction 
Cataract with uncertain record of 
previous extraction 
Diabetic eye disease 
AMD and cataract 
AMD and other 
Cataract and other 
Other 
Never seen by eye specialist 
4(26.7%) 
2(13.3%) 
2(13.30/o) 
22 (19.5%) 2(13.30/o) 
24 (24.5%) 
17 (17.3%) 
16 (16.3%) 
20(20.4%) 
1 (0.90/0) 0 1 (1.0%) 
14(12.4%) 2(13.3%) 12(12.2%) 
2(l. 80/o) I (6.7*/o) l(I. 0%) 
2(l. 8%) 0 2(2.0%) 
4(3.50/o) 1(6.7%) 3(3.10/o) 
3(2.6%) 1(6.7%) 2(2.0%) 
Table 9.4 Likely causes of visual impairment among people eligible for referral 
to an ophthalmologist at baseline by randomised group (for those with data 
available) 
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For people with a diagnosis of cataract, an attempt was made to distinguish 
between those people who had previously had a cataract extraction and 
those who had not. However, as can be seen from the table, this was not 
always entirely clear from the information extracted from the notes. Where 
there was uncertainty people were classified as unclear. 
The pattern of diagnoses are not typical of all older people with reduced 
vision. This is because the eligibility criteria for referral to an ophthalmologist 
excluded people who were registered blind and partially sighted, and also 
excluded people who had seen an ophthalmologist in the past 12 months. 
The proportions of people with age related macular degeneration, and to a 
lesser extent diabetic eye disease and glaucoma, are therefore lower than 
among the general population of people in this age group with visual 
impairment. 35; 37; 258 
Likely effectiveness of interventions for visual Impairment found 
The effectiveness of interventions for reduced vision were summarised in the 
literature review presented in Chapter 1, section 2. As discussed there, while 
it has been estimated that over 70% of the visual impairment present in 
people aged 65 and over is potentially remediable, 35 this high proportion may 
not apply to people identified in this trial. In the study by Reidy et al, visual 
impairment was defined as binocular visual acuity less than 6/12. The lower 
cut off to define visual impairment in this trial (visual acuity less than 6/18 in 
either eye), and the older age of participants meant that visual problems were 
more likely to be due to serious eye disease such as macular degeneration 
or glaucoma and less likely to be due to refractive error or cataract than in 
the population identified by Reidy et al. 35 
Uptake and consequences of referrals 
As explained above in section (e), detailed information about the results of 
referrals was only available for people who completed an outcome 
assessment. 
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Optician refeffals 
As discussed in Chapter 3, "referral to an optician" actually meant that the 
participant was advised to visit an optician. Data about the uptake and 
consequences of optician referrals are derived entirely from self-report. This 
was because it would have been difficult to collect data about participants 
from optician records for two reasons. Firstly participants could choose to go 
to any optician(s) they liked in any geographical location. Secondly, there 
would be no record of contact with an optician in the participant's medical 
record unless the optician made a specific recommendation to the general 
practitioner that the patient be referred to an ophthalmologist. The totally self- 
reported nature of the data about optician referrals therefore means that 
some caution should be exercised in interpreting the data. 
Of the 79 people eligible for referral in the universal screening arm, 36 people 
(45.6%) completed an outcome assessment and had data about the result of 
the referral available. In the targeted screening arm, of the 8 people eligible 
for referral, 4 (50%) completed an outcome assessment and had data about 
the result of the referral available. 
The results of the referrals are shown in table 9.5. 
As seen previously, there was a high level of ownership of glasses among 
those eligible for referral to an optician even before the baseline screening 
assessment. The proportion of people advised to see an optician who 
reported attending an optician at least once after the baseline screening was 
high at 80% (32 out of 40). Clearly many of these people may have attended 
an optician anyway even without screening. A total of 14 people when 
specifically asked remembered going to the optician as a result of being 
advised to do so at the baseline screening assessment. Of the remaining 
people, 14 said they went regularly already, and 4 could not recall whether 
the reason they went had anything to do with the baseline assessment. 
Quite high numbers of people had had new glasses or lenses recommended 
since the baseline assessment. By the time of the outcome assessment, all 
people eligible for referral to an optician at baseline owned glasses. The 
uptake and consequences of optician referrals are shown in table 9.5. 
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Ophthalmology referrals 
Of the 2ýO people eligible for referral in the universal screening arm at 
baseline, 65 people (29.6%) completed an outcome assessment and had 
data about the result of the referral available. In the targeted screening arm, 
of the 29 people eligible for referral, 10 (34.5%) completed an outcome 
assessment and had data about the result of the referral available. 
The results of the referrals are shown in table 9.6. 
New diagnoses and interventions 
Among people who did attend, there was a range of new diagnoses and 
treatments for eye problems (table 9.6). Newly diagnosed cataract was much 
the commonest category, with the majority of those being diagnosed having 
had surgery, which for four people had also involved further treatment for 
complications. A small number of people (five) were on cataract surgery 
waiting lists. As described above, the outcome assessments were 
undertaken three to five years after the baseline screening. The five people 
awaiting cataract surgery had not been placed on waiting lists immediately 
following the baseline assessments. Although they had seen an 
ophthalmologist within one year of the baseline screen, either the diagnosis 
of cataract or the decision to offer them surgery had occurred between 1 and 
4 years after this first appointment. 
There were several new diagnoses of age related macular degeneration 
(AMD). There were no people for which photocoagulation therapy was 
recorded. Photodynamic therapy was not available in the United Kingdom 
during the study period. There was one recorded referral to a low vision 
service for a patient with newly diagnosed AMD. There were six new 
registrations as partially sighted or blind: five of these people had AMD and 
one person had glaucoma. 
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All Targeted Universal 
number screening screening 
M group group 
number _C/6) 
number 
Eligible for referral 75(100%) 10(100%) 65(100%) 
Had ever seen an ophthalmologist (except in last 
12 months) 
51(680/o) 5(50%) 46 (70.8Yo) 
Evidence of a new referral to an ophthalmologist 
following the baseline assessment 
Attended an ophthalmologist following the 
basefine assessment 
Action taken* 
Cataract diagnosed 
Had cataract surgery 
On a waiting list for cataract surgery 
Cataract diagnosed but no action taken 
Diagnosis of age related macular degeneration 
Diagnosis of glaucoma 
Glaucoma surgery or laser treatment 
MEdical treatment of glaucoma 
Medical treatment other than glaucoma 
Diagnosis of retinal vein occlusion 
Diagnosis of refractive error 
Low vision referral 
Registered as partially sighted since baseline 
screening assessment 
Registered as blind since baseline screening 
assessment 
No new diagnoses or treatments (definite 
recording) 
41 (54.7'Yo) 3(30%) 38 (58-51/o) 
36(48%) 1 (100/0) 35 (53.8%) 
22 (29.3%) 1(101/0) 21(32.3%) 
16 (21.3%) 1 (100/0) 15 (23.11/6) 
5 (6.7*/o) 0 5(7.730/o) 
1 (1.3%) 0 1 (1.5%) 
7(9.3%) 1(10%) 6(9.2%) 
3 (4 */o) 0 3(4.60/o) 
2(2.70/o) 0 2 (3.11/6) 
3 (4'Yo) 0 3(4.6%) 
7(9.3%) 0 7(10.80/o) 
1 (1.3%) 0 1 (1.5%) 
1 (1.3%) 0 1(1.5%) 
1 (1.3%) 0 1 (1.5%) 
4(5.3%) 0 4(6.20/o) 
2(2.6%) 0 2(3.1%) 
5 (6.7'Vo) 0 5(7.7%) 
4 people can be in more than category for action taken 
Table 9.6 Uptake and consequences of ophthalmology referrals by randomised 
group for those with outcome data available (all diagnoses are newly recorded 
since the screening assessment) 
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Reasons for non-uptake of referrals or interventions 
Optometry (table 9.5) 
Six people who were referred to an optician did not attend (all in the universal 
screening arm). Of the four people who gave a reason, one said they were 
already under an ophthalmologist and three said they did not think they 
needed glasses. 
Five people in the universal arm did not obtain their recommended new 
glasses. Of these, three people cited cost as the reason they did not obtain 
new glasses and two people said they did not think they needed them. 
Ophthalmology (table 9.6) 
Whether referrals happened 
Whether people eligible for referral were actually referred was assessed from 
three different data sources: a tick box on the detailed baseline screening 
assessment forms; a search of patient medical notes for a new referral letter 
or evidence that they had seen an ophthalmologist since the baseline 
assessment; and asking the patient whether since the baseline assessment 
they had seen (or been invited to see) an ophthallnologist. 
When a participant was found to be eligible for referral to an ophthalmologist, 
the screening findings and the recommendation that the patient be referred 
was communicated in writing by the research nurse to the general 
practitioner. The referral depended on the general practitioner writing a 
referral letter, so clearly there was scope for nurse recommendations not 
being translated into referrals. 
There was clear evidence of a new referral for only 54.7% (41/75) of people 
who were eligible for referral following the baseline screening assessment. 
Possible explanations for this apparent under-referral are explored below. 
Factors associated with refeffal 
The proportion of people eligible for referral to an ophthalmologist for whom 
there was clear evidence of a new referral differed by randomised group 
(58.5% in the universal screening group versus 30.0% in the targeted group), 
]so 
although the numbers in the targeted group were small. In the targeted 
group, participants who completed a detailed assessment had been selected 
on the basis of having a range of problems found during the brief screening 
assessment. As a consequence of this, the people eligible for referral to an 
ophthalmologist in the targeted group were more frail and more likely to have 
multiple problems requiring intervention than people in the universal group. 
These factors may explain the lower proportion eligible for referral who 
actually were referred. 
There was marked practice variation in the proportion of people eligible for 
referral to an ophthalmologist for whom there was clear evidence of a new 
referral. In the universal screening arm, the proportion of eligible people who 
were referred ranged between practices from 33% to 100%. In the targeted 
screening arm, the numbers eligible in individual practices were very small, 
but again variation was seen with in one practice both eligible patients being 
referred and in another none of the four eligible patients being referred. Four 
of the practices were fundholding at the time of the baseline assessment, and 
there was anecdotal evidence from the research nurses that some 
fundholding general practitioners were concerned about the financial 
implications of multiple referrals arising from the multidimensional screening 
assessments. Excluding practices in which one or zero people were eligible 
for referral to an ophthalmologist, the proportion of people eligible who were 
referred was slightly lower in the fundholding practices (49% versus 58%). 
The difference was not significant (P=0.23) and caution is required in 
interpreting the difference based on such a small number of selected 
practices. 
Characteristics of people who were referred compared with people who were 
not referred are shown in table 9.7. 
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Characteristic 
All eligible for 
referral (n=75) 
Not referred 
(n=34) 
Referred 
(n=41) 
Median age 8 1.9 years 82.5 years 8 1.4 years 
Proportion male 25.3%(19) 26.5%(9) 26.8%(Il) 
Living alone 54.7%(41) 52.9%(18) 51.2%(21) 
Cognitive impairment at baseline* 17.3%(13) 20.6%(7) 12.2%(5) 
Mean binocular presenting logMAR' 0.319 0.265 0.354 
score 
Mean number of referrals arising 1.49 1.51 1.48 
from baseline screening assessment 
Previously seen an ophthalmologist 86.8%(65) 97.1%(33) 78.1%(38) 
* scored less than 24 on the mini mental state examination 
Table 9.7 Participants who were eligible for referral to an ophthalmologist: 
characteristics of people who were referred compared with people who were not 
referred 
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The age and sex distributions of those eligible who were and were not 
referred were similar. The proportion of people living alone was again similar 
among those referred and not. However, people who were not referred were 
more likely to have had evidence of cognitive impairment at the baseline 
screening assessment, indicated by a score of less than 24 on the mini 
259-261 mental state examination. 
Previous research has identified that greater severity of the problems 
identified by screening262 and a lower number of different recommendations 
for referra1125; 263 are associated with higher physician adherence to 
recommendations for referral arising from multidimensional screening 
programmes. As seen in table 9.7, people who were referred had worse 
vision than people who were not referred (the difference equivalent to about 
one line of vision on a Snellen chart), in line with previous research. 
However, the mean number of referrals recommended following the baseline 
assessment were similar for those referred and not referred. 
People who were not referred were more likely to have previously seen an 
ophthalmologist. Data about previous eye disease was available for 58 of 
those people eligible for referral: 24 of those not referred and 34 of those 
referred. The distribution of previous diagnoses of eye disease was different 
for those referred and not referred. People who were not referred were more 
likely to have previously diagnosed age related macular degeneration (52% 
vefsus 28% for those referred) or diabetic eye disease, and less likely to 
have previously diagnosed cataract (22% versus 31% for those referred). 
The numbers of people with other diagnoses were too small to interpret 
meaningfully. 
Uptake of refeffals 
Where there was evidence that a new referral had taken place, the uptake In, 
terms of attendance was high at 87.8% overall (36 out of 41 referrals). Of the 
five peopleW'ho did not attend, three gave a specific reason: one forgot about 
the appointment; one could not get to the hospital; and one did not think she 
needed to go. 
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Although the adherence by general practitioners to the recommendation for 
referral appears low, we do not have adequate data to be able to judge the 
appropriateness of the decisions to refer or not refer. Referral would have 
involved a clinical judgement about whether the patient would be likely to 
benefit from referral, and may have taken into account patient preferences. 
Referring someone who did not want to be referred would be a waste of time 
and resources as well as going against a patient's wishes. When people 
were referred, attendance at the clinic following referral was high. Previous 
studies have found rates of patient adherence to referrals arising from 
multidimensional assessments in the range of 46% to 76%. 125; 151; 264-268 The 
high uptake in this trial could partly reflect appropriate selection by general 
practitioners of people referred. However, this is speculative and it is possible 
that the uptake of referrals would have been just as high among those not 
referred. 
Effects on vision among people referred and treated 
While. the objective of the trial was to reduce the prevalence of visual 
impairment in the population, looking at the visual outcomes of those people 
eligible for referral and those who received interventions can help provide an 
insight into the effects of the screening intervention on vision. 
Eligible for optometry referTal 
Among the 87 people eligible for referral to an optician following the baseline 
screen, 40 had an outcome assessment, shown in table 9.8. At baseline, all 
40 had visual acuity of less than 6/18 in one or 
both 
eyes and there was no 
change in this by the time of outcome assessment (table 9.7). However, 
there was some improvement in the proportion of people with binocular 
presenting visual acuity of less than 6/18, with around a one third reduction. 
The mean logMAR scores are presented for the better eye in order that the 
effect of pinhole correction can be assessed (binocular pinhole corrected 
acuity not being available). At baseline, the mean presenting best eye acuity 
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was substantially improved by pinhole correction, suggesting uncorrected 
refractive error. By the time of outcome assessment, there was little 
improvement in the mean presenting best eye acuity with pinhole correction, 
indicating a lower level of uncorrected refractive error than had been present 
at baseline. Thus, while there was little improvement in presenting visual 
acuity between baseline and outcome assessments, there was some 
evidence that the level of uncorrected refractive error had been reduced. The 
lack of improvement in presenting vision could partly be due to an overall 
deterioration in vision between the two assessments which were three to five 
years apart. 
Among this 21 participants who were referred to an optician and who 
obtained new glasses or lenses, the mean logMAR best eye presenting 
vision improved from 0.373 at baseline to 0.210 at outcome (not included in 
the table). Particularly when considered with the likely underlying 
deterioration in vision with time, this indicates that vision was substantially 
improved when people obtained new lenses. (See appendix 12 for details of 
the relationship between Snellen visual acuity and logMAR scores). 
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Eligible for ophthalmology refeffal 
Among the 249 people eligible for referral to an ophthalmologist following the 
baseline screen, 75 had an outcome assessment, shown in table 9.9. At 
baseline, all 75 had visual acuity of less than 6/18 in one or both eyes. Again, 
there was no change in this by the time of outcome assessment. The 
prevalence of binocular presenting visual acuity of less than 6/18 was much 
lower at baseline, at 20% in both arms, with a slight worsening by the time of 
outcome assessment. 
The mean presenting binocular logMAR acuity showed a small improvement 
of around 0.05 logMAR points. This improvement was restricted to the 
universal screening group, but the results for the targeted screening group 
were based on only ten participants. 
157 
cl 
ol 
I. 
- 
. 5ý 2 CD 
00 
ý 
1-0 
ý 
%-4 C) 11-1 CD 
, -*, F 1 0 CD Q 0 0 , 0 CD en R as t, Vq, 
1 m mu 0 e e m 0 
Z: 0 
Ei 
(L) 
0 
ý ru Ici 4) 2 
et ý N s . ý tn e IU 
- 00 00 
- aý x: 
9 Z r, 
%) .! i .2 - a 
> 
00 
o 
.S Irl . .0 ýfa 00 
AN Al 42 C! 
a =3 :: j . - 
to) cn 
CIN %0 
vi CD 
el cl 
0 0%" 
0., 
C Ok... 
res 
00 vi 
ei ;ýe 
;3 .2 .2 ZZ 
tu U 4.1 Illý 
la 
w. 
CL) 
No 
Q 
a 
0 O-w .M 
Cit 
:EZ, 
>X po c3ý 
CDN 
OJ :s ju ct Z E4 0 
Co 
Effect of cataract surgery 
Sixteen participants who were referred to and attended an ophthalmologist 
following the baseline screen had had a cataract extraction by the time of 
outcome assessment (table 9.6) Although all sixteen continued to have visual 
acuity less that 6/18 in either eye at outcome, there was an improvement in 
their mean presenting binocular acuity. At baseline, the mean binocular 
logMAR acuity for these 16 people was 0.316, and at outcome assessment it 
was 0.168 (a change from a Snellen equivalent of 6/12 to 617.5), in line with 
expected benefits in this age group. 92 
Only one of the 16 people who had a cataract extraction were in the targeted 
screening arm, so a breakdown of these results by randomised group would 
not be useful. People did not have their visual function measured at baseline, 
meaning only changes in acuity can be assessed. 
Changes in vision among people who did not have cataract surgery 
There were twenty people who were referred to and attended an 
ophthalmologist following the baseline screen who did not have a cataract 
extraction by the time of outcome assessment (table 9.6) Among these 
people, there was no improvement in vision by the time' of outcome 
assessment: in fact there was a slight worsening. At baseline, the mean 
logMAR acuity for these 20 people was 0.352, and at outcome assessment it 
was 0.360. Again, because, participants did not have their visual function 
measured at baseline, only changes in acuity can be assessed. 
9.3 Summary 
It is unlikely that visual acuity was measured perfectly at baseline and 
reduced visual acuity does not accurately capture all aspects of the need for 
interventions to improve vision. 
However, it is still likely that screening did identify a large proportion of those 
people who could have benefited from interventions to improve their vision. 
High levels of visual impairment were identified. The proportion that could be 
attributed to refractive error (inferred from improvement in acuity with use of a 
pinhole occluder) was relatively low (about 17%), but this was likely to have 
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been an underestimate, largely because of difficulties with using a pinhole 
occluder. Better methods of detecting uncorrected refractive error are 
needed. 
Around one third of people identified as having visual impairment that could 
not be attributed to refractive error at baseline had seen an ophthalmologist 
in the previous 12 months, and a further 14% were already registered as 
blind or partially sighted. Overall, around one fifth of all those screened were 
eligible for referral to an optician of an ophthalmologist. This high proportion 
of people eligible for referral suggests that if recommendations for referral 
were taken up and effective treatments were obtained, there could have been 
a substantial reduction in the levels of visual impairment among people 
screened. 
Data on the causes of non-refractive visual impairment were only available 
for around half those people eligible for referral. Age related macular 
degeneration was, as expected, common. A high proportion of people had a 
diagnosis of cataract, but there was some uncertainty about the proportion 
who had already had treatment for their cataract(s). 
Only a very small proportion (2.6%) of those eligible for referral had never 
seen an ophthalmologist. 
While a range of effective interventions for reduced vision exist, it was difficult 
to assess the extent to which the people identified with low vision could be 
expected to benefit. Clearly in order to benefit, people would first have to be 
referred to and attend eye services. Most people eligible for referral to an 
optician already attended an optician at least occasionally prior to screening 
and owned glasses. However, there was evidence of uncorrected refractive 
error suggesting their glasses were not optimal. Around one third of those 
eligible for referral to an optician reported that they specifically visited aid 
optician as a result of being advised to do so after screening. By the time of 
outcome assessment, around half of these eligible for referral had obtained 
new glasses and all people who had been eligible for referral now owned 
glasses. Although the observed improvements in vision between the 
screening and outcome assessments among people referred to an optician 
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were modest, this must be seen in the context of their being a three to five 
year interval during which time some deterioration in vision may have 
occurred. There was evidence of a reduction in the level of uncorrected 
refractive error among people who obtained new lenses after screening, but 
the total numbers benefiting in the context of the trial were small. All data 
about use of optician services and glasses relied on self-report from 
participants and could be subject to some error in recall. 
We only managed to obtain information on reasons for non-uptake of optician 
referrals and interventions from a relatively small number of people: too small 
to draw firm conclusions. However, high cost was specifically raised by half 
of those who gave a reason for not obtaining newly recommended glasses. 
There was evidence of a new referral to an ophthalmologist for only just over 
half of those people eligible for a referral. This could possibly be an 
underestimate, for example if people were referred to an ophthalmologist 
without a referral letter being filed in the patient record or the letter was not 
extracted by the research nurse during the notes search. However, in 
previous trials of multidimensional screening, similarly low levels of clinician 
adherence to recommendations for referral have been found, with a range of 
49% to 79% . 
125; 265; 267,270 There was a marked variation in rates of adherence 
to recommendations for referral between practices, with limited data to 
suggest that adherence was lower in fundholding practices. ' Possible 
cognitive impairment at baseline was associated with a lower likelihood of an 
eligible participant being referred, presumably reflecting a clinical judgement 
by the general practitioner about the appropriateness of the referral. People 
who were referred had lower visual acuity than those not referred, in line with 
previous work showing the severity of the problem predicted clinician 
adherence with a referral recommendation. 262 Although the data were 
somewhat limited, there was some evidence that people with a previous 
diagnosis of age related macular degeneration were less likely to be referred, 
while those with a previous diagnosis of cataract were more likely to be 
referred. This may reflect judgement by the general practitioners about the 
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likely benefits to the patient arising from the referral, a factor previously 
shown to affect clinician adherence with referral recommendations. 262 We 
were unable to assess the appropriateness of the decisions to refer. 
Where there was evidence of a new referral to an ophthalmologist, 
attendance rates at the clinics were high at 87.8%. Previous studies have 
found rates of patient adherence to referrals arising from multidimensional 
assessments in the range of 46% to 76%. 125; 151; 264-268 Although none of the 
previously reported rates for uptake of referrals by patients were specifically 
derived from ophthalmology referrals, the rate in this trial was noticeably 
high. A variety of new diagnoses were made among those people who 
attended and a number of different interventions occurred. Much the 
commonest intervention was cataract extraction. The total number of people 
referred who subsequently had a cataract extraction was small at 16, but 
their vision improved. However, for the remaining people who attended their 
ophthalmology referral, there was no improvement in visual acuity from 
baseline. It is possible that some of these people may have benefited from 
rehabilitation or other measures that improved their visual function without 
improving measured visual acuity. However, because visual function was not 
assessed at baseline, we could not assess this. 
About half the people referred to an optician obtained new lenses, their level 
of uncorrected refractive error was reduced and their presenting vision 
improved. Similarly, around half the people referred to an ophthalmologist 
had cataract surgery and their vision improved. 
' 
However, in the context of 
the trial population, the numbers of people benefiting were small. These 
findings are consistent with the findings in the whole population screened, 
among whom little or no improvement in vision overall was seen due to 
screening. 
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CHAPTER 10. DISCUSSION AND CONCLUSIONS 
10.1 Discussion 
Introduction 
The systematic review of randomised trials (Chapter 2) showed there was no 
evidence for the effectiveness of screening older people for visual 
impairment. 271; 272 Factors common to all the existing trials were identified that 
could have contributed to the observed lack of effectiveness: 
e -lack of a clear plan of intervention for those people found to have visual 
impairment; 
the use of single questions about visual difficulties as both the screening 
tool and to assess outcome; 
the fact that visual function was not measured at outcome. 
Visual outcomes were therefore assessed in a lar! er trial of multidimensional 9 
assessment of older people in a nested trial design that overcame the 
possible drawbacks identified in the previous trials. The new trial again found 
no evidence for the effectiveness of screening for visual impairment, although 
a small beneficial effect could not be excluded. In Chapter 9, a range of 
process measures were considered as possible explanations for the effect 
observed in the trial. In this chapter, aspects of the trial design and execution 
are considered and the implications for practice, policy and research 
considered. 
The screening interventions compared 
This trial was not a straightforward comparison of screening versus no 
screening. At the time the trial was started, there was a contractual obligation 
on primary care teams to offer an annual screening assessment to all 
patients aged 75 and over (the "over 75s check"), specifically including an 
22 assessment of vision. It was therefore not possible to have a "no screening" 
control arm in the trial. The screening intervention in the targeted intervention 
group of the MRC trial of the assessment and management of older people in 
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the community was designed to be the minimal screening assessment that 
covered all areas specified for the over 75s check in the general practice 
contract. The targeted screening arm acted as the comparison group for the 
purposes of the nested vision screening trial. 
Targeted screening group 
In the targeted arm, all participants were asked about visual problems as part 
of a brief assessment. Criteria for then being offered a more detailed 
assessment (that included a visual acuity screen) were three or more 
problems identified from the brief assessment or any one of four "serious" 
symptoms (unexpected weight loss, frequent falls in previous month, 
vomiting blood, coughing blood). Among the 1684 participants in the targeted 
screening arm of the nested vision screening trial who completed a brief 
assessment, 150 (8.6%) reported sufficient problems to be eligible for a 
detailed assessment, and 120 attended (see Chapter 6, especially figure 6.1 
and table 6.6). A total of 29 people in the targeted arm were eligible for 
referral to an ophthalmologist, and a further eight people were eligible for 
referral to an optician. Therefore a total of 2.2% (37/1684) were eligible for 
referral to the eye services. 
Universal screening arTn 
In the universal screening arm, all participants were offered both brief and 
detailed assessments. 220 people were eligible for referral to an 
ophthalmologist, and a further 79 people were eligible for referral to an 
optician. Therefore a total of 18.0% (299/1662) of pa4icipants in the universal 
screening group were eligible for referral to the eye services. 
M- 
Fossible effects on the trial result 
If referral to the eye services had a large impact on improving vision, there 
could have been a improvement in the prevalence of visual problems in the 
targeted screening group (which was effectively the control comparison 
group in the trial) and hence an under-estimation of the effectiveness of 
screening in the trial. However, given the very small proportion of people 
eligible for referral in the targeted group (2.2% compared with 18.0% in the 
universal screening group), even if referral had had a dramatic effect on 
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vision, there would have been little impact on the overall prevalence of visual 
problems in the targeted group and thus little impact on the trial result. 
In fact, as seen in Chapter 9, even among those people eligible for referral to 
the eye services following screening, the improvements in vision were 
I 
modest overall. 
i In summary, although a small number of people in the comparison or control 
arm of the trial did have a visual screen, this was unlikely to have had a 
substantial effect on the estimate of effectiveness of screening from the trial. 
Trial outcomes 
Visual acuity 
Measurement effor 
As described in Chapter 9 in the context of visual acuity testing at the 
screening assessment, there was likely to be some measurement error in the 
visual acuity outcome measurements. However, for the outcome 
assessments, the research nurses received a full day training focused 
entirely on vision. In addition the design of the data collection form (appendix 
8) helped reduce the possibility of invalid values for visual acuity being 
entered. The numbers of missing, implausible and inconsistent values were 
very low indeed. 
As with the baseline screening assessments, the research nurses were 
asked to take steps to ensure adequate lighting. Just over half the outcome 
assessments were undertaken in peoples' homes where lighting levels are 
likely to have been more variable than in the clinic setting. 64 However, the 
proportion of people who had their vision measured at home was similar in 
the two arms of the trial. The use of a one metre testing distance because of 
space restrictions was low at 6.2%, and again the proportion was similar in 
the two arms of the trial. 
Overall, although there was likely to have been some measurement error, it 
seems unlikely that error in the visual acuity outcome assessments could 
have affected the results of the trial substantially. 
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One or both eyes 
The primary acuity outcome measure was visual acuity less than 6/18 in 
either eye, with binocular presenting acuity as a secondary outcome 
measure. The main reason for this choice was that it directly measured the 
intervention. Eligibility for referral to eye services was based on reduced 
visual acuity in either eye, not on binocular or better eye acuity. 
In developed countries, interventions (such as cataract extraction) are 
undertaken on the basis of reduced acuity in one eye, even if the acuity is 
relatively good in the other eye. This is justified because there is evidence 
that second eye surgery for cataract (after successful surgery for cataract iq 
the first eye) produces similar gains in terms of visual function as first eye 
surgery. 273; 274 In contrast to this finding, it has been shown that acuity in the 
better eye is a good predictor of binocular acuity, and certainly a much better 
predictor than acuity in the worse eye. 275 Rubin et al suggest that this 
apparent contradiction may be explained by second eye surgery having a 
beneficial effect on measures such as reading speed, mobility and self 
perceived visual disability, 276; 2 "77 even though it has relatively little effect on 
binocular acuity. 
Visual function 
As previously discussed in Chapters 1 and 3, visual acuity is not the only 
factor that influences a person's visual function. Visual field loss, reduced 
contrast sensitivity, glare, reduced stereoacuity and poor home lighting can 
have an adverse effect on vision, even though on formal testing visual acuity 
may be preserved. Rather than attempting to undertake a complex battery of 
objective ophthalmological measures, and also because in recent years the 
value of visual function indices in assessing the effectiveness of interventions 
to improve vision has become widely accepted, we assessed visual function 
as a subjective measure of how visual problems (of whatever sort) affected 
peoples' ability to function in an everyday setting. 85 
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Choice of visual function scale 
At the time we designed the outcome data collection, the National Eye 
Institute Visual Function Questionnaire was emerging as a leading research 
tool for assessing visual function, in part because of its promotion by the 
National Eye Institute. The shortened 25 item version was developed to 
measure the dimensions of self-reported vision related health status that are 
of greatest importance to people with chronic eye disease and to be quicker 
and easier to administer. The main reason for choosing this particular tool 
was that it was specifically developed to be able to assess people with a 
broad spectrum of eye diseases and vision impairments. In addition, the NEI 
VFQ includes an assessment of the psychological and emotional impact of 
rý-duced vision. Although the NEI VFQ had been little used in the United 
Kingdom, in the pilot study there were no problems with its use when 
compared to the VF-14 scale which had been extensively used in the United 
Kingdom. The VF-14 was initially developed specifically in the context of 
cataract. The NEI VFQ was therefore chosen given its development among 
people with a broader spectrum of causes of reduced vision. 
A generic vision-related quality of life question 
' 
naire called the VCMI has 
been developed in the United Kingdom . 
185The initial validation study of the 
final version was undertaken in 92 people and suggested the VCMI was a 
promising instrument. However, at the time we were designing the outcome 
assessments for the vision screening trial, the VCMI had only just been 
published and, particularly among very elderly people, there was no 
experience of its use outside of the validation work undertaken by the 
developers. 
The trial result for the NEI VFQ composite score was consistent with the 
visual acuity results. In this trial, the correlation coefficient for the composite 
NEI VFQ-25 score and the presenting binocular logMAR visual acuity was - 
0.53 (the negative simply a function of the fact that better visual acuity 
produces a lower logMAR score). The correlation coefficient for the 
composite NEI VFQ-25 score and the presenting best eye logIVIAR visual 
acuity was -0.50 and for the presenting worst eye was -0.44. These 
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correlation coefficients are somewhat lower than those recorded by 
Mangione et al in a North American population: -0.72 for the better eye and - 
0.69 for the worst eye. 203 The figures from North America are derived from a 
specially assembled test sample of 598 people. 183 This sample was a mixture 
of 476 people with, reduced vision due to a single eye disease and 122 
people with no eye known eye disease (except possible refractive error). The 
age of the sample varied by diagnostic category, but overall was 
considerably younger than the participants included in this trial. Differences in 
results for the North American sample and this trial population could 
therefore be expected. However, the differences in the correlation 
coefficients are not large enough to suggest that the NEI VFQ-25 is less valid 
among a United Kingdom population. ý 
A problem with the 25 item NEI VFQ evident in this trial was a ceiling effect, 
whereby the majority of participants obtained very high scores. The median 
score was 93.4, and the 25 th centile was 82.9. This ceiling effect means that 
the NEI VFQ may be insensitive to small differences in visual function among 
people with quite high levels of visual function. 
NEI VFQ-25 subscales 
The longer 51 item NEI VFQ is divided into 13 sub-scales. However, factor 
analysis of the NEI VFQ-51 suggests that it measures only four different 
domains: general health, ocular pain, vision expectations and daily 
functioning. 85 In reducing the 51 item scale to 25 items, all the vision 
expectation questions were dropped. This suggests that the NEI VFQ-25 
measures three domains only. 
The low number of items in most of the sub-scales, the large number of sub- 
scales (and therefore comparisons), the possible impact of missing values, 
and the suggestion that in fact only three domains are measured by the 
various sub-scales, all mean that great caution is required in the 
interpretation of the sub-scale results. In fact in this trial, the sub-scale results 
were all consistent with the visual acuity and VFQ composite score results. 
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Overall it can be concluded that while there were some imperfections in the 
outcomes measured in the trial, the outcome data were likely to have been 
adequate to assess whether the vision screening intervention had a 
beneficial effect on vision. 
Time PeriOd and aftrition between screenina and outcome assessment 
Time period 
As seen in Chapter 7, the time period between screening and outcome 
assessment was quite long, with a median of 3.9 years. It is possible that 
improvements in vision occurring soon after screening could have been 
missed, with progressive disease or new eye problems cancelling out these 
earlier gains during the extended follow-up. However, as seen in table 7.5, a 
substantial proportion of participants were assessed between 1.6 and 3 years 
after baseline screening, and the intervention did not appear to be more 
effective in this sub-group. In fact, the effectiveness of the screening 
intervention on vision did not vary by period of follow-yp at all (table 7.8). 
Therefore although the follow-up period was relatively long for many 
participants, it did not appear to have a major effect on the effectiveness of 
screening. 
Attrition 
The response rates and reasons for non-response by randomised group 
were presented in table 7.1. As discussed in detail in Chapter 7, the 
apparently low response rate to the outcome assessments was largely due to 
the high mortality rate of people in this age group and the relatively long 
follow-up period. The death rates were very similar in the two arms. The 
possible effect of mortality on the trial outcomes is considered below. 
Excluding people who had died, the response rate was 62.8%, which for a 
trial in this age group is comparatively high. Only 28% of people who could 
have completed an outcome assessment (i. e. were alive and were not too ill, 
in hospital or had moved away) refused or did not respond, meaning that 
72% of people who could have been seen by the study nurses did have an 
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outcome assessment. However. there was some imbalance in response rate 
by randomised group. Overall there was a 5.7% difference between the two 
groups, with a lower response rate in the universal screening group. The 
possible effects of this differential in response rate across the two groups 
was considered in some detail in Chapter 7. To have affected the trial results, 
non-response would need to have been associated with vision. Among 
people who completed baseline screening, non-response to the outcome 
assessment was not associated with vision. Although there is no clear 
evidence to suggest that the difference in response rate to the outcome 
assessments in the two arms led to bias in the result, a small effect cannot 
be entirely excluded. 
Effect of mortality on outcomes 
Just over one third of participants had died by the time of outcome 
assessment (shown in table 7.1), with the proportions being very similar in 
the two arms of the trial. It is possible that some people could have been 
referred to the eye services and obtained help with their vision following the 
screening assessment, but died prior to having an outcome assessment. This 
could have reduced the observed effectiveness of screening. While we 
cannot know the visual outcomes following screening for those people who 
had died, we can gain some impression of the possible effect of mortality on 
the trial outcomes. 
Firstly, if mortality did affect the outcome, it would be expected that the trial 
outcome would differ by period of follow-up, with more people dying as the 
follow-up period increased. However, as seen in table 7.8, the effectiveness 
of the screening intervention on vision did not vary at all by period of follow- 
up. Secondly, we can undertake a sensitivity analysis to assess the effect of 
mortality if we assume that the visual outcomes of people who died were the 
same as people who did not die. That is, for people who were not referred to 
the eye services but who died, we assume their vision followed the pattern of 
people who were not referred to the eye services and did not die. Similarly, 
we assume that for people who were referred to the eye services but who 
died, their vision followed the pattern of people who were referred to the eye 
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services and did not die. This assumption may be over-optimistic, because 
people who died within 1.6 to 5 years of screening may well have been more 
frail and have had less improvements in vision than people who did not die. 
However, although it may be over-optimistic, this assumption is still useful for 
a sensitivity analysis. Imputing the visual acuity results as described, the 
odds ratio of having impaired vision (defined as visual acuity <6/18 in one or 
both eyes) comparing the universal screening group with the targeted 
screening group was 1.17,95% confidence interval 0.86 to 1.57. P=0.49. 
This is almost identical to the main trial result observed (odds ratio 1.11), 
further suggesting that the high mortality rate had little effect on the 
effectiveness estimate. 
Other trial factors possibly affectinq the results 
Confounding 
The jandomised design of the trial reduced the scope for confounding. 
However, in spite of the large number of participants, the cluster 
randomisation meant that confounding could still have been an issue 
because of variation between practices and the fact that there were 
effectively only 10 randomised units in each arm. 
As seen in Chapter 6, the randomised groups were well balanced at both 
practice and individual level. Also as seen in Chapters 7 and 8, the inclusion 
of a range of potential confounding factors in the outcome models had no 
appreciable impact on the estimate of effectiveness. 
Bias 
Randomisation procedure and allocation concealment 
Randomisation procedure and allocation concealment are rightly seen as 
critical issues in randomised trials of individuals. ' 33; 179 Like most cluster trials, 
the way that randomisation was executed in this trial meant that allocation 
was effectively concealed. Practices agreed to participate in the trial before 
they were randomised, and because of this time sequence and because 
randomisation was done centrally by computer, neither the practice nor the 
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trial co-ordinators could know which arm of the trial a practice would 
be 
randomised to. 
The baseline interventions were carried out as part of the routine "over 75 
health checks" in the trial practices. Participants would have been very 
unlikely to know the details of the differences between the two interventions 
being tested. 
Contamination 
The scope for contamination (i. e. people in the targeted screening arm 
having a detailed assessment even though they were not eligible or vice 
versa) was greatly reduced by the cluster design. In the targeted arm, all 120 
people who had a detailed assessment met the eligibility criteria for a 
detailed assessment. In the universal screening arm, 132 people who 
completed a brief assessment did not have a detailed assessment. The 
reasons for this attrition are given in figure 6.1. A further 35 people had a 
detailed assessment without having completed a brief assessment, but this 
would not be expected to have an effect on the result of screening. 
The low level of contamination is reflected in the per-protocol results for the 
trial, which are virtually identical to the intention to treat results (Chapters 7 
and 8). 
Blinding of outcome assessments 
Blinding of outcome assessment is known to affect the results of randomised 
trials. 133 In this trial, the research nurses were aware of whether the practice 
they worked in had been randomised to the targeted or universal screening 
arm. Some of the research nurses who carried out the outcome assessments 
were the same nurses who carried out the baseline screening assessments. 
However, the cluster design meant that nurses were undertaking outcome 
assessments on participants in one arm of the trial only, making such 
blinding almost an irrelevance. For example, all the participants assessed by 
a nurse in one of the practices allocated to universal screening would have 
been offered the same detailed assessment. Knowledge of the intervention 
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the practice had been allocated to would therefore be unlikely to have an 
impact on the outcome assessments. 
Power 
Outcome data were available for 1807 people, 90.4% of the target of 2000 
derived from the power calculation. Thus the trial had slightly lower power 
than we had planned. The confidence intervals for the primary outcome 
measures provide a good indication of the degree of random error around the 
results. 
The odds ratio for the primary visual acuity outcome measure as was 1.11, 
with a 95% confidence interval of 0.76 to 1.62, P=0.58. To help interpretation, 
the result can be expressed as a relative risk, allowing the percentage 
change in the outcome to be assessed. The relative risk was 1.08,95% 
confidence interval 0.85 to 1.37. The lower level of the 95% confidence 
interval for the primary visual acuity outcome indicates that a small beneficial 
effect (of around a 15% reduction in visual impairment) cannot be excluded. 
However it is of course unlikely that the "true" estimate of the effect would be 
towards one extreme of the confidence interval. 
For the NEI VFQ-25 composite score, the difference between the two groups 
was 0.41, with a 95% confidence interval -1.68 to 2.50, P=0.69. Even if the 
"true" effect were the upper level of the confidence interval, an improvement 
of 2.50 in the composite VFQ-25 score would represent only a very small 
overall benefit. 
Explanations for the lack of effect observed 
Complex intervention trials 
In recent years there has been increasing recognition of the need to explore 
in detail explanations for the effect or lack of effect observed in complex 
intervention trials. 278 With regards to health promotion interventions in 
primary care, the need to clarify the theoretical basis for the intervention and 
specify and assess process measures was identified in the MRC Topic 
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Review of Primary Health Care . 
21 These ideas have recently been developed 
into a three part framework for considering complex interventions: 
279 
the evidence and theory that informs the intervention 
the implementation of essential processes; 
the context within which the intervention will be operationalised. 
With regards to this trial, some elements of this approach were successfully 
completed. The detailed literature review (Chapter 1) broke the complex 
intervention of screening older people for impaired vision down into different 
stages, each of which contributes to the effectiveness of the intervention. The 
systematic review of existing trials identified possible explanations for the 
lack of effect previously observed and informed the design of the new trial. 
However, although attempts were made to measure process variables during 
the trial, the research resources available were limited. The main focus of 
effort was obtaining sufficient data to be able to answer the primary 
objectives of the trial: assessing the overall effectiveness of testing visual 
acuity as part of a multidimensional screening assessment. The primary 
research objective was met, but at a cost to the secondary objective of 
identifying barriers to improving vision among older people. 
Explanatory factors 
These were considered in detail in Chapter 9 and only a few key points are 
surnmarised and briefly discussed here. 
High levels of visual impairment were found among participants: almost 29% 
had a visual acuity less than 6/18 in either eye. In spite of a high level of 
glasses ownership, 17.5% people with visual impairment had evidence of 
uncorrected refractive error. The level of uncorrected refractive error would 
have been under-estimated because many eligible people did not complete 
a pinhole assessment. 
probably under-estimated, largely because of difficulties using a pinhole 
occluder in this age group. Among people in whom refractive error was 
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diagnosed, around half obtained new glasses and the level of uncorrected 
refractive error was reduced. 
For people with visual impairment not thought to be due to refractive error, 
35% had seen an ophthalmologist in the past 12 months and a further 14% 
were registered blind or partially sighted. Both these groups were not eligible 
for referral. Only around half of those people recommended for referral to an 
ophthalmologist were actually referred, although when referral did occur, 
attendance at eye clinics was high. People with worse vision were more likely 
to be referred and people with evidence of cognitive impairment at the time of 
screening were less likely to be referred. However, explanations for the low 
adherence by general practitioners to recommendations for referral are 
lacking. 
Around half of those who attended an ophthalmologist following screening 
had cataract surgery and their vision improved. Among the remaining people 
who attended an ophthalmologist following screening, there was no 
improvement in visual acuity. It is possible that some of these people 
received interventions for low vision that were of benefit in terms of function 
and quality of life, but that would not be expected to improve visual acuity. 104 
We did not measure visual function at baseline so cannot assess changes by 
the time of outcome assessment. A recent review and a subsequent postal 
survey of low vision services in the United Kingdom found inadequacies of 
service provision in their distribution and comprehensiveness. "'; "' It is 
therefore likely that while some people identified at screening as being 
visually impaired may have benefited from low vision services, others would 
not have been offered the full range of services from which they could have 
benefited. 
Pragmatic nature of the trial 
This was a pragmatic trial designed to assess the effect of a policy decision 
to include a visual acuity component in a multidimensional screening 
assessment for older people. The possible problems observed such as the 
low completion rate for the pinhole assessment and the low referral rate by 
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general practitioners, are components of the effectiveness of the intervention 
in everyday practice. Although such problems could have be overcome 
through rigorous adherence to a study protocol by highly motivated and 
trained clinicians, this would actually provide a less useful measure of the 
effectiveness of the, intervention in everyday practice. The trial was carried 
out to a large extent within the context in which the intervention, if introduced, 
would be operationalised. 
The trial findinqs in the context of the previous trials 
From the systematic review of the five previous trials of screening older 
people for visual impairment using self reported measures of visual problems 
for both the baseline screen and the outcome assessment, the pooled odds 
ratio for visual problems at outcome was 1.04 (95% confidence interval 0.89 
to 1.22, P=0.63). In the new trial, the odds ratio of having impaired vision 
(defined as visual acuity <6/18 in one or both eyes) was 1.11,95% 
confidence interval 0.76 to 1.62, P=0.58 (table 7.6). The results for the visual 
function composite score were very similar - virtually no difference between 
the groups (difference in score 0.41,95% confidence interval -1.68 to 2.50, 
P=0.69). Overcoming the possible problems identified with the existing trials 
included in the meta-analysis did not lead to a different estimate of the effect 
of screening, suggesting that these problems were not the explanation for the 
lack of effectiveness of screening. 
Because of the cluster design of the new trial and because of a difference in 
the interventions being assessed in the new trial and the five previous trials, it 
is not appropriate to incorporate the results of this trial in the existing meta- 
analysis. 282 
10.2 Implications for practice and policy 
The aim of population screening of older people for visual impairment is to 
discover visual impairment in those who are not presenting to the health 
services, and to offer them interventions to improve their vision. The 
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evidence from randomised controlled trials undertaken to date does not 
currently support the inclusion of a visual component in multidimensional 
screening programmes for older people in a community setting. Vision is 
specifically listed as a domain to be included in the Single Assessment 
Process to be offered to all older people proposed in the National Service 
Framework for Older People. 27 The most recently issued guidance about the 
Single Assessment Process recommends the inclusion of two questions 
about self-perceived visual problems . 
28 However, the evidence to date does 
not support either the inclusion of questions about vision nor visual acuity 
testing. 
There was evidence that uncorrected refractive error found at screening was 
improved by people attending opticians and obtaining new lenses. It is likely 
that uncorrected refractive error is under-detected among older people, and 
the levels detected in this study were almost certainly an under-estimate. 
Better detection and management of uncorrected refractive error offers scope 
to improve vision among this age group. However neither nurses nor doctors 
in general practice are trained to accurately assess refractive error, and 
general practices also lack the equipment required. In addition, it is unlikely 
that an adequate assessment of refractive error could be undertaken in the 
context of a multidimensional screening assessment in which vision is only 
one of many domains being assessed. 
The use of optometry services to identify visual problems among the older 
population may provide scope for better detection and management of 
refractive error. The re-introduction of free sight tests for older people has 
removed one barrier to optician services. Opticians are also better placed to 
measure other visual factors such as visual fields or contrast sensitivity that 
can have an impact on peoples' lives. If opticians were able to refer directly 
to ophthalmology services, the problems of under-referral for non-refractive 
error related visual impairment could probably be overcome. However, at 
present in the United Kingdom the screening role for opticians is limited to 
glaucoma screening for people at high risk, and, in some areas, screening 
people with diabetes for retinopathy. The extent to which opticians are 
integrated into local health systems varies. Developing a closer working 
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relationship with opticians offers a possible way forward for Primary Care 
Organisations trying to reduce visual problems among older people. 
Identifying problems that warrant referral to specialist services -is a central 
aim of multidimensional screening for older people. A key finding in this trial 
was that only around half of those people for whom referral to an 
ophthalmologist was recommended were actually referred. The explanation 
for this low rate of adherence was not clear, nor whether the decisions to 
refer or not were appropriate. However there are good grounds for measuring 
clinician adherence to recommendations for referral in future programmes of 
multidimensional screening for older people, including an assessment of the 
appropriateness of the referral decision and the extent to which the patient 
was involved in the decision. Previous work has shown that when 
participants in multidimensional screening programmes are advised about 
the need for referral and the participants themselves see the doctor and 
request the referral, there is an 11 fold increase in doctor adherence to the 
referral recommendation. 267 Patient empowerment may therefore be an 
effective method of improving clinician adherence to recommendations for 
referral. 
10.3 Implications for research 
Further work is clearly required to identify effective strategies to detect and 
improve visual problems among older people. 
There are a number of unresolved issues around optimal tools to be used for 
screening for visual impairment, particularly in the context of 
multidimensional screening in primary care. If primary care teams are to be 
expected to detect refractive error, better methods of diagnosis which can be 
completed by a higher proportion of the older population than the pinhole 
assessment will be needed. Whether visual acuity is a good screening tool to 
identify people who are likely to benefit from interventions to improve their 
vision needs to be assessed. The value of screening for other measures 
such as visual fields or contrast sensitivity warrants further work. While single 
questions about self-reported visual difficulties are poor predictors of low 
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visual acuity, the development of brief screening instruments that assess 
visual function could be of great value. 
With regards to multidimensional assessment for older people, a notable 
feature of this trial was the low level of ophthalmological referrals for those 
people deemed eligible for referral following screening. There has been some 
previous research on this issue (described in Chapter 9), but this has not 
focused specifically on eye referrals. There is scope for more research on the 
determinants of clinician adherence to recommendations for referrals arising 
from multidimensional assessments. Specific issues of interest are assessing 
the appropriateness of the referral decisions made and the role of the patient 
in the decision whether to refer or not. 
The effectiveness of an increased role for optometry services in the detection 
and management of visual problems among older people on a population 
basis warrants evaluation. 
Although attempts were made in this trial to examine and explore process 
measures, this was not the primary aim of the trial and the data available 
were limited in both amount and depth. Detailed prospective research on the 
detection, referral, diagnosis, and management of visual problems in older 
people could help shed further light on the reasons for the ineffectiveness of 
screening and offer more pointers for further research. As well as looking at 
health service issues, research from the perspective of the older people 
themselves is also needed. Areas which particularly need to be addressed 
include: older peoples' perceptions of their visual problems and of the need 
for interventions; and perceived barriers to interventions to help their vision. 
Clearly much of this research would need to be qualitative in nature. 
10.4 Summary of findings 
4, A systematic review of randomised trials found no evidence to support the 
inclusion of a visual component in multidimensional screening 
programmes for older people. However, the existing trials used questions 
about self-reported visual difficulties as a screening tool and to assess 
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outcome; lacked a clear plan of intervention for those people found to 
have visual impairment; and did not measure visual function as an 
outcome. 
The present trial was nested within a larger cluster randomised trial of 
multidimensional screening for people aged 75 years and over. General 
practices were randomised to a targeted screening strategy in which only 
a small proportion of participants with a range of health problems were 
offered visual acuity screening or to a universal screening strategy in 
which all participants were offered visual acuity screening. Around 220 
eligible participants were randomly sampled from ten practices in each 
arm of the trial and visual acuity and visual function were measured three 
to five years after the screening intervention. 
I 
9 The response rate to the basline assessments was around 76%. 
eA high level of visual impairment was found: almost 29% of people had 
visual acuity of less than 6/18 in either eye. 
* Among people with visual impairment, 17.5% could be attributed to 
refractive error. Uncorrected refractive error was under-detected because 
the pinhole assessment was completed by a minority of participants. 
@ Of the remaining people with visual impairment, 35% had seen an 
ophthalmologist in the previous year and a further 14% were registered 
blind or partially sighted. 
9 Over one third of eligible participants died before having an outcome 
assessment. Of those alive, the response rate to the outcome 
assessment was 67.8% in the targeted group and 57.9% in the universal 
group. 
Around half the people referred to an optician had obtained new lenses 
and their level of uncorrected refractive error improved. 
Only 52% of the people recommended for referral to an ophthalmologist 
had been referred by their general practitioner: among those referred the 
attendance rate was over 80%. 
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Among people who attended an ophthalmology clinic following referral, 
around half had a cataract extraction and their vision improved. However, 
there was no improvement in visual acuity for the remaining half who did 
not have a cataract extraction. 
9 Three to five years after the initial screening intervention, 37.0% 
(307/829) of people in the universal group had visual acuity of less than 
6/18 in either eye compared with 34.7% (339/978) of people in the 
targeted group (odds ratio 1.11,95% confidence interval 0.76 to 1.62, 
P=0.58). The composite score of the 25 item National Eye Institute Visual 
Function Questionnaire (maximum score 100, higher scores indicate 
better function) was 86.03 in the universal group and 85.62 in the targeted 
group, a slightly better score (difference 0.41,95% confidence Interval - 
1.68 to 2.50, P=0.69). 
* Possible factors contributing to the observed lack of benefit include: 
only around half those recommended for referral to an 
ophthalmologist were referred; 
under-detection of uncorrected refractive error; 
differential response rate to the outcome assessment between the 
two randomised groups; 
inadequacies in the outcome measures used to assess benefits; 
the intervention and visual acuity outcome focused on the worse 
eye rather than on peoples' vision; 
the intervention was not optimised prior to implementation; 
chance. 
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10.5 Summary of recommendations 
4P Visual impairment is common and disabling among older people and 
there is potential to improve the vision of people in this age group. 
e The evidence from randomised controlled trials undertaken to date do not 
support the inclusion of a visual screening component in multidimensional 
screening programmes for older people in a community setting. 
e The recommendation that an assessment of vision be included in the 
Single Assessment Process proposed in the National Service Framework 
for Older People is not supported by the evidence. 
The effectiveness of an optimised primary care based screening 
intervention that overcomes possible factors contributing to the observed 
lack of benefit in trials to date needs to be assessed. 
9 Specific issues to be addressed include: 
the appropriateness of visual acuity as a screening tool for primary 
care to identify those people who can benefit from visual 
interventions; 
whether use of the pinhole occluder in primary care can be 
improved through training or whether alternative strategies to 
detect uncorrected refractive error are needed; 
assessing the benefits of referral to an ophthalmologist for older 
people with reduced vision that is not due to cataracts; 
identification of factors influencing clinician and patient adherence 
to recommendations for referral arising from multidimensional 
assessments and the appropriateness of these referrals; 
outcome measures that are better able to assess the benefits of 
screening; 
o the effectiveness of an increased role for optician services in the 
detection and management of visual problems among older 
people. 
182 
* Complex intervention trials should include a substantial element of 
research that examines process measures and aims to explain the 
reasons for the effectiveness observed in the trial. 
e Given the importance of visual impairment among older people, further 
research into strategies to improve vision of older people is warranted. 
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Appendix 1 
Search strategiesused for the systematic review of randomised 
trials 
The following strategy was used to search CENTRAL Issue 1 2002: 
#1 VISION-SCREENING: ME 
#2 MULTIPHASIC-SCREENING: ME 
#3 MASS-SCREENING: ME 
#4 PREVENTIVE-HEALTH-SERVICES: ME 
#5 DIAGNOSTIC-SERVICES: ME 
#6 (screen*) 
#7 (((((#l or #2) or #3) or #4) or #5) or #6) 
#8 AGED*: ME 
#9 (((geriatric* or elder*) or "older people") or senior*) 
#10 (#8 or #9) 
#11 (V and #10) 
#12 GERIATIC-ASSESSMENT: ME 
#13 HEALTH-SERVICES-FOR-THE-AGED: ME 
#14 ((#ll or #12) or #13) 
The following strategy was used to search MEDLINE up to March 2002: 
#1 "MULTIPHASIC-SCREENING"/ all subheadings 
#2 "MASS-SCREENING"/ all subheadings 
#3 "DIAGNOSTIC-SERVICES"/ all subheadings 
#4 screen* or assessment or surveill* 
#5 (#4 in TI) or (#4 in AB) 
#6 #1 or #2 or #3 or #5 
#7 explode "AGED"/ all subheadings 
#8 (geriatric or elder* or older people or senior*) 
#9 (#8 in TI) or (#8 in AB) 
#10 #7 or #9 
#11 "GERIATRIC-ASSESSMENT"/ all subheadings 
#12 "HEALTH-SERVICES-FOR-THE-AGEDII/ all subheadings 
#13 #11 or #12 
#14 "VISION-SCREENING"/ all subheadings 
#15 explode "EYE-DISEASES"/ all subheadings 
#16 eye* or vision or visual or macular degeneration* or cataract* or 
presbyopia 
#17 (#16-in TI) or (#16 in AB) 
#18 #15 or #17 
#19 #6 and #10 and #18 
#20 #13 and #18 
#21 #10 and #14 
#22 #19 or #20 or #21 
To identify randomised controlled trials, this search was combined with 
the Cochrane Highly Sensitive Search Strategy phases one and two as 
contained in the Cochrane Reviewer's Handbook. 
The following strategy was used to search EMBASE up to March 2002. 
*1 "SCREENING"/ all subheadings 
#2 "MASS-SCREENING"/ all subheadings 
#3 "PREVENTIVE-HEALTH-SERVICE"/ all subheadings 
#4 (screen* or assess* or surveill*) 
#5 (#4 in TI) or (#4 in AB) 
#6 #1 or #2 or #3 or #5 
#7 "AGED"/ all subheadings 
#8 (geriatric or elderly or older people or senior*) 
#9 (#B in TI) or (#8 in AB) 
#10 #7 or #9 
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#11 explode "EYE-DISEASE"/ all subheadings 
#12 eye* or vision or visual or macular degeneration* or cataract* or 
presbyopi* 
#13 (#12 in TI) or (#12 in AB) 
#14 #10 or #13 
#15 explode "VISION-TEST"/ all subheadings 
#16 #6 and #10 and #14 
#17 #10 and #15 
To identify randomised controlled trials, this search was combined with 
the following search: 
#1 "RANDOMIZED-CONTROLLED-TRIAL"/ all subheadings 
#2 "RANDOMIZATION"/ all subheadings 
#3 "CONTROLLED-STUDY"/ all subheadings 
#4 "MULTICENTER-STUDY"/ all subheadings 
#5 "PHASE-3-CLINICAL-TRIAL"/ all subheadings 
#6 "PHASE-4-CLINICAL-TRIAL"/ all subheadings 
#7 "DOUBLE-BLIND-PROCEDUREII/ all subheadings 
#8 "SINGLE-BLIND-PROCEDURE"/ all subheadings 
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 
#10 RANDOM* or CROSS? OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER* in 
TI, AB 
#11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near (BLIND* or MASK*) in 
TI, AB 
#12 #9 or #10 or #11 
#13 HUMAN in DE 
#14 (ANIMAL or NONHUMAN) in DE 
#15 #13 and #14 
#16 #14 not #15 
#17 #12 not #16 
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Appendix 2 
Data extraction sheets for the systematic review of randomised 
trials I 
Study ID: 
STUDY PROFILE(Two groups) 
Number of 
eligible 
patients 
Number 
excluded 
Excluded 
Withdrawn 
Lost to 
follow-up 
Died 
R 
Number 
randomised to 
treatment 
Number analysed 
in treatment group 
Number 
refused to take 
part 
Number 
randomised to 
control 
Excluded 
Withdmwn 
Lost to 
follow-up 
Died 
Number analysed 
in control group 
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Study ID: 
STUDYPROFILE(More than two groups) 
Number of eligible 
patients 
Number 
excluded 
Group 1 Group 2 Group 3 
treatment: treatment: treatment: 
Number Number Number 
randomised randomised randomised 
Number 
refused to take 
part 
Group 4 
treatment: 
Number 
randomised 
Excluded Excluded I I Excluded 
Withdrawn Withdrawn Withdrawn 
Lost to Lost to Lost to 
follow-un fhUnw-tin 
Died Died Died 
Number 
analysed in 
Group I 
Number 
analysed in 
Group 2 
Number 
analysed in 
Group 3 
Number 
analysed in 
Group 4 
Appendix 2 page 2 
Study ID: 
Study Quality Assessment Form 
Grade each of the following aspects of trial quality: 
A- Adequate 
B- Unclear 
C- Inadequate 
D- Not used in this review as a measure of quality 
Selection bias (allocation concealment) 
Was the sequence of allocation of participants to groups concealed 
until after treatments were allocated? 
A: Adequate 
Centralised randomisation either by a central office or pharmacy; On-site 
computer system, provided that the computer file containing the assignments is 
locked; Serially numbered sealed opaque envelopes or sequential administration 
of pre-numbered or coded containers to enrolled participants; Other approaches 
that appear to offer adequate concealment combined with the statement that the 
person who generated the allocation did not administer it. 
B: Unclear 
List or table used; Envelopes but no qualifying statement; An apparently 
adequate concealment but other information in trial indicates concealment may 
not have been adequate 
C. Inadequate 
Alternation; Case record numbers; Dates of birth or days of the week; Any 
allocation that is entirely transparent before allocation 
Performance bias (masking ofparticipants and researchers), 
2. Were the recipients of care unaware of their assigned treatment? 
3. Were persons providing care unaware of the assigned treatment? 
Detection bias 
4. Were persons assessing outcome unaware of the assigned 
treatment? 
Attrition bias 
Were rates of follow-up similar in the comparison groups? 
6. Was the analysis 'intention-to-treat' (were all patients analysed as 
randomised)? 
Grade 
II 
II 
II 
II 
I1 
I1 
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DATA EXTRACTION (DICHOTOMOUS OUTCOMES) 
Outcome 
Time Treatme t group Contro group 
(months) Observed Total Observed Total 
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Appendix 3 
Description of the MRC Trial of the Assessment -and Management 
of Elderly People in the Community 
Description of the MRC Trial of the Assessmentand Management of 
Elderly People in the Community 
Investigators: 
Professor Astrid Fletcher, London School of Hygiene and Tropical Medicine 
Dr Dee Jones, University of Wales College of Medicine 
Professor Chris Bulpitt, Royal Postgraduate Medical School 
Dr Alistair Tulloch, University of Oxford 
Collaborator: Professor Mike Drummond (University of York) 
Steering Committee: 
Professor Andy Haines (Chairman), , Professor Grimley Evans, Professor Karen 
Luker, 
Dr Carol Brayne, Professor C Donaldson, Dr M Vickers plus the trial investigators 
Observers: Dr Glanz (Department of Health), Dr Henningan (Scottish Health Office) 
In 1994 the Medical Research Council funded a large trial to compare different methods 
of assessment and management of older people: namely targeted versus universal 
screening, and primary care versus hospital geriatric services. The trial, which is being 
conducted in 106 General Practices in the UK, will determine the cost effectiveness of 
these different strategies of assessment and management with effectiveness measured 
by mortality, hospital admissions and quality of life. The trial is a community-based 
randomised controlled trial with a2 stage design. in both stages the unit of 
randomisation is the general practice. 
Stage 1 
The aim of Stage 1 is to evaluate the case-finding methods. Practices are equally 
randomised to a short questionnaire (brief assessment) administered either by post, by 
a lay person, or by a nurse. Practices are also equally randomised to one of the 
following: a detailed examination by the study nurse in all patients (irrespective of their 
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responses on the brief assessment) or a detailed assessment only in those patients 
who "trigger" on the brief assessment. This design tests targeted (detailed only if 
triggered) versus universal screening (detailed assessment of all patients). The brief 
assessment questionnaire, covers all the areas specified in the GP contract with a 
graded response format to questions on : social environment, activities of daily living, 
sensory problems (vision and hearing), mobility, physical symptoms including 
continence, mental condition, use of medication. Additional questions on alcohol 
consumption, - cigarette smoking and physical activity have been included for 
epidemiological purposes. Criteria for triggering to the detailed assessment are 3 or 
more problems identified from the brief assessment or any one of 4 "serious" 
symptoms. The detailed assessment covers the same areas as specified above but in 
greater depth for example, Glasgow Acuity Charts for vision, whispered voice test for 
hearing, Mini Mental State Examination for cognitive impairment, and the Geriatric 
Depression Scale, assessment of symptoms and problems with urinary and faecal 
continence. Additional biological measurements include: blood pressure, heart rate, 
anthropometry, dipstix for blood, protein, urine and a blood sample for a full 
biochemical screen. Patients are also assessed for need for other services such as 
chiropody, home helps, and home modifications. 
Stage 2 
The aim of Stage 2 is to evaluate the management of patients Identified from the 
detailed assessment. Practices are equally randomised to the primary care team, or the 
local multidisciplinary geriatric team, balanced across the Stage 1 randomisation. The 
study nurse follows a standard protocol based on results and responses in the detailed 
assessment to make referrals to (I) the teams (ii) other medical services, health care 
workers or agencies (iii) emergency referrals to the GP. Conditions for referral Include 
common conditions and sources of disability and handicap in older people such as 
vision and hearing impairment, depression, incontinence. 
Outcome measures The principal outcome measures are: mortality and hospital 
admissions (collected in all practices) and quality of life (collected in a random sample 
of 23 practices). Trial patients are registered with ONS for mortality follow-up. Use of 
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services is ascertained by cross sectional and longitudinal sampling throughout the 
study in order to provide a full economic evaluation. 
Trial population The trial is being conducted in practices recruited through the MRC GP 
Research Framework. Practices are stratified by the key factors that will influence the 
outcome measures: Jarman score as a measure of deprivation, mortality measured by 
Standardised Mortality Rates. The patient population included is all patients aged 75 
years and over, excluAng anyone in long-term care or with terminal disease. 106 
practices and over 35,000 patients are participating in the trial with response rates 
ranging from 80% to the brief questionnaire, 76% to the detailed assessment and 91% 
to the Quality of life interview. The collection of the baseline assessments is now 
complete and the trial is in the phase of collecting the outcome data. The trial will 
terminate data collection at the end of 2000 with publication in 2001. 
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Appendix 4 
Nested vision screening trial procedures manual 
SCREENING OLDER PEOPLE FOR IMPAIRED VISION: 
A NESTED TRIAL WITHIN THE MRC TRIAL OF 
ASSESSMENT AND MANAGEMENT OF ELDERLY PEOPLE 
IN THE COMMUNITY 
Manual of procedures 
For further information or if you have any queries 
Please contact either Smita, Patel or Liam Smeeth at: 
Epidemiology Unit 
London School of Hygiene and Tropical Medicine 
Keppel Street 
London 
WCIE 7HT 
Tel: 020 7927 2296 
Fax: 020 7580 6897 
I 
CONTENTS 
Introduction 3 
Description of study 
Day to day running of study 5 
The assessment schedule 10 
Measuring visual acuity 14 
Extracting data from 
patients" notes 20 
Making claims 22 
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INTRODUCTION 
This manual of procedures attempts to cover all aspects of the research nurses role in the 
study. There are bound to be things we have forgotten or that are not clear. Apologies for 
these: suggestions for improvements are always welcome. 
Many of the instructions here will appear to be somewhat basic or simple. We do (honestly) 
realise that you are experienced nurses who know what you are doing. Many of the things 
included here are "common sense". There are good scientific reasons for the simplicity and 
the lengthy descriptions. These are to ensure that: 
" all research nurses follow exactly the same procedures 
" you have a reference manual available that will hopefully cover most eventualities. 
The main thing is: please do not feel patronised or insulted. 
DESCRIPTION OF THE VISION SCREENING STUDY 
Background 
A number of studies have shown that many older people have eyesight problems which are 
not being treated properly. In 1990, legislation was introduced which required GP's to 
regularly check the well-being of all their patients over 75 years of age, including eyesight. 
We recently performed a thorough review of research on vision testing of elderly people in 
general practice. This showed that merely asking elderly people about their vision did not 
seem to help. We now need to know whether actually testing older peoples' vision using a 
chart, and referring people with problems to the eye services, does any good. 
As you know, the MRC Elderly Screening Trial was set up a few years ago. It is looking at 
many different aspects of the well-being of people over 75 years, but without this additional 
study it cannot tell us whether testing vision actually helps. 
How will the new study be carried out? 
As part of the MRC Elderly Screening Trial practices were randomly allocated as follows: 
Ann A: as one of the 35 questions, participants were asked: "Do you have difficulty 
seeing newsprint, even if you are wearing glasses. " (The detailed ifpositive arm) 
Arm B: as well as the above question in the brief assessment, all participants had a detailed assessment. Distance visual acuity was measured using a Glasgow Acuity Chart 
and people with reduced vision were referred to an ophthalmologist or advised to see an 
optician. (The detailed always arm) 
In this study, we will go back and test the vision of a randomly selected sample of around 150 
people., We have randomly selected 10 practices from each of the above two groups. 
As well as measuring visual acuity, we want to measure visual function using a specially designed questionnaire. 'Wisual function! ' is a measure of the impact of visual problems on a 
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person's life. In recent years the value of visual function indices in assessing the effectiveness 
of interventions to improve vision has become widely accepted. We also want to collect data 
about what happened to those people who were found to have visual problems at the baseline 
assessment. 
By comparing the vision of people in groups A and B, we will be able to find out whether 
testing older peoples' vision using a chart and referring people with problems to the eye 
services is effective in improving vision. 
How will this study benefit older people? 
Visual impairment is a crippling blow to an elderly person and is 91ý important cause of 
reduced independence, quality of life and of falls. This study has the potential to answer a 
simple question about how to bring about a real improvement in quality of life to the elderly. 
The intervention, if effective, is simple and cheap enough to be implemented within the NHS 
without difficulty. 
Who is funding the research? 
The study is being funded by the Medical Research Council. 
Who is organising the research? 
The research is being organised by researchers at the London School of Hygiene and Tropical 
Medicine and at Moorfields Eye Hospital, London. 
The main people involved from the London School of Hygiene and Tropical Medicine are: 
Professor Astrid Fletcher, the principal investigator of the MRC Elderly Screening Trial 
and the Head of the Epidemiology Unit at the London School of Hygiene and Tropical 
Medicine. 
Dr Liam Smeeth, a GP and an epidemiologist. He is co-ordinating the study. 
Smita Patel who is responsible for the day to day running of the study. 
From Moorfields Eye Hospital: 
Mr Richard Wormald, a consultant ophthalmologist and head of the Ophthalmic 
Epidemiology Unit 
o Jennifer Evans, an ophthalmic epidemiologist. 
Richard and Jenny organised the visual component of the baseline assessments in the MRC 
Elderly Screening Trial. 
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DAY TO DAY RUNNING OF THE STUDY 
Introduction 
You will be provided with a list of all patients who need to be invited to have an assessment. The likely total 
will be around 150. 
Your task is to undertake assessments on as many people as possible from this list: ideally all 
of them. The proportion of people you manage to see is probably the single most important 
factor in the success of this study. 
Who is included? 
The list of patients is a random sample drawn from all those patients who were eligible for 
inclusion in the MRC Elderly Screening Trial. To the best of our knowledge all the patients 
included in the list were alive and still registered with the practice at the time of putting the 
lists together (April 2000). 
It is very important that as many people as possible are invited to participate. Many people 
with health problems remain eligible for the study. For example, people in the following 
groups should not be excluded from the study. People who: 
" are registered blind or partially sighted 
" have recently seen an ophthalmologist or optician 
" are on a waiting list for eye treatment, for example cataract surgery 
" are housebound 
" have hearing impairment 
" are infirm. or very old 
" are depressed 
" have cognitive impairment 
Who is excluded? 
The only reasons to exclude people from participating in the stlidy are: 
1. The patient has died. 1 2. The patient has left the practice or moved away. 
They really are too ill to participate. 
By "too ill to participate" we mean that because of illness the patient would find it difficult or 
unpleasant to complete an assessment, or that you would feel uncomfortable undertaking an 
assessment. We understand that undertaking assessments with some patients may be di&ult 
or challenging. However, these are likely to be the patients with the most to gain. In addition, it is important for good research practice that as many people as possible are included. 
There are two issues to bear in mind in deciding whether someone is too ill to participate. Firstly the assessment is non-invasive. The patient will have nothing physical done to them 
and only needs to answer some questions and read some letters on a chart. Secondly, many "ill" people are the very people who could gain a lot from help with their eyesight. For 
example there is good evidence that people who are depressed or housebound tend to have a high level of vision problems, and that they benefit greatly from measures taken to improve their vision. 
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INVITING PATIENTS TO PARTICIPATE 
The invitation letter 
Decide a good time for you. If you know that the patient is housebound or virtually 
housebound, offer to visit them at home. 
On the invitation letter: 
" fill in the patients name 
" delete one of the options "please come to the surgery/ I will visit you at home" 
" fill in the time and place 
Try and give people between 5 and 10 days notice. 
Before the time offered 
Telephone the patient a few days before the appointment or suggested visit. Check the 
following: 
" did they receive the invitation? 
" could they read it? 
op did they understand it? 
" Are they happy to participate 
" can they attend/ be there when you visit 
" do they have any queries or concerns? 
If necessary, arrange an alternative time at this Point. 
What to do if a patient does not arrive or is not in when you visit 
We will use the phrase "did not attend" (DNA) for an episode of a patient not arriving at the 
practice for their appointment or either not being at home or not being ready to have an 
assessment when you visit. 
First "did not attend" (DNA) 
Jf you had not managed to speak to the patient before the appointment, go over the points 
above. If you had spoken to the patient before the appointment, ask: 
" was there a particular problem? 
" did they remember the appointment? 
" are they still happy to participate? 
Arrange another time. 
Telephone the patient a few days before the second appointment or suggested visit. 
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Second DNA 
Try and speak to the patient again. Ask: 
" was there a particular problem? 
" did they remember the appointment? 
" are they still happy to participate? 
Arrange another time. 
If the previous appointments had been at the surgery, offer to come to the patient's 
home. 
Telephone the patient a few days before the third appointment or suggested visit. 
Thirci DNA 
Try and speak to the patient again. Use your discretion about whether to try again. 
PROBLEMS 
The patient is not on the telephone 
Most people in this age group will be known to the practice. Find out how the practice 
normally communicates with the patient. 
If necessary, be ready to call round to the patient's home. 
The patient finds it difficult to get to the surgery 
Please affange to see them at home. 
The patient does not want to come to the surgery or would prefer to be soon at 
home 
You may not feel that a home visit is wan-anted on health grounds alone. For example you 
may know the patient does come to the surgery to see the doctor. However, if offering to visit 
the patient at home means they will have an assessment that they otherwise would not have, 
then please do arrange to see them at home. 
The patient feels they do not need an eye test 
This is particularly likely to be true for people who are in one or more of the following 
groups: 
" registered blind or partially sighted 
" have recently seen an ophthalmologist or optician 
" are on a waiting list for treatment, for example cataract surgery 
" h6u-sebound 
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For some patients, such as those who are housebound, this feeling may be due to low 
expectations in old age or a feeling that nothing can be done to help. They may actually 
benefit a lot from some help with their eyesight. 
For some patients, you may agree with them that they are unlikely to get much benefit from 
an eye test. We suggest an explanation along the following lines: 
"While many older people will benefit from an eye test, it is true that some people may not 
get a lot of benefit. However, the main reason for testing your eyes at this time is as part of a 
research study that aims to improve our knowledge of how to help aU old people with their 
eyesight. Even if you feel you do not need an eye test or that you will not benefit, by taking 
part in the study you will be helping other people". 
The patient has died or moved away since the lists of pat 
! 
ients were prepared 
People may have died or moved away by the time you come to invite them. There are spaces 
on the patient lists for you to record these details. 
THE LOG SHEETS 
As well as the list of patients, there are log sheets for you to record everything that happens 
about each patient in the study. There are two different types of log sheet. 
The 'master' logsheet 
The first version is a master copy that includes details of all the patients. This is for you to 
keep for the duration of the study. Please fill it in as you go along. Some of the columns ask 
for a date. Others simply for a tick. There is a column for free text or comments. 
For example, if you send out a first invitation letter to a patient, write the date that you sent it 
in the appropriate box for that patient in the column headed "first invite sent". 
The monthly log sheets 
The second version is currently blank apart from the column headings. We would like you to 
fill in one of these blank log sheets as you go along, using a separate sheet for each month. 
The monthly log sheets should include details of everything that happens during a single 
month: from the first day to the last day inclusive. Again, some of the columns ask for a date, 
others simply for a tick. There is a column for free text or comments. 
For example, if you send out a first invitation letter to a patient, fill in the patient's 
identification number in the first column and write the date that you sent it in the appropriate 
box in the column headed "first invite sent". 
Please fill in the month and dates referred to at the top of the sheet. The first sheet should be 
used from the date you start to the end of the month you start in. For example if you start the 
study on the 21" of april, you should fill in your first monthly log sheet for the period 21" 
april to 30'hapril inclusive. Your second monthly log sheet will be for the period I't may to 31' may inclusive and so on. Your final log sheet should start on the first day of the final 
month and end on the day you complete the study. 
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once completed, please photocopy the monthly log sheet before returning it to us at the 
london school of hygiene and tropical medicine. 
Returning assessment schedules, consent forms and data extraction forms. 
At the end of each month please, preferably within two weeks of the month ending: 
1. Check you have completed the master logsheet 
2. Check you have completed the relevant monthly logsheet 
3. PhotocOP-Y the monthly logsheet 
4. Check you have all the relevant: 
9 Completed assessment schedules 
4p Consent forms 
e Data extraction forms for patients who need one. 
5. Send us the following by special delivery 
e One copy of the monthly logsheet 
e The completed 
=* Assessment schedules 
Consent forms 
=* Data extraction forras 
6. Start a new monthlY log sheet. 
Practice staff and administration 
You may ask someone in the practice (such as a receptionist or secretary) to do some of the 
administrative work. This may include tasks such as sending out letters or going to the post 
office. This is up to you and the practice to decide. If this does happen, please keep a record 
of how much time they spend on the study. Please use the column on the claim form called 
"Staff administration coste' (see below). 
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Screening older people for impaired vision: 
The assessment schedule 
The assessment schedule is in two parts: 
1. A questionnaire administered as an interview 
A tcst of visual acuity 
Questionnaire administration 
Role of the interviewer 
The interviewer is responsible for: 
* Motivating the patient 
* Asking the patient the questions in the questionnaire in a neutral and standard way 
* Accurately recording the patient! s answers 
Preparing for the Interview 
* Familiarise yourself with the questionnaire. You may find it helpful to practice on a 
couple of willing volunteers particularly to familiarise yourself with the use of the filter 
questions in the questionnaire. Hesitation during questionnaire administration can 
negatively effect rapport with the patient. 
* Look up the required information about the baseline assessment (Q 3.2) and record it in 
the questionnaire. 
* Flick through the patient's questionnaire beforehand and make sure it has all its pages. 
* Ensure you have a room where you can interview the patient in private and without 
distraction. 
* Ensure you have somewhere to test visual acuity. This needs to be well-lit with the testing 
distance of 3 meters already marked out. Use the tape measure provided. 
* Arrange seating appropriately (e. g. if the patient is known to have a hearing problem 
make sure you are sitting opposite them and they have a clear view of your face. If the 
patient wears a hearing aid it would be helpfid to check they are wearing it and it is turned 
on). 
Using the questionnaire 
(a) Dealing with the patient 
* Introduce yourself to the patient. Remind them who you are and why you have asked to 
see them (please use the attached standard introduction). 
+ The questionnaire seeks the patient's view on how their vision effects their day-to-day 
activity and lifestyle., The interviewer must not influence or guide the patient in their 
answers. Ask the questions exactly as they are worded in the questionnaire and record 
the patient's answer exactly. 
* Be aware of your verbal and non-verbal behaviour. For example, verbal or non-verbal behaviour that conveys surprise, disbelief or sympathy can influence the patient's 
subsequent answers to questions. 
* It is important that you do not let: any prior knowledge of the patient's vision status influence your behaviour to the patient or their responses to the questionnaire. 
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* Speak slowly and clearly 
Give the patient time to think and reply. Adapt the pace of the interview to the patient. 
Repeat the question if necessary. Do not re-word the question upon repetition. 
(b) Visual Function Questionnaire 
* Section 2 of the questionnaire is a standardised Visual Fundion Questionnaire. 
* Use the folder of flash cards provided. 
* Show the patient the relevant flashcard. 
* Read out the question. 
* Stress the underlined words in your intonation when reading the question to the patient. 
* If necessary repeat the question. 
* Then read out all the possible answers. 
* If the patient states their answer before you have read all the options, ask them to listen to 
all the possible options first and then answer. 
(c) Recording the patient's answers 
Record the patient's answers during the interview (i. e. do not record the patient's answers 
ftorn memory). 
Record the patient's answers clearly and legibly in pen (not pencil). Patient explanations 
about why they have acted or behaved in a particular way should be recorded as fully as 
possible. 
At the end of the interview, before the patient leaves the room, check the questionnaire 
for completeness. Have all questions been answered? 
If you tick/circle the wrong answer cross out the mistake and initial the error response. 
Tick/circle the correct answer. 
* Please do not leave answers blank. It is impossible to know from blank answers whether 
the question was ever asked. There should always be a way to record "not applicable, " or 
space to write an answer that does not fit into the categories given. 
* Some of the pages in section 3 will only apply to a minority of patients. Please tick the 
not applicable box at the top of each page that does not apply. 
At the end of the assessment, please fill in the section at the bottom of the front cover. In 
particular decide whether you need to complete a data extraction form. 
Troubleshooting 
Q What do I do if the patient does not understand a question? 
A This should not be a big problem because this is a tried and tested questionnaire. 
However, if a patient does not understand a question, repeat the question exactly as it is worded in the questionnaire. Do not re-word or interpret the question for the 
patient. If the patient asks you what a question means ask the patient what they think 
the question means. If the patient's interpretation is correct then confirm their interpretation as correct. If the patient is not correct ask them what else they think the 
question might mean, and so guide them to the correct interpretation of the question. 
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What do I do if a patient wants to prematurely terminate the interview before 
finishing the questionnaire? 
A Ask the patient why they want to stop. If you can shape circumstances to facilitate 
the completion of the interview Please do so. For example, if the patient needs a 
break for some reason then give them a break. If the patient definitely wants to stop 
then of course please stop. Remember to record the interview as incomplete on the 
questionnaire and state the reason why the interview was terminated 
What do I do if I notice an inconsistency in the way the patient has answered the 
questions (e. g. the patient's answer to a question does not make sense given their 
answer to a previous question)? I 
A Inconsistencies may occur because the patient misunderstood the question or the 
interviewer misunderstood the patient's answer or the patient did not express 
themselves clearly enough. Tell the patient yoA like to check you understood them 
correctly and would like to repeat the question if that is alright with them. If the 
patient's response remains 'inconsistent' record their answer and do not question 
them on their response. 
What do I do if the patient 'jumps the gun' and answers one question with 
information that will be sought in answer to a later question? 
A Politely stop the patient and tell them that you'll be asking 
ýem 
about that matter in a 
minute. Do not jump ahead in the questionnaire and make the related entry. It is 
important not to alter the sequence of the questionnaire. I 
What do I do if I have any other questions about the administration of the 
questionnaire? 
A Please contact: Dr Liam Smeeth, Epidemiology Unit, London School of Hygiene and 
Tropical Medicine, Keppel Street, London WC IE 7HT Tel: 020 7927 2296 Fax: 
020 7580 6897 E mail: liam. smeeth@lshtm. ac. uk 
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Screening older people for impaired vision: 
standard introduction to the interview assessment 
V- 
1- ur the purposes ofstandardisation it is important that the questionnaire is 
introduced to allpatients in the same way. For that reason please say the 
following before starting to complete the questionnaire with the patient., 
"Hello , thank you for taking the time to see me. My name is 
and I am the nurse who wrote to you. As I mentioned in my letter, we are doing 
a study to look at the effects of vision screening on older people. This vision 
study involves answering some questions about what you think about your 
vision, as well as having your vision checked. The vision check consists of 
reading some letters! on a chartJ will show you. The whole thing should take us 
about 30-45 minutes to complete. 
I'd like to repeat that the information from this vision check will be 
confidential. If I find you have a problem with your vision, then with your 
permission I will inform your GP. Only myself, your GP and the researchers at 
the London School of Hygiene & Tropical Medicine will know the identity of 
people in the study. 
Did you get a chance to read the patient information leaflet I sent you with my 
letter? (If no, ask if would they like time to read Whave it read to them now? ). 
Have you any questions? 
Askpatient to sign consentform 
If the patient agrees to proceed: 
"Let's start by my asking you a few questions. These questions are about how 
your vision effects your day-to-day life. The important thing is to tell me what 
you think about your vision. There are no right or wrong answers to these 
questions. I will read the questions to you followed by a list of answers that you 
can choose from. If you'd like me to repeat something or speak more slowly or 
quickly or loudly just let me know. Here's Question L. 
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Screening older people for impaired vision: 
Measuring visual acuity 
Visual acuity is tested using a Glasgow Acuity Chart. This is actually a booklet and is an 
example of a-special sort of chart called a LogMAR chart. The 
booklet is a little more 
complicated than the Snellen charts most people are used to. However there are good reasons 
for using the Glasgow Acuity Chart rather than the Snellen chart. Design problems in the 
Snellen chart include the alteration in the number of letters on each line, and the irregular 
progression of the size of the letters as one moves up or down the chart. 
[-ne -aspect of the Glasgow Acuity Chart is that a larger score indicates worse vision. Very 
00 isio 4v 
2ood 
vision may produce a minus (negative) score. 
Test conditions 
Do the test under well-lit conditions but avoid strong overhead lights which may dazzle the 
patient. Light should shine on the chart but not into the patient's eyes. Keep the lighting 
conditions constant. 
Measure vision at 3 metres. Use the tape measure provided to measure distance. It is very 
important that the test is done at 3 metres - considerable effort should be made to find a 
suitably lit 3 metre space at the practice. For home visits it may not b, e possible to find a 
suitable 3 metre space. You may have to do the test at 1 metre. The test is less accurate at I 
metre. 
Always tick the box on the form to indicate at which distance the test was done. 
Doing the test 
Start by testing their vision using both eyes at the same time, followed by each eye 
separately. When you are testing vision in each eye separately the patient must be asked to 
cover the other eye. They can use the palm of their hand or the "occluder" part of the pinhole, 
depending on what is easiest for them. Alternatively a patch may be used. 
Glasses 
The patient should wear the glasses they normally use for driving or watching television. If 
they normally do not wear glasses but use them for specific activities requiring distance 
vision they should put these glasses on for the entire visual acuity test. We want to measure 
visual deficit arising because patients do not have glasses rather than because they choose not 
to wear the spectacles which they have been prescribed. The invitation letter asks them to 
bring any glasses they own with them to the assessment. 
Please check any glasses used are reasonably clean: ask the patient to clean them if the lenses 
are dirty. 
Using the booklet 
Hold the booklet vertically. If it is held at an angle reflections will make the letters difficult 
to see. 
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The participant should be encouraged to try and read every letter on a line. Encourage them 
not to stop if they say they cannot see it: try and get them to attempt every letter. A phrase 
such as "It doesWt matter if you get it wrong but have a try" may be used to persuade them to 
finish the line. 
If you think the participant may be memorising the letters, you can ask them to read a line 
from right to left. 
The cards 
The testing procedure is summarized in the flow chart (page 18). 
The first three cards are called the "screener cards. " The remaining cards simply called "line" 
and a number. The screener cards are used to determine the starting point for the 
measurement of acuity with the line cards. 
Information about each card is printed on the back of the preceding card. This means that the 
information visible refers to the card that is visible when the booklet is opened flat or opened 
and folded in two. 
The screener cards 
Ask the participant to read the letters on screening cards I to 3 in turn. The patient should be 
encouraged to respond until they get a letter wrong. The last successful response to a letter is 
used to select the appropriate line card to start acuity testing. For example, if a patient reads 
the four letters on screener card I correctly they are shown screener card 2. Now say they 
read H and 0 correctly on screener card 2, but then get Y wrong. The smallest letter they read 
correctly was 0. The table headed Screener 2 shows you that testing should begin with line 
card 6 (HYOU). 
The line cards 
The appropriate card is selected and the patient is asked to try and identify each of the 4 
letters presented. If the patient is able to identify correctly 3 or 4 letters on a line then the next 
card in the series should be presented. If they identify 3 or 4 letters again, go on to the next 
card. Continue until they can only read I or 2 letters correctly on a line. Use the number of 
letters they identify on this line to score the vision. If they identify 3 or 4 letters and you 
present the next line but they cannot correctly identify any letters, go back to the previous 
line and ask them to re-read it. Score this line even if they can still read 3 or 4 letters - you know they cannot read the next line. 
The vision is scored according to the number of letters read on the last line on which at least 
I letter can be read. The score should be read off from the score card on the back of the card. For example, if they read 3 letters on line I correctly then their score would be 0.825 for a 
test done at 3 metres. 
In the table fill in the line number, number of letters correct and the score. 
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A larger score indicates worse vision 
Good vision may produce a minus (negative) score 
Problem: the patient who cannot read any of the letters 
if a participant is unable to read Line I (the biggest letters) at 3 metres, reduce the test 
distance to I metre (again using the tape measure provided). Take the vision as before, score 
for "I metre" in the results table on the back of the testing cards. Tick the 1 metre box on the 
assessment form. If even at I metre they are still unable to read any of Line I tick the 
appropriate box in the questionnaire (unable to read at 1 metre). 
The visual acuity results grid 
Look up the scores obtained in the grid on page 19 of the assessment schedule. This grid 
shows all possible measurements with the Glasgow Acuity Card. If any measurement falls in 
the shaded area (i. e is 0.5 or greater), it means that the patient has poor vision and should be 
re-tested with the pinhole. 
If all measurements fall in the non-shaded area (i. e. are less than 0.5), that is the end of the 
test. 
Pinhole testing 
Before carrying out pinhole testing, write in the scores without pinhole from 
the previous page for each eye. 
Pinhole vision is only done for each eye separately: not for both eyes at the same time. One 
eye is covered and the patient looks through the pinhole with the other eye. If the patient has 
problems holding the pinhole they may balance it on their nose - using the "occluder" part to 
cover the other eye; this is why it is the shape it is. 
Take the vision at 3 metres to start with, even if the patient was down to I metre distance for 
initial testing. 
In the table fill in the line number, number of letters correct and the score. 
If the score in either eye improves with pinhole from 0.5 or more to less than 0.5 then the 
participant should be advised to see an optician. This means the score fell into the shaded 
area of the grid without a pinhole but falls into the non-shaded area with the pinhole. When 
vision improves with a pinhole it indicates that the vision may be improved with glasses. 
Anyone whose vision score in either eye remains 0.5 or more using the pinhole (remains in 
the shaded area) should be referred to an ophthalmologist unless: 
they have been seen by an ophthalmologist in the previous year 
are registered blind or partially sighted 
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The patient needs to see both an optician and an ophthalmologist 
A small number of patients may therefore fit the criteria for being advised to see an optician 
by the research nurse (because the vision improved in one eye) and be for being referred to an 
ophthalmologist by the GP (because the vision did not improve in the other eye). This is not a 
problem. Many patients with eye problems in everyday practice go and see an optician before 
they see an ophthalmologist. , 
The vision is worse with the pinhole 
Do not be alarmed if vision gets worse with the pinhole - this sometimes happens because the 
pinhole lets through less light. Use the non-pinhole vision score to decide if the patient needs 
to be referred to an ophthalmologist: i. e. a score in either eye of 0.5 or more and have not 
been seen by an ophthalmologist in the previous year and are not registered blind or partially 
sighted. 
Advice about driving 
If the patient scored 0.4 or more (e. g. 0.450,0.575) when testing both eyes together, their 
eyesight may be below the currently recommended level of vision required for driving. This 
means that the logMAR score for both eyes together was below the dashed line on the visual 
acuity results grid. 
You will have asked if the patient is currently driving during the interview (Q 15, section 2). 
If the patient's vision appears to fall below the driving requirement: 
" tell the patient their vision may fall below the level required by law for driving 
" advise the patient not to drive until they have had their eyes checked by an optician, their 
GP or an ophthalmologist 
" tell the patient that it is their responsibility not to drive 
" tell the patient that you are informing the GP of your findings. 
" refer the patient to their GP using the standard notification letter 
" advise the patient it may be helpfid for them to see an optician for two reasons: 
I They will be able to test the patient's eyes more accurately than the testjust performed. 
=> They may be able to improve the patient's vision with new or updated glasses. 
It is the patient's responsibility to: 
1. Stop driving 
2. Inform the Driver and Vehicle Licensing Agency if your findings are confirmed by an 
optician, ophthalmologist or their GP. The address they should write to is given in the information leaflet. 
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It is not your responsibility to inform the Driver and Vehicle Licensing Agency about your 
findings. 
Give the patient a copy of the study leaflet: INFORMATION FOR DRIVERS 
The GP notification letter 
Please fill this in for all patients. Please tick either "yes" or "no" or "not applicable' (where 
included). -- 
The "snellen equivalent, ' for the logMAR scores is given on the testing cards. There is a 
single snellen equivalent for each card, even though each card has four possible logMAR 
scores. This is because the logMAR scores are more finely detailed. 
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SUMMARY OF VISUAL ACUITY TESTING, 
Use the screening cards to identiN 
the line at whic to start the test 
*Ask the patient to rd all 4 letters on the line 
0 lefters seen 1 or 2 le tt rs seen 3 or 4 lefters seen 
I 
Go back a line Po forward a line 
(bigger leti ers) (smaller letters) Score the number 
of letters correctly 
identified on this 
line 
Ask the patient to read 
all 4 letters pn the line 
Repeatthe 
pro6ess from* 
Sc; ore the number of 
letters correctly 
identified on this line 
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Patient contact with eye services: data extraction forms 
The data extraction forms exist to provide a structured way of extracting data bout contact 
with eye services included in the patient's GP record. 
A data extraction form should be completed for the following patients: 
1. All patients who report ever having seen an ophthalmologist (QI. 4) 
2. All patients who were eligible for referral to an ophthalmologist following the baseline 
assessment of the MRC Elderly Screening Trial (Q3.2b) 
The patient does not need to be present for completion of the data extraction form. However, 
we recommend that you complete the data extraction form soon after seeing the patient. 
Please go through the notes and idlentify ALL the lettcrs which refer to eye problems or deal 
with referrals to or from any eye specialist - optician, ophthalmologist or eye hospital. Please 
look through all the notes, notjust since the start of the MRC Elderly Study. We are 
interested in all eye problems, not just those identified during the study. 
Please return the completed data extraction form with the completed assessment schedule. 
The data extraction form is in two parts. 
Section 1 
This section relates to the time period prior to the date of the baseline assessment (or the 
invitation to the baseline assessment for those patients who were eligible for a baseline 
assessment and did not complete an assessment for any reason). 
We do not require complete details of every letter. We need to know: 
whether the patient has ever been referred to anyone about their eyes 
whether the patient has ever seen, anyone about their eyes 
what diagnoses were made 
what treatments the patient received. 
Fill in the total number of letters which relate to eyes and that are dated prior to the date of 
the baseline assessment. ýI 
Fill in the dates of the earliest and latest letters. 
Write down any diagnoses or treatments, with the date (year only). 
If you are not sure what a word or some words mean, write them down. If you do not know if 
something is a diagnosis, treatment or neither of these, write it down where ever there is 
sufficient space. 
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You do not need to repeat diagnoses which do not change: write down the earliest reference 
to it. For example, a patient was diagnosed with chronic open angle glaucoma affecting the 
left eye and the earliest letter mentioning this diagnosis was dated 1973. 
Write down "Chronic open angle glaucoma left eye 1973". You do not need to write down 
the diagnosis of glaucoma again, even though it will probably be mentioned in subsequent 
letters. 
Not needing to repeat terms only applies to letters dated prior to the date of the baseline 
assessment. 
Section 2 
This section relates to the time period on or after the date of the baseline assessment (or the 
invitation to the baseline assessment for those patients who were eligible for a baseline 
assessment and did not complete an assessment for any reason). 
Please allocate a number to the letters in chronological order, letter number I being the first 
letter identified dated after the date of the baseline assessment. There is a separate space on 
the form for each letter. 
For this section we do require details of every letter relating to eyes or vision. For each letter 
dated after the baseline assessment please complete the following information: 
* who the letter was from and who it was to 
o what diagnoses were made 
o any treatments that were recommended or the patient receivqd. 
Write down any diagnoses or treatments. If you are not sure what a word or some words 
mean, write them down. If you do not know if something is a diagnosis, treatment or neither 
of these, write it down where ever there is sufficient space. 
if there are more than six letters please use the extra sheets proýided. Use one cxtra sheet for 
each additional letter. On each extraý sheet, please fill in: 
" the patient identification number 
" the letter number as allocated by you. 
Please staple the extra sheets to the data extraction form. 
If you have any difficulty with the 
Data extraction form please telephone 
Liam Smeeth on 020 7927 2297 
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MONEY 
Making claims 
Please send claims cycry month to: 
MRC General Practice Research Framework Co-ordinating Centre 
MRC, Epidemiology and Medical Care Unit 
Northwick Park Hospital 
Watford Road 
Harrow 
Middlesex 
HAI 3UJ 
The study code name is Smeeth. This odd choice is to prevent confusion with claims made 
for the Elderly Screening Trial or for the other vision study that you may have been involved 
in. 
What to claim for 
The main items will be: 
" Time spent undertaking the assessments 
" Time spent travelling to and from home visits 
" Travel costs to and from home visits 
" Paperwork for each assessment: 
filling in the GP notification letter 
completing the data extraction forms when indicated 
filling in the master and monthly logsheets 
Consumables: 
" telephone calls 
" stationery 
" postage 
Administration: 
" sending out invitations 
" making telephone calls 
" sending completed forms to the London School of Hygiene and Tropical Medicine 
9 claims 
You may ask someone in the practice (such as a receptionist or secretary) to do some of the 
administrative work. This is up to you and the practice to decide. If this does happen, please 
use the "other expensee' section of the claim form 
Training 
Please claim for: 
e your time spent reading over the assessment schedule, data extraction form and procedures 
manual 
* your time spent undergoing training 
any travel expenses. 
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Appendix 5 
Participant invitation letter 
Practice headed notepaper 
Eyesight in older people 
Dear 
We would like to ask for some help with a research study. The study is trying 
to find out how the Health Service can help improve older people's eyesight. 
The study is part of a larger study called the MRC Elderly Screening Trial. 
you may remember having a health check between one and four years ago as 
part of this larger study. 
If you agree to take part, you will have a short interview with the nurse about 
your eyesight. The nurse will then check your vision by asking you to read 
Sonle letters on a chart.: If you are found to have a problem with your vision, 
you may be asked to see your GP, be referred to an eye specialist, or the nurse i 
, nay recommend that you see an optician. The whole appointment will take 
around 45 minutes to complete. 
]3e, fore you decide whether to take part it is important for you to understand 
, Wily the research is being done and what it will involve. Please read the 
CrIclosed information leaflet. Your decision will not affect the standard of care 
you receive. 
Could you please come to the surgery on/ I will visit you at home on: 
please let me know as soon as possible if this time is not convenient for you. 
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please bring the following with you when you come: 
+ your glasses if you have any 
1 
46, Any letters, appointment cards or other record oý when you went to an 
optician or an ophthalmologist (hospital eye specialist) 
We feel this is a worthwhile study and hope you will be able to take part. I 
look forward to seeing you. 
yours sincerely, 
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Participant information leaflet 
London School of Hygiene & Tropical Medicine 
(University of London) 
Keppel Street London WCI E 7HT -011111111iiý, % 0 
Direct line: 020 7927 2296 
ail: liam. smeeth@lshtm. ac. uk 
Department of Epidemiology & Population Health 
Epidemiology Unit 
Eyesight in older people: information for participants 
We are inviting you to take part in a research study. This new study will assist us in 
looking for the best way to care for elderly people's eyesight. This leaflet will provide 
information about what the study will involve. 
0 VVhat is the purpose of the study? 
The aim of this study is to measure the benefits of different ways of testing for eye 
problems in older people. It is part of the ongoing Elderly 
$creening Trial which is 
funded by the United Kingdom Medical Research Council. We hope this new study 
will lead to more effective care for those people with problems with their eyesight. 
-VVhy have I been chosen? 
About 150 patients in your doctor's practice aged 75 and over have been randomly 
selected to take part. 
po I have to take part? t 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be asked to sign a consent form when you come and see the nurse. You will be free 1 
to withdraw at any time and without giving a reason. Your decision will not affect the 
standard of care you receive. 
What will happen to me if I take part? 
-you will either need to attend the surgery once or the nurse will come and see you at 
home. You will be asked to sign a consent form agreeing to take part in the study. You 
will then have a short interview with the nurse about your eyesight. The nurse will then 
check your vision by asking you to read some letters on a chart. If you are found to 
have a problem with your vision, you may be asked to see your GP, be referred to an 
eye specialist, or the nurse may recommend that you see an optician. The whole 
, appointment will take around 45 minutes to complete. 
The nurse will not give you any tablets or medicines, and you will not be asked for a 
blood sample. 
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What do I have to do? 
Please bring the following with you when you come: 
Your glasses if you have any 
Any letters, appointment cards or other record of when you went to an opticiall or 
an ophthalmologist (hospital eye specialist) 
if the time given is inconvenient, we can offer you a different day or time. You can eat 
or drink normally before the appointment and you should continue witli any 
medications you are on. 
NVhat are the possible disadvantages and risks of taking part? 
Apart from spending 30 to 45 minutes with the nurse, there are no disadvantages or 
risks involved in taking part in this study. 
What are the possible benefits of taking part? 
A free test of your eyesight! The information we get from this study will 1111'01*111 Lis 
about the best way to help older people with their eyesight. 
Poor eyesight and driving 
if the nurse discovers that your visual acuity (how well you can see) is below tile 
currently recommended level for fitness to drive, she will advise you ofthis. You 
will be advised to stop driving immediately. The nurse will advise you to go and see 
an optician both to confirm her findings and to see if your vision can be improved 
with new or altered glasses. If the optician confirms the nurse's findings, you will be 
legally obliged to stop driving and to inforill the Driver and Vehicle Licensing 
Agency of the fact that your vision is below the level required to drive. Tile nurse 
will also advise you to see your GP to discuss your fitness to drive. 
Will my taking part in this study be kept confidential? 
If you consent to take part in the research, the nurse you see as part oNlie research may 
inspect your medical records. All information that is collected about you during the 
course of the research will be kept strictly confidential. Any information abOUt YOU 
which leaves the surgery will have your name and address removed so that you cannot 
be recognized from it. 
What will happen to the results of the research study? 
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The results will help us carry out future studies about elderly people's eyesight. You 
will not be able to be identified in any report or publication. 
Who is organizing andifunding the research? 
The study is being organised by researchers at the London School of Hygiene and 
Tropical Medicine and at Moorfields Eye Hospital, London. The United Kingdom 
Medical Research Council is funding the study. 
Contact for further information 
please contact <(Research Nurse -b 
or <<Research Nurse_2>>, the research nurse at the 
practice on <(Telephone 1)) 
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Consent form 
Name of patient: ------------------------------- 
Patient Identification number: -------------------- 
CONSENT FORM 
Date of birth -------------------- 
Title of Project: Eyesight in older people 
1.1 confirm that I have read and understood the information sheet 
for the above study and have had the opportunity to ask 
questions. I 
2.1 understand that my participation is voluptary and that I am free 
to withdraw at any time, without giving any reason and without 
my medical care or legal rights being affected. 
i 
3.1 give permission for the researchers to ýave access to my 
medical records. 
4.1 agree to take part in the above study. 
Name of patient Date 
Name of person taking consent Date 
Signature 
Signature 
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Appendix 8 
Assessment schedule 
Patient ID number 
IIIIIII-I 
Date of birth 
IIII 
EYESIGHT IN OLDER PEOPLE 
ASSESSMENT SCHEDULE 
Date of Interview 
IIII 
Interviewer name 
Place of Interview Practice 
El Patients home 
Other 
Before seeing the patient please fill in question 3.2 on page 11 
Have the relevant parts of each section been completed? 
If no give reason 
El D 
yes Section I no 
Section 20 yes 
El 
no ------ 
Section 3 yes 
El 
no 
Section 4 yes 
M 
no 
If )fou answered yes 
to Q1.4 or Q3.2 Filled In? 
[: 1 
NIA 
[: 1 
yes no 
please 
fill In data extraction form 
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SECTION 1 
IE Do you have any problems with your eyesight? 
11 
Yes 11 No 
a) Do you own any glasses? 
Yes El No If No, go to Question 1.3 
(b)Do you wear them: 
R All the time 
Ej For reading only 
El Other please specify --------------------------- 
H Are you registered as blind or partially sighted? 
F] No 
F] Blind 
E] Partially sighted 
Have you ever seen an ophthalmologist/ hospital eye specialist? 
Yes 
No 
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SECTION 2: THE VF-14 QUESTIONNAIRE 
IEI (a)Do you have difficulty, even with glasses, reading small print such as labels 
On medicine bottles; a telephone book or food labels? 
Yes 
No 
F1 NotApplicable please give reason ----------------------------- 
(b)If yes, How much difficulty do you currently have? 
El A little 
0A moderate 
amount 
A great deal 
El Unable to do the activity 
(a)Do you have difficulty, even with glasses, reading a newspaper or book? 
Yes 
E] No 
NotApplicable please give reason ----------------------------- 
(b)ff yes, How much difficulty do you currently have? 
El A little 
Ej A moderate 
amount 
El A great deal 
El Unable to do the activity 
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(a)Do you have difficulty, even with glasses, reading a large-print book or 
large print newspaper or numbers on a telephone? 
--[: ] Yes 
No 
NotApplicable please give reason ----------------------------- 
(b)If yes, How much difficulty do you currently have? 
El A little 
F1 A moderate 
amount 
EJ A great deal 
11 
Unable to do the activity 
IHI (a)Do you have difficulty, even with glasses, recognising people when 
they are close to you? 
Yes 
No 
El NotApplicable please give reason 
(b)ff yes, How much difficulty do you currently have? 
El A little 
A moderate 
amount 
A great deal 
Unable to do the activity 
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(a)Do you have difficulty, even with glasses, seeing steps, stairs or kerbs? 
--[: ] Yes 
E] No 
El Not Applicable please give reason ----------------------------- 
+ 
(b)lf yes, How much difficulty do you currently have? 
El A liftle 
0A moderate 
amount 
El A great deal 
11 Unable to do the activity 
Hil (a)Do you have difficulty, even with glasses, reading traffic signs, street signs 
Or shop signs? 
--J] Yes 
0 No 
El NotApplicable i please give reason ----------------------------- 
(b)ff yes, How much difficulty do you currently have? 
El A little 
El A moderate 
amount 
EJ A great deal 
1: 1 Unable to do the activity 
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ED (a)Do you have difficulty, even with glasses, doing fine handiwork like 
sewiing, knitting, crocheting or carpentry? 
Yes 
No 
El Not Applicable please give reason ----------------------------- 
(b)lf yes, How much difficulty do you currently have? 
11 
A liftle 
A moderate 
amount 
A great deal 
El Unable to do the activity 
Eil (a)Do you have difficulty, even with glasses, writing cheques or filling out forms? 
Yes 
No 
El NotApplicable please give reason ------------------------ 
(b)ff yes, How much difficulty do you currently have? 
El A liftle 
El A moderate 
amount 
El A great deal 
El Unable to do the activity 
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D 2.9 (a)Do you have difficulty, even with glasses, playing, games such as 
bingo, or dominoes? 
Yes 
No 
Not Applicable please give reason ----------------------------- 
(b)If yes, How much difficulty do you currently have? 
El A liftle 
A moderate 
amount 
El A great deal 
n Unable to do the activity 
(a)Do you have difficulty, even with glasses, taking part in sports like bowling, 
tennis or golf? 
Yes 
No 
El Not Applicable please give reason ----------------------------- 
(b)lf yes, How much difficulty do you currently have? 
nA little 
EJ A moderate 
amo* 
El A great deal ' 
El Unable to do the activity 
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EHI (a) Do you have difficulty cooking, even with glasses? 
Yes 
No 
Not Applicable, please give reason ----------------------------- 
(b)If yes, How much difficulty do you currently have? 
El A little 
A moderate 
amount 
A great deal 
El Unable to do the activity 
EHI (a)Do you have difficulty, even with glasses, watching television? 
Yes 
No 
NotApplicable please give reason 
(b)If yes, How much difficulty do you currently have? 
El A little 
F1 A moderate 
amount El A great deal 
EJ Unable to do the activity 
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L2.13 I Do you currently drive a car? 
Yes (2.131) 
El No 10 If No, go to Question 2.16 
2.14 How much difficulty do you have driving during the day because of your 
I Vision? Do you have: - 
F1 No difficulty 
F1 A little difficulty 
A moderate amount of difficulty 
A great deal of difficulty 
EE How much difficulty do you have driving at night because of your 
Vision? Do you have: - 
No difficulty 
A little difficulty 
A moderate amount of difficulty 
A great deal of difficulty 
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Have you ever driven a car? 
Yes El No p If No, go to Section 3 
2.17 1 When did you stop driving? 
n Less than 6 months ago 
6-12 months ago 
More than 12 months ago 
Why did you stop driving? 
F1 Vision 
F1 Other illness 
n Other reason 
Any other comments: 
---------------------------------------------- 
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SECTION 3 
FHI (a) Have you seen anyone about your eyes or bought any glasses in the last five years? 
Yes- probably in 
the last 5 years 
Where was this? 
No: never or definitely 
Stop and go to 
more than 5 years ago section 
4-. 
vision testing 
Ask about each of the following options in turn 
Optician 
Ophthalmologist (hospital eye specialist) 
GP practice 
Bought some glasses in a shop or 
chemist without having an eye test 
Other 
[: ýil Was the patient: 
Yes No 
Du 
DU 
DLI 
DLI 
0 El 
(a) Advised to see an optician after the baseline elderly screening trial assessment? 
n 
Yes -*. go to Question 3.3a F] No 0. Continue from page 13 
(b) Referred to an ophthalmologist after the baseline elderly screening trial assessment? 
11 
Yes --o. go to Question 3.3b El No 0. Continue from page 13 
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_ý. 
ý3 Do you remember: 
(a) being advised to see an optician after the baseline assessment? 
or 
(b) being referred to an ophthalmologist after the baseline assessment? 
El Yes No 0 Continue from page 13 
Did you go to the ophthalmologist / optician as a result of the baseline assessment? 
El Yes 0 Continuefrom page13 
El No Gently ask why not ------------------------------ 
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THIS PAGE IS ONLY FOR THOSE WHO HAVE SEEN AN OPTICIAN: 
Tick if not applicable Ej 
What made you decide to go to the optician? 
El Go regularly 
El Problems with eyesight 
11 Advised to go by someone Who? ------------------------------ 
El Other 
[ýE 
What happened? Were you advised to: 
Continue with the same glasses 
Change your lenses or glasses 
El Get some glasses for the first time 
11 Other 
If the optician recommended a change in your 
lenses, or new glasses, did you buy them? 
El Yes F] No Why not 
Do you still wear them? 
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THIS PAGE IS ONLY FOR THOSE WHO HAVE SEEN AN OPHTHALMOLOGIST: 
Tick if not applicable 
Why did you go to the ophthalmologist? 
F] Referred by GP 
El Other 
(a)Did they recommend any treatment or help with your eyesight? 
f Yes El No --0' Continue from page 15 as relevant 
(b)What has happened since then? 
1: 1 Nothing Why? 
------------------------------------------ 
ElPrescribed 
some eye medicine, drops or ointment 
Name of medicine, drops or ointment if known ------------------------------ 
E]On 
a waiting list for surgery 
El Had surgery 
El Referred to another eye service 
Details 
Please write any further description here: - 
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THIS PAGE IS ONLY FOR THOSE WHO HAVE SEEN SOMEONE AT THEIR 
GP SURGERY ABOUT THEIR EYES: 
Tick If not applicable 
M 
L3.11 I 
Why did you go? 
Who did you see? 
What happened during your visit? 
------------------------------------- M-W 
WM--MMM-M-- 
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THIS PAGE IS ONLY FOR THOSE WHO HAVE SEEN SOMEONE 
OTHER THAN AN OPTICIAN, OPHTHALMOLOGIST OR SOMEONE AT THEIR GP 
, SURGERY ABOUT THEIR EYES: 
F-3.1-4] 
Why did you go? 
Who did you see? 
What happened? 
Tick If not applicable M 
------------------------- m m--mmm m_m-m mmm- 
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SECTION, 4: 1 VISUAL ACUITY 
Test the patient whilst they are wearing their usual glasses. Using the Glasgow chart, 
measure the patient's vision at 3 metres. If the patient cannot see the biggest letters, 
then measure at 1 metre. Measure both eyes first, then each eye separately. Scores 
can be plus or minus. The greater the score, the worse the vision. 
Line Number Logmar Measured at Unable to read 
number correct score 3m Im at lin 
Both eyes 
Left eye 
Right eye 
Look up the scores obtained in the grid on page 19. This grid shows all possible 
measurements with the Glasgow Acuity Card. If a measurement falls In the shaded 
area, it means that the patient has poor vision and should be re-tested with the 
pinhole. If all measurements fall in the non-shaded area, that ; is 
the end of the test. 
ACTION 
Any shaded (score is 0.5 or greater in either eye): re-test using a pinhole. 
Applies Yes 
Go to 
pinhole 
testing 
No 
Go to 
ACTION 
point 3 
page 18 
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PINHOLE TESTING Tick if not applicable Fý 
Before pinhole testing, write In the scores without pinhole for each eye from the 
previous page. 
Score With pinhole Measured at Unable to 
without Line Number Score read at 1m, 
pinhole* number correct 3m 1M 
Left 
eye 
Pight 
eye 
*from previous page 
Look up the scores obtained in the grid on page 15. If a measurement that fell In the 
shaded area without the pinhole falls in the non-shaded area with the pinhole, It 
suggests that the patient needs new glasses. If the score from either eye is in the 
shaded area even with the use of the pinhole, this suggests the patient needs to be 
seen by an ophthalmologist. 
ACTION 
1. Any score that previously, fell in the shaded area without the pinhole falls In the non- 
shaded area with the pinhole (minus scores, or scores less than 0.5): advise the 
patient to see an optician. 
Patient advised 
M Yes El No ff No, why not .............................. 
2. Any shaded score even with the pinhole (score is 0.5 or greater In either eye): ask if 
patient has seen an ophthalmologist/hospital eye specialist in the last year: 
El Yes No 
If No, recommend GP refers to an ophthalmologist, unless the patient is registered as blind or partially sighted (Question 1.3). 
Letter sent to GP recommending I referral: 
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1: 1 Yes El No ff No, why not ------------------------------- 
3. Does the patient currently drive? Yes No 
(Question 15, section 2) Fý End of 
acuity 
testing 
point 4] 
4. If the patient scored 0.4 or more when testing both eyes together, their eyesight 
may be below the currently recommended level of vision required for driving. This 
means that the logMAR score for both eyes together was below the dashed line on 
the visual acuity results grid. 
Yes No 
Did the patient score 0.4 or El El 
more when testing both eyes together? 
If the answer is yes, their eyesight may be below the currently recommended level of 
vision required for driving. If the patient is currently driving and their vision appears to 
fall below the driving requirement, take all the following actions: 
Action taken 
Yes No 
Tell the patient their vision may fall below the level required M F1 
by law for driving and give them the information leaflet for 
drivers 
Advise the- patient not to drive until it is clear they can El 
satisfy the m edical requirements for fitness to drive 
(because they have their eyes tested again by an- optician, 
ophthalmologist or their GP and are told their vision is good 
enough to drive) 
Tell the patient that it is their responsibility not to drive 
and to inform the Driver and Vehicle Licensing Agency if the 
findings are confirmed by an optician, ophthalmologist Pr their GP. 
Tell the patient that you are informing their G'P of, your findings 
Refer the patient to their GP using the standard notification letter 
Advise the patient it may be helpful for them to'see an optician F1 El 
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If any action has been ticked no, please state why 
Give the patient a copy of the study leaflet: INFORMATION FOR DRIVERS 
VISUAL ACUITY RESULTS GRID 
I GOOD VISION I 
-0.3 -0.275 -0.25 -0.225 
-0.2 -0.175 -0.15 -0.125 
-0.1 -0.075 -0.05 -0.025 
0 0.025 0.05 0.075 
0.1 0.125 0.15 0.175 
0.2 0.225 0.25 0.275 
... .?............. ............. 
Q 
.............. 
Q ý5 
.......... 
Q-. 375 
............. . 0.4 0.425 0.45 0.475 
0.5 0.525 0 . 
55 0.575 
0.6 0.625 0.65 0.675 
0.7 0.725 0.75 0.775 
0.8 0.825 0.85 0.875 
0.9 0.925 0.95 0.975 
1 1.025 1.05 1.075 
1.1 1.125 1.15 1.175 
1.2 1.225 1.25 1.275 
1.3 1.325 1.35 1.375 
Patients who could not read any letters at I metre 
I BAD VISION I 
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Example of flashcard used with the National Eye Institute Visual 
Function Questionnaire 
Question 1 
In general, would, you say 
your overall health is: 
Excellent 
Very good 
Good 
Fair 
Poor 
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Referral lefter: research nurse to general practitigner 
General practice headed paper 
Screening older people for impaired vision: a nested trial 
within the MRC Trial of Assessment and Management 
of Elderly People in the community 
Notification of results of vision testing 
Date: 
Re 
Dear 
I saw this patient today and tested their vision as part of a vision screening component ofthe MRC Trial 
of Assessment and Management of Elderly People in the Community. The results were as follows: 
Logmar Snellen With use of Measured at Unable to read 
score equivalent pinhole 3m Im at Im 
Both eyes 
Left eye 
Right eye 
A GP referral to an ophthalmologist 
was recommended by the study protocol 
(because the patient has visual acuity of less than 6/18 snellen 
equivalent that does not improve with use of a pinhole; has not 
seen an ophthalmologist for one year or more; and is not 
registered blind or partially sighted). 
The NFIS costs of all such referrals have been approved by the 
Directorate. 
Yes F-I No F] 
relevant NI IS Research and Development 
I have advised the patient to see an optician Yes No F1 
for formal testing and refractive correction 
(because the patient has visual acuity of less than 6/18 snellen 
equivalent that improved with use of a pinhole) 
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The patient is currently a car driver 
For those who currently drive: 
The patient's vision appears to fall below the 
currently recommended minimum level required 
for driving 
I have advised the patient not to drive, and given 
them an information leaflet about their fitness to drive 
I have asked the patient to see their GP about their 
fitness to drive 
Yours sincerely, 
Research nurse 
Yes El No 
Ycs F-I No F1 
Yes Fý Not r-ý 
applicable 
Yes Not 
applicable 
If you have any clinical or scientific queries about this letter, please contact Dr Liam Smeeth, the 
trial co-ordinator. His contact details are as follows: 
Dr Liam Smeeth 
Epidemiology Unit 
London School of Hygiene and Tropical Medicine 
Keppel Street, London WC IE 7HT 
Tel: 020 7927 2296 Fax: 020 7580 6897 
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Medical records data extraction form 
MRC ELDERLY STUDY: NESTED VISION TRIAL 
Patient contacts with hospital eye services 
Only for patients eligible for referral to an ophtahlmologist following the baseline assessment 
ID NUMBER E] [: ] [: ] EJFý F-I 
Date of baseline assessment: 
Please go through the notes and identify ALL the letters which refer to eye problems or deal with 
referrals to orftom any eye specialist - optician, ophthalmologist or eye hospital. Please look 
through all the notes, notjust since the start of the MRC Elderly Study. We are interested in all eye 
problems, notjust those identified during the study. 
SECTION 1: ANY LETTERS ABOUT EYES DATED BEFORE THE DATE OFTIIIý' 
BASELINE ASSESSMENT 
Are there any letters about eyes before the date of the detailed examination yes/no 
if no go to section 2 
Number of letters: 
Ealiest date: 
Latest date: 
Who are the letters from: 
Yes No 
GP (referral to eyes services) 
Opthalmologist 
Optometrist 
Other (details) 
DIAGNOSIS: Please write down any terms which you think rýfer to the diagnosis even ýfyou are 
not sure what they mean. 
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TREAT M ENT: Please write down any terms which you think refer to treatment even ifyou are not 
sure what they mean 
SECTION 2: ANY LETTERS ABOUT EYES DATED AFTER THE DATE OF THE 
BASELINE ASSESSMENT 
Are there any letters about eyes after the date of the baseline assessment yes/no 
if no stop 
Number of letters: 
Ealiest date: 
Latest date: 
GP REFERRAL 
Is there a referral letter to an ophthalmologist 
dated after the date of the baseline assessment yes/no 
If no, is there any other evidence of a referral eg a note in the medical record yes/no 
Details 
Date of referral 
RESPONSE FROM OPHTHALMOLOGIST 
Are there any letters from an ophthalmologist 
dated after the date of the baseline assessment yes/no 
If the patient was referred, is there a letter that states 
the patient did not attend the appointment yes/no 
Date of letter 
ALL LETTERS ABOUT EYES DATED AFTER THE DATE OF THE BASELINE 
ASSESSMENT 
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Please allocate a number to the letters in chronological order, letter number I being thefirst letter 
ident4ied dated qfter the date of the baseline assessment. If there are more than 6 letters please use 
extra sheets being sure tofill in the id numberfor each. For each letter dated a er the baseline Of 
assessment please complete the following information: 
LETTER NUMBER I Date of letter _/_/ 
PURPOSE OF LETTER: eg, reportftom ophthalmologist, referral to optician 
DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even ij'you are 
not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refer to treatment even q'you tire not 
sure what they mean 
LETTER NUMBER 2 Date of letter 
PURPOSE OF LETTER: eg, reportftom ophthalmologist, referral to optician 
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DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even ifyou are 
not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refer to treatment even ifyou are not 
sure what they mean. 
LETTER NUMBER 3 Date of letter 
PURPOSE OF LETTER: eg, reporiftom ophihalinologist, refti-ral to optician 
DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even ýfyou are 
not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refir to treatment even q'you are not 
sure what they mean 
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LETTER NUMBER 4 Date of letter _/_/ 
PURPOSE OF LETTER: eg, reportftom ophthalmologist, reftrral to optician 
DIACAOSIS: Please write down any terms which you think refer to the diagnosis even ifyou are 
not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refer to treatment even ýfyou tire not 
sure what they mean 
LETTER NUMBER 5 Date of letter _/_/ 
PURPOSE OF LETTER: eg, reportftom ophthalmologist, rejýrral to oplician 
DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even if, you (ire 
not sure what they mean. Please record any vision measurements. 
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PURPOSE OF LETTER: eg, reporIftom ophthalmologist, reftrral to optician 
DIAGNOSIS: Please write down any terms which you think refer to the diagnosis even Y'you are 
not sure what they mean. Please record any vision measurements. 
TREATMENT: Please write down any terms which you think refer to treatment even ýfyou (ire not 
sure what they mean 
Any other comments: 
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Appendix 12 
The relationshipbetween Snellen visual acuity and logMAR scores 
The relationship between Snellen visual acuity and logMAR 
scores 
Sndlen acuity at 6 metres logMAR score 
6/3 -0.3 
6/3.75 -0.2 
615 -0.1 
6/6 0.0 
6n. 5 0.1 
6/9.5 0.2 
6/12 0.3 
6/15 0.4 
6/19 0.5 
6/24 0.6 
6/30 0.7 
6/38 0.8 
Notes: 
The IogMAR score is derived from the angular size of the smallest 
letters that can be read. Larger angles indicate worse vision, and 
therefore higher logMAR scores indicate lower visual acuity. 
Because a logMAR score of 0.0 is to equate to a Snellen acuity of 6/6, 
logMAR acuity better than 6/6 will have a negative sign. 
Each line on the logMAR chart has four letters, and each letter 
i correctly identified reduces the logMAR score by 0.025 log units. Thus 
identifying all four letters on a line reduces the logMAR score by 0.1 
units, and the next smallest line is then tested. 
Appendix 12 page I 
